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The abbreviations used in this thesis are those recommended in the 
Biochemical Journal with the following additions:
APC Antigen Presenting Cell
BdUR Bromodeoxyuridine
C region Constant region
CD Cluster of Differentiation
CD25 Low affinity receptor for IL-2 receptor
(Tac)
Con A Concanavalin A
CRBC Chicken Red Blood Cells
CTL Cytotoxic T Lymphocytes
D region Diversity region
ECM Extracellular matrix
EDTA Ethylene Diaminetetra acetic acid
ER Endoplasmic Reticulum
FACScan Fluorescence Activated Cell Scanner
FITC Fluoroisothiocyanate
FL1,2,3 Fluorescence channels 1,2,and 3
FSc Forward Scatter of light
GO, 1,2 Gap phase 0,1,2 of the DNA cell cycle
HLA Human Leucocyte Antigen
HPF High Power Field
VICAM-1 Intercellular adhesion molecule -1
IEL Intraepithelial lymphocyte
IFN , Interferon
Ii Invariant chain
IL Interleukin
J region Joining region of TCR
LAK cell Lymphokine activated Killer cell
LFA-1 Leucocyte function associated antigen-1
LPS Lipopolysaccharide
M Mitotic phase of the DNA cell cycle
MHC Major Histocompatibility Antigen
MI Mitotic Index
PBL Peripheral Blood Lymphocytes
PBS Phosphate Buffered Saline
PE Phycoerytherin
PI Propidium Iodide
rh IL-2 recombinant human interleukin 2
RPMI Roswell Park Memorial Institute
S Synthetic phase of the DNA cell cycle
SSc Side Scatter of light
Tc T cytotoxic cell
TCR T Cell Receptor
Th T helper cell
TIL Tumour Infiltrating Lymphocytes
TNF Tumour Necrosis Factor
V region Variable region of TCR
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SUMMARY
Uveal melanoma, although a comparatively rare tumour of man, is the 
commonest malignant tumour of the eye. The tumours can be composed of 
varying cell types; pure spindle, pure epithelioid and a mixture of spindle and 
epithelioid cells, with a worse prognosis being associated with the pure 
epithelioid cells. Approximately 5-12% of uveal melanomas contain a 
lymphocytic infiltrate amenable to study. The eye has classically been referred 
to as an immunologically privileged site of the body lacking interaction of 
cells of the immune system. Such tumours and their associated infiltrates have 
previously only been studied by immunocytochemical techniques which is a 
non- quantitative and very subjective method of analysing cell surface marker 
expression. However, flow cytometry is a modem method of studying cell 
surface marker expression which makes use of fluorescently labelled 
antibodies specific for these molecules. It gives quantitative analysis of a large 
number of cells from a substantial section of the sample in a short period of 
time and allows small changes in fluorescence to be quantified.
The work in this thesis describes a flow cytometric analysis of not 
only the cell surface markers of the uveal melanoma cells themselves but also 
the lymphocytes which infiltrate them. In addition, the cell cycle of the tumour 
cells was analysed. Among the questions of interest are the immunological 
status of tumours within a privileged site, such as the eye, and the 
comparison with extra-ocular tumours, in particular cutaneous melanoma 
which has been treated by various immunological therapeutic strategies. The 
basic questions addressed were the origins of the tumours infiltrating 
lymphocytes. Either they represent a small population of cells which invade 
the tumour and then expand in this site, or they represent a population which
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are expanded elsewhere and activated on site. The data from this work 
indicates that the latter option is the more likely.
In particular it was proposed to study the tumour infiltrating 
lymphocytes (TILs) in terms of their activation status compared to peripheral 
blood lymphocyte (PBLs). Among 27 uveal melanomas, 5 were found to 
contain TILs. Four had high levels of lymphocytes and the 5th had 
comparatively low levels but adequate numbers for comprehensive analysis. 
The TILs were analysed to determine the relative proportions of lymphocyte 
subsets and markers of activation. The results show the predominance of 
CD8+ T cells and insignificant levels of B cells present within the infiltrate. 
The TILs were found to be activated to a higher degree when assayed for 
levels of histocompatibility antigen, HLA DR, possibly indicating the antigen 
presenting capabilities of the T cells. The CD4+ T cells expressed more of the 
activation marker CD25 (Tac, IL-2R) which has relevance to the modem 
methods of immunotherapy of malignant neoplasms, especially malignant 
cutaneous melanoma.
It was then decided to examine the TELs in terms of the expression of 
specific Vp regions of the T cell receptor (TCR) indicating whether the cells 
were clonal in the site of the tumour.This was done by using a panel of 
fluorescently labelled monoclonal antibodies to subfamilies of the TCR.
While the TILs have the ability to locate selectively within the tumour it 
was found that in the 6 uveal melanomas and the 4 breast carcinomas studied, 
the TILs comprised a population expressing a diversity of TCR VP genes. No 
probe was highly dominant or unrepresented in any of the tumour samples or 
PBL samples indicating that within the limitations of the monoclonal 
antibodies used the cells are not responding to a defined antigen or 
superantigen in a clonal manner.
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In the light of many early reports of a systemic immune response to 
tumours, a study was performed to identify if such a response could be 
demonstrated for uveal melanoma. Patient PBL samples, pre-operatively and 
1 week post-operatively, were prepared and analysed in terms of the 
lymphocyte phenotype activation status. There was no significant difference 
between the PBL samples in the same patient for the time points measured, 
indicating a lack of systemic immune response.
The relevance of adhesion molecules expressed on the tumour cells 
was studied to investigate if these correlate to relevant parameters on the 
lymphocytes within the tumour. Twenty uveal melanomas were studied for 
the expression of the intercellular adhesion molecule -1 (ICAM-1), and also 
Class I and II (HLA DR) MHC antigens. It was found that ICAM-1 was 
present on a high percentage of tumour cells and there appeared to be a 
negative correlation between the presence of ICAM-1 and HLA DR. There 
was no correlation between the levels of TILs and the expression of Class I or 
ICAM-1 on the tumour cells, but there was a correlation between the levels of 
TILs and HLA DR present on the tumour cells. Class I was present on the 
mixed spindle/ epithelioid cell populations to a higher degree and HLA DR 
was detected on a slightly higher percentage of the pure spindle cells than the 
other cell types. This indicates the difference in the cell types of the tumours. 
However, ICAM-1 is expressed on all 3 cell types at similar levels.
Further studies were performed by analysing ICAM-1, Class I MHC 
and HLA DR on the TILs of 5 patients with uveal melanoma. ICAM-1 was 
found on higher percentages of the TILs than PBLs. CD8+ T cells also had a 
higher level of expression than the CD4+ T cells on both the TILs and PBLs. 
Class I MHC was found on a high percent of the lymphocyte populations 
whatever the source, as expected, and HLA DR was expressed on the TILs 
to a greater extent than on the PBL. In 3 of the 5 TIL samples there was also
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data on the relevant tumour samples. Within this small sample number there 
appeared to be a correlation between the expression of HLA DR bearing 
CD4+ TILs and Class I expressing tumour cells, and also between the HLA 
DR bearing CD8+ TILs and HLA DR expressing tumour cells.
Finally it was decided to study the tumour cells at a nuclear level. In 
other studies, immune response has been related to abnormal DNA content 
(aneuploidy). Flow cytometry has often been used to perform ploidy analysis 
of primary tumour cells since epithelial tumours such as those of the breast 
and colon contain a high percentage of cells with abnormal DNA.
In this study 32 uveal melanoma tumours were prepared for FACScan 
analysis to determine the percentage of cells in each phase of the cell cycle. It 
was found that only 1 tumour contained abnormal (aneuploid) DNA and the 
remainder contained normal diploid DNA similar to the patient PBL samples. 
The tumour that contained the abnormal DNA was identified as being an 
epithelioid tumour. The majority of the diploid DNA was in the Go/Gl phase 
of the cell cycle. A correlation was performed between the tumour cell type 
and the proliferation index (G2/M/S) and it was found that the mixed spindle/ 
epithelioid cells were proliferating to a higher extent than the pure epithelioid 
or spindle cells. This finding seemed simply to be due to the small number of 
epithelioid tumour obtained since in contrast, pathology reports state the 
mitotic index (MI), of the tumour, another indicator of proliferation, and it 
was found that the pure epithelioid cell had a greater mean MI than the other 
cell types.
In all of these studies other than the cell cycle, considerable inter- patient 
and inter- tumour variation was apparent. It seems very probable that 
immunological or other therapeutic strategies will have to take this factor into 
account.
CHAPTER 1
INTRODUCTION
1.1 THE EYE
1.1.1 General structure of the eye
The eyeball is situated in a bony cavity of the skull called the orbit 
(Figure 1.1). In man, it is approximately spherical having a mean diameter of 
about 24mm and a weight of about 7g. Except at the anterior pole, the eye has 
3 distinct layers: the outermost protective coat, the sclera (from the Greek, 
scleros meaning hard); the middle nutrative coat, the uveal tunic (from the 
Latin, uva, meaning grape due to similarity in shape and size to a grape skin); 
the innermost coat, the retina (from the Latin word translated as a "net like 
structure").
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Figure 1.1: Schematic diagram of the eye
21.1.2 The uveal tunic
The sclera is replaced by the transparent cornea at the anterior pole of 
the eye. The uveal tunic is divided into 3 parts, the choroid, the ciliary body 
and the iris (Figure 1.1) which are highly vascularised and pigmented 
structures and together play a nutritive role. The choroid lies beneath the 
retina and provides the outer retina with its metabolic requirements. The 
ciliary body alters the refractive power of the lens and produces the aqueous 
humour. Finally, the iris regulates the amount of light that reaches the retina. 
Both the ciliary body and the iris exist in the anterior portion of the eye. The 
retina not only contains the light receptors but also nerve cells, including the 
fibres which converge at the optic disc to form the optic nerve and blood 
vessels.
1.1.3 The inner compartments
The interior of the eye contains the lens, the aqueous humour, and the 
vitreous humour. The aqueous humour is in two compartments: the anterior 
chamber is contained between the cornea, the anterior surface of the iris and 
the central portion of the anterior surface of the lens; the posterior chamber is 
contained between the surface of the iris, the ciliary body, suspensory 
ligaments and the edges of the lens.
1.1.4 Immunologic privilege in the eye
The anterior chamber of the eye is considered the classic example of a 
privileged site in which histocompatible allografts escape immunological 
recognition and undergo prolonged and sometimes permanent residence 
(Head and Billingham,1985). The immunological privilege has been attributed 
to the isolation of these sites from the lymphoblastic system, thus preventing 
these cells from interacting with the immune system. Other areas of the body
that exhibit this phenomenon include the brain (Head and Griffin, 1985) and 
the pregnant uterus (Beer et al., 1976).
Comeal transplantation has been performed on animal subjects for 
over 150 years and on human patients for over 80 years (Trevor- Roper,
1972). In the United States, 30,000 comeal transplants are performed each 
year, with a success rate of well over 90%. Thus along with the anterior 
chamber, the cornea is a major area of immunologic privilege in the eye. It 
would thus seem that the cornea, the comeal graft bed and the anterior 
chamber exist in an environment free of immune- mediated diseases.
However, this is an oversimplification, as the eye is apparently vulnerable to a 
wide range of autoimmune diseases.
Historically, 3 basic hypotheses have been offered to account for the 
privileged existence of comeal allografts (Silverstein and Khoudadoust,
1973).
(1) The simplest is that the cornea similar to some neuronal tissue, is devoid 
of major histocompatibility complex (MHC) antigens (Section 1.4.1). Thus 
alloreactive T cells would not recognise comeal cells. The absence of MHC 
antigens would not only prevent the arousal of an alloreactive response, but if 
a response were initiated, the grafts would be immunologically invisible. This 
theory has been unequivocally disproved, since some findings indicate not 
only that the cornea is vulnerable to immunological attack, but that it is 
capable of eliciting an alloimmune response that results in graft rejection. 
Studies in rats, rabbits and mice indicate that heterotopic transplantation of 
corneas to subdermal graft beds leads to rapid sensitization and swift rejection 
of the allografts (Billingham and Boswell, 1953; Khoudadoust and 
Silverstein, 1966; Chandler et al., 1983; Streilein et al., 1982).
MHC antigens (Section 1.4.1) have been found in all three layers of cornea
( Mayer et al., 1983; Treseler et al., 1984). The density of antigens differs 
between the cells of the corneal epithelium, stroma, and endothelium and in 
fact in rat comeal endothelium cells express small quantities of MHC Class I 
antigens and no detectable MHC Class n  antigens (Treseler and Sanfilippo, 
1986).
Comeal endothelium grafts stimulate robust cytotoxic T lymphocyte 
(CTL) responses following heterotopic grafting in the rat (Treseler et al.,
1986). Although MHC Class I antigen expression is greater in the epithelium 
than the endothelium, heterotopic transplantation of isolated allogeneic comeal 
epithelium fails to induce detectable anti- MHC class I CTL responses in rat 
(Treseler et al., 1986). The mere expression of MHC antigens on comeal cells 
does not ensure the induction of alloimmune response, but comeal allografts 
still have the potential to be immunogenic.
(2) The second hypothesis suggests that the donor cells are rapidly replaced 
by host cellular components in the graft bed, so that the cellular elements of 
the graft are replaced before the host's immune system can be aroused.
Again this idea has been refuted by such findings using tritiated 
thymidine to distinguish donor cells from recipient cells where by it has been 
demonstrated that long term survival of donor cells occurs (Chi et al., 1965). 
Clinical findings support this idea, since immunological rejection can occur 
over a decade after comeal transplantation (Silverstein and Khoudadoust,
1973).
(3) The third and perhaps the most widely acceptable hypothesis relates to the 
nature of the avascular comeal graft bed. The absence of blood and lymph 
vessels at the interface of the graft and the graft bed is thought to prevent the 
escape of alloantigen to the regional lymphoid tissues.
Thus the avascular graft, and the graft bed conspire to produce a state 
of immunological ignorance. To study this, corneal allografts were 
transplanted heterotopically (i.e. to an abnormal anatomical site) into 
subdermal graft beds, richly endowed with blood vessels and lymphatics, 
forcing the induction of alloimmunity. These grafts were compared with 
orthotopic grafts (i.e. into the normal anatomical site). If the avascular graft 
bed contributes to the survival of the allograft, it could be predicted that 
heterotopic corneal grafts would suffer significantly higher rejection rates than 
the orthotopic counterparts. This indeed was the case, as 100% of the fully 
allogeneic heterotypic comeal allografts were rejected in the mouse model 
(Chandler et al., 1983; Streilein et al., 1982; Matoba et al., 1986). In contrast, 
only 55-57% of fully allogeneic grafts failed when grafted orthotopically 
(Callanan et al., 1988; Williams and Coster, 1985).
Maumenee (1951) performed studies showing that rabbits bearing 
long- term orthotopic comeal allografts rejected skin grafts from donors who 
provided their comeal grafts. Skin graft rejection indicated that the initial 
comeal allograft failed to stimulate alloimmunity and that the graft bed 
produced an afferent blockade of the immune response. However, skin graft 
rejection led to the rejection of 90% of the previously clear comeal grafts. 
Thus, the corneal grafts initially displayed immunological privilege, but were 
antigenically vulnerable to an ongoing systemic immune response.
The high incidence of spontaneous neoplasms that occur in patients 
suffering from immunological disorders and in transplant recipients subjected 
to prolonged immunosuppression were earlier cited as evidence in support of 
the immune surveillance theory (Burnet ,1970) (Section 1.5.1). It is thus 
reasonable to suspect that the same situation occurs with immunological 
privilege sites. This is not the case (Head and Billingham, 1985), since the 
incidence of spontaneous neoplasms in immunologically privileged sites is not
higher than that occurring at other anatomical regions. In the case of the eye, 
tumours of the cornea are virtually unknown and the most common 
intraocular tumours occur in the posterior compartments of the eye.
An important question to be asked is: are highly immunogenic tumours that 
undergo spontaneous immunological rejection at extraocular sites exempt 
from immunologic rejection within the immunologically privileged confines of 
the anterior chamber ? This has been studied using P91 mastocytoma, a 
highly immunogenic mutant of the P815 mastocytoma, which undergoes 
immunological rejection following subcutaneous transplantation in syngeneic 
hosts (Niederkom and Meunier, 1985). Rejection is T cell mediated. 
Following anterior chamber transplantation, the tumours grow progressively 
for 3 weeks, but during the 3rd and 4th week post transplantation, an intense 
inflammatory response is elicited and culminates in ischemic tumour necrosis 
(Niederkom and Meunier, 1985). The eye is left irreparably damaged after 
another 5-7 days (phthisis bulbi). Immunologic findings support the 
proposition that rejection is predominantly a DTH (Delayed Type 
Hypersensitivity)- mediated process (Niederkom and Knisely, 1988). The 
host also develops tumour- specific CTLs and antibodies, but neither is 
involved in the rejection of the tumour.
1.2. NEOPLASTIC DISEASE
1.2.1 M alignancy
The size of an organ and the number of cells it contains are both 
normally maintained at constant and optimal values by the mechanisms which 
control the mitotic activity of the cells. Neoplasia is a state in which the 
control mechanisms become deficient and an excessive proliferation of the 
cells continues indefinitely without relation to normal growth and tissue 
repair. This gives rise to an neoplasm, an abnormal tissue mass, or tumour
( from the Latin meaning a swelling). Tumours are conveniently classified 
into 2 main types: benign and malignant Benign tumours proliferate locally 
and are composed of differentiated cells resembling the tissue of origin. These 
structures are usually encapsulated, and readily removed by surgical 
procedures. Malignant tumours are not encapsulated and their edges are ill- 
defined. The cells are less well differentiated than the cells of origin and if left 
untreated the cells are capable of spreading into surrounding tissue. If the 
tumour invades blood vessels or lymphatics, the cells carried to other parts of 
the body may proliferate to form secondary tumours in a process referred to 
as metastasis (Section 1.2.3).
1.2.2 Classification of malignant tumours
Tumours are classified according to their tissue of origin. A malignant 
tumour of the epithelial tissue is referred to as a carcinoma (the suffix "-oma" 
meaning a mass or swelling) if it is derived from the surface epithelium or an 
adenocarcinoma if it is derived from the glandular epithelium. A malignant 
tumour of the connective cells of the muscle is called a sarcoma and tumours 
of the nerve cells are referred to as neuroblastomas and gliomas. Of particular 
interest to this thesis are tumours of the pigmented tissue. These malignant 
tumours are called melanomas and usually refer to lesions of the skin, 
cutaneous melanoma, but melanoma can also be associated with the certain 
areas of the eye (Section 1.3).
1.2.3 M etastasis o f malignant neoplasms
As mentioned previously (Section 1.2.1) tumour cells have the ability 
to spread and grow not only in the neighbouring tissue but also in other 
organs far removed from the original tumour site. The importance of 
metastatic spread in determining clinical outcome in cancer patients has 
initiated efforts to increase understanding of the pathobiology of this process.
Considerable importance has been given to the demonstration that populations 
of metastatic and non- metastatic cells could pre- exist within the same 
primary tumour (Fidler and Kripke, 1977). Selection of particular cells during 
the complex process of cancer spread may result in the cellular composition of 
the secondary tumour being different from that of the primary tumour ( Poste 
and Fidler, 1980). This was studied by comparing primary and secondary 
growths or by comparing variant lines differing only in their malignant 
behaviour (Hart et al., 1989). Recent efforts have been made to study genes 
controlling the metastatic behaviour utilising primary and secondary growths 
(Section 1.6.1). Gain and loss of a wide variety of different gene products 
has been documented during the progression of various cancers (Klein and 
Klein, 1985). Increased expression of specific adhesion molecules (Section
1.4.6) has been implicated in the increased spread of malignant melanoma 
(Johnson et al., 1989). In contrast with these results in melanoma are the 
findings from colorectal cancer where allelic deletions involving chromosome 
18q, which occur relatively late in progression, have been determined to 
involve a gene specifying a protein with sequence similarity to neural cell 
adhesion molecules (Fearon et al., 1990). Whether these changes in genes 
encoding in cell- cell adhesion molecules is involved in controlling the 
metastatic potential of tumours is yet to be determined.
Conversion of non metastatic tumour cells to fully metastatic phenotype has 
been achieved in a number of experimental tumour systems by transfecting the 
benign population with an activated oncogene, generally of the ras family 
(Section 1.6.1) (Kyprianou and Isaacs, 1990).
A possible candidate for a metastasis- regulating gene, nm 23, has 
been identified, and is expressed to different degrees in cells of differing 
metastatic capacity (Steeg et al., 1988). It was originally identified and 
isolated from variant lines of a murine melanoma cell line, but the human 
homologue of this gene has now been cloned (Steeg and Liotta, 1990).
9Expression of nm23 RNA was found to be down regulated in metastatic 
variants in a wide variety of experimental tumour models.
Thus, work is being performed to identify genes controlling the 
metastatic potential of tumours. In addition it would be interesting to ask 
why tumours metastasise to one area of the body in preference to another.
1.3 UVEAL MELANOMA
1.3.1 Introduction
Uveal melanoma is a malignant neoplasm that occurs in the iris, ciliary 
body, or the choroid (Section 1.1) (Figure 1.1), and is derived from 
melanocytes of the neural crest origin (Rawles, 1947). They contain the 
pigment melanin, synthesised from tyrosine via DOPA (3,4- 
dihydroxyphenylalanine) and dopaquinone, using tyrosine as a catalyst. 
Although apparently amelanotic tumours are well recognised, they usually 
contain small amounts of melanin. Metastatic secondary tumours may lose 
their ability to secrete melanin. The neural crest -derived melanocytes and the 
tumours that arise from them are more like those found in the skin and much 
research performed into ocular melanomas shadows that into cutaneous 
melanomas.
Intraocular melanomas, like their cutaneous counterparts, are 
considered to be relatively antigenic, and studies using animal models 
suggests immunological responses elicited by uveal melanomas may influence 
the development of systemic metastases (Niederkom, 1987).
1.3.2 E pidem iology
Malignant melanomas are the most common primary tumours of the 
iris; their reported incidence varies between 49% and 72.4% (Heath, 1964; 
Duke etal .,1958; Ashton, 1964). The incidence of malignant melanomas of 
the iris compared with the incidence of melanomas of the rest of the uvea is
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low, but the ratio varies in the different countries, for example, 1:6 in 
Germany (Holland, 1967), 1:15 in the United States (Ranes etal .,1958),
1:19 in Finland (Raivio, 1977), and 1:30 in Denmark (Jensen, 1963). In 
general the incidence is approximately 6 per million per year in Caucasians 
(Jensen, 1963) and much lower in the pigmented races (Apple et al .,1983).
The sex ratio is approximately equal and although there have been reports of a 
higher incidence of melanoma of the iris in women (Martin- Jones ,1946), 
there are also reports of the opposite to this (Cleasby, 1958; Callender et a l ., 
1942) The mean age of presentation of uveal melanomas is 53 years 
(Benjamin et aL, 1948).
1.3.3 H istology
Uveal melanomas consist of pure spindle cells (Figure 1.2), pure 
epithelioid cells (Figure 1.3) but more commonly mixed spindle/ epithelioid 
cell populations (Figure 1.4). The cell type determination is a useful 
prognostic indicator for the survival of the patient after enucleation. Evidence 
of epithelioid cells is associated with a poor outlook (Callender et al 1942). 
Histologically, aggregates of lymphocytic infiltration are seen in about 5-12 % 
of uveal melanomas (Lang et al .,1977; Durie et a l , 1990) (Figure 1.4).
1.3.4 Diagnosis and treatment
Most patients with intraocular melanoma initially complain of painless 
deterioration of their vision. The tumour can be diagnosed sometimes only 
during routine ocular examination or it can be identified when the painful eye r
is removed (enucleation), upon loss of sight. In the latter, the media is opaque 
(Makely and Tweed, 1958) and thus the tumour cannot be identified during 
examination of the intact eye. Examination is by ophthalmoscopy (Norton,
1965), transillumination (Coleman et al., 1974), computerised tomography 
(Mafee et al., 1985), and magnetic resonance imaging ( Chambers et al.,
Figure 1.2: Photograph (x25) of tumour section (stained with
haematoxylin and eosin) containing pure spindle 
cells.
Figure 1.3: Photograph (x25) of tumour section (stained with
haematoxylin and eosin) containing pure epithelioid 
cells.

EPITHELIOID
CELLS
LYMPHOCYTIC AGGREGATES
SPINDLE
CELLS
Figure 1.4: Photograph (X40) of tumour tissue section (stained with
haematoxylin and eosin) containing mixed spindle and 
epithelioid cell populations. Lymphocytic aggregates can 
also be detected in this tissue section
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1987). The uptake of the radioisotope, 32P, or other radioactive tracers 
(Packer, 1984) can also give useful information about the tumour, but one of 
the best method for diagnosis is by histological examination of the tissue 
samples obtained by biopsy (Foulds, 1985).
Until recently the standard method for the treatment of uveal 
melanomas has been enucleation, except for iris melanomas which can be 
easily excised. This has lead to mixed reports that removal of the eye actually 
results in an increase in the mortality rate of patients with uveal melanoma 
(Zimmerman etal., 1978). Other workers have challenged the statistical 
methods on which such impressions are based (Seigal et al.,1979) and thus 
consider prompt enucleation to be life- saving (Manschot etal., 1980). The 
latter hypothesis is supported by reports of a very high mortality from 
metastatic disease in patients with uveal melanoma who refuse treatment. 
(Raivio, 1977). Some workers have suggested that removal of the primary 
tumour interferes with protective immunological mechanisms (Zimmerman et 
al., 1979), but these results were obtained by the use of animal models.
Thus conservative forms of therapy aimed at eradicating the tumour 
whilst preserving a functional eye have been developed. These include 
photocoagulation (Meyer- Schwickerath and Bomfeld, 1983; Foulds and 
Damato, 1986), photochemotherapy using photosensitising agents (Tse et 
al., 1984), radiotherapy (Fairchild, 1984), and surgical resection (Foulds, 
1978). These methods used either alone or in combination have proved 
successful in over 80% of cases, and seem to prevent metastatic disease as 
effectively as enucleation
1.3.5 Prognosis
Following enucleation, orbital recurrence occurs in 2.5-12% of cases 
and metastatic disease ultimately arises in about 50% of all patients, usually 
within the first 5 post- operative years (Jensen 1982).
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The risk of metastatic disease has been studied by a number of 
workers (Davidorf and Lang, 1974; Shammos and Blodi, 1977; Packard,
1980; Seddon et al., 1983) and they have shown that poor prognosis is 
associated with tumour size, anterior location, extraocular extension, epithelial 
cellularity (Section 1.3.3) and nucleolar pleomorphism. Metastases first tend 
to appear in the liver and cause death within a few months ( Char, 1978).
High mortality is also associated with a rare subtype of uveal melanoma, 
consisting of flat diffuse tumours (Font et al., 1986). Liver disease (Pascal et 
al., 1988), intercurrent illness (Leff et al., 1985), pregnancy (Apple et al., 
1983) and smoking (Keeney et al., 1982) all have been considered to have 
adverse effects on survival.
1.4 GENERAL IMMUNOLOGY
1.4.1 Major Histocompatibility Antigens
The MHC is a genetic region found in all mammals whose products 
are primarily responsible for rapid rejection of grafts between individuals. In 
man the MHC is the HLA gene cluster present on chromosome 6, and 
occupies about 1/3000 of the total genome. Three major sets of molecules are 
encoded within this region: Class I,II, and ID antigens. Class I and II genes 
encode molecules involved in immunological recognition. Class in genes 
encode some of the complement components concerned in the cleavage of C3, 
a central event in the generation of a B cell inflammatory response.
The products of the Class I gene (Class I antigens) comprise a 
transmembrane glycoprotein, encoded by the HLA-A, -B, and -C genes, that 
is non- covalently associated with the polypeptide p2- microglobulin which is 
encoded outside the MHC (Bjorkman et al., 1987). Class II proteins consist 
of 2 non- covalently associated peptides, referred to as a  and P chains, both 
of which are encoded by the MHC. The class II ap heterodimer assembles
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transiently in the endoplasmic reticulum (ER) with a third chain, the invariant 
chain, to form a heterotrimeric complex.
1 .4 .1 .1 Structure of the Class I MHC
The structure of the Class I antigens differs from that of the Class II 
antigens (Section 1.4.1.2). Each Class I antigen consists of one glycosylated 
polypeptide chain (Mr 45,000) non- covalently associated with non­
glycosylated peptide (p2- microglobulin Mr 12,000) (Figure 1.5). p2- 
microglobulin also occurs free in serum or urine as a small globular peptide 
which has a similar tertiary structure to an immunoglobulin constant region 
domain. It is non-covalently bound to the a3 domain of the Class I heavy 
chain on the outer side of the plasma membrane. The highly conserved a3 
domain does not directly interact with antigen or the T Cell Receptor (TCR) 
(Section 1.4.3) but can influence recognition of antigenic determinants located 
within the a l  and a2 domains (Maziarz et aly 1988). Three Class I loci have 
been localised to the human MHC: HLA-A, HLA-B and HLA-C. Using X- 
ray crystallography Bjorkmann et al (1987) have shown that antigen peptides 
bind to a cleft between a l  and a2 domains (Section 1.4.4). With few 
exceptions, Class I heavy chains seem to need p2- microglobulin and a tightly 
bound peptide for their conformational integrity (Cresswell et al,, 1987; 
Townsend et al., 1989; Schumacher et al.y 1990; Townsend et al., 1990).
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Figure 1.5: A schematic diagram of the structure of the
Class I MHC showing the three domains and 
the (32 microglobulin.
1.4.1.2 Structure of the Class II MHC
The Class II antigen consists of 2 distinct polypeptide chains (Figure
1.6), the a  chain and the (3 chain. Both chains traverse the membrane and are 
held together by non- covalent forces. They each carry carbohydrate and the 
shorter p chain ( Mr 28,000) contains the alloantigenic sites. Both chains also 
have 2 globular domains and all except the a l  domain are stabilised by 
disulphide bonds. Three families of Class II antigens have been characterised 
in man, HLA-DR, -DQ and -DP. Class I and Class II contain element that 
have conserved primary sequences, suggesting Class II molecules may be 
structurally similar to Class I.
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Figure 1.6: Schematic representation of the Class II
MHC molecule.
1.4.1.3 Function o f the MHC
T cells recognise short peptides from processed antigens in the 
framework of MHC Class I and Class n  products (Townsend et al 1985). 
CTLs involved in recognition and rejection of virally infected cells and foreign 
tissue grafts recognise HLA-A and -B on the foreign cells, and in cooperation 
with T- helper (Th) cells, cause the destruction of the foreign cell. CTL of a 
particular haplotype from an animal infected with a virus are primed to kill 
cells infected with that virus. It is found that they will not kill cells of a 
different haplotype infected with the same virus. Similar principles of
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haplotype restriction apply to T- h cells which recognise antigen on 
macrophages and B cells.
In general, T cells do not recognise free antigen. They recognise it on 
the surface of other cells, such as specialised antigen presenting cells (APC), 
including macrophages, bone- marrow- derived dendritic cells and vascular 
endothelial cells, or on virally infected cells as mentioned previously. APC 
actually take up the antigen that they will present The antigen is internalised 
by APC and are then degraded by proteolytic enzymes in the 
phagolysosomes. Some of the material is only partly degraded and is re­
expressed at the cell surface, where it comes to be physically associated with 
MHC molecules (Section 1.4.4)
Proteins must be processed, and presented to T cells. For viral and 
endogenous proteins this involves intracellular degradation to an oligopeptide, 
binding to a Class I MHC molecule, transportation to the cell surface and 
finally engagement with the TCR. In vivo, peptide binding to class I MHC 
molecules is restricted to the ER (Section 1.4.4.1). The source of the peptide 
can be protein found in a variety of cellular locations including the cytoplasm, 
nucleus and mitochondria. The fact that intracellular membranes prevent 
simple diffusion of other intact or degraded proteins from these compartments 
to the ER, indicated the involvement of a specific transport mechanism 
(Townsend et al, 1985).
In addition to MHC antigen and TCR interactions, it has been shown 
that CD8 and CD4 on T cell subsets appear to function as cellular adhesion 
molecules in the binding of antigen- bearing cells (Bierer and Burakoff, 1988) 
(Section 1.4.2). It has been demonstrated that CD8 interacts with the a3 
domain of Class I (Ratnofsky et al., 1987), and that CD4 interacts with Class 
II (Sleckman et al., 1987). Class I- CD8 binding can occur on non- T cells 
(Norment et a l , 1988) and can be inhibited by either antibodies to CD8 or
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Class I MHC indicating that CD8 can interact with class I MHC molecules 
independently from the TCR.
1.4.1.4 HLA disease association
Various HLA molecules have been found to be associated with a long 
list of diseases including multiple sclerosis, psoriasis, haemachromatosis, 
coeliac disease and diabetes mellitis, myasthenius gravis, ankylosing 
spondilitis and thyrotoxicosis (Tiwari and Terasaki 1985). Of these diseases 
multiple sclerosis, diabetes mellitis, myasthenia gravis, and thyrotoxicosis 
have implications for ophthalmology.
In ocular tissues, Class I HLA molecules are expressed in the vascular 
endothelium. Opinions differ as to whether other ocular tissues express Class 
I or Class II HLA molecules in the absence of disease. (Bakker and Kijlstra,
, 1985)
1.4.2 Role o f CD4 and CD8
The cell specific CD4 and CD8 glycoproteins which are encoded by 
genes which are cloned and well characterised, separate most mature T 
lymphocytes into mutually exclusive subsets. In general, most Th cells 
express the CD4 surface marker and recognise antigen in association with 
Class II MHC molecules while cytotoxic cells (Tc) express CD8 on their 
surface and recognise antigen in association with Class I molecules (Section 
1.4.1).
CD4 is single chain polypeptide of Mr 55,000-67,000. CD8 can be 
expressed as a heterodimer of a  (Mr 34,000-38,000) plus (3 (Mr 28,000- 
30,000) subunits, or as a - a  homodimer (Figure 1.7). CD4 and CD8 appear 
to stabilise and increase the avidity of the interaction between TCR- CD3 
(Section 1.4.3.2.) and the antigen- MHC complex (Section 1.4.1) by binding 
to monomorphic determinants on MHC Class I and II molecules. This
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association may link CD4 and CD8 to the TCR- CD3 complex during antigen 
presentation (Section 1.4.4.) (Figure 1.8).
CD4 and CD8 possess intracellular domains that physically associate 
with the T cell specific tyrosine protein kinase, pp56 ^  (Rudd e ta l, 1988; 
Veillette et a l , 1988). Close association of CD4 and CD8 to the TCR-CD3 
complex during T cell activation by antigen or mitogen might allow p p 5 6 ^  to 
phosphorylate physiological substrates, such as the £ chain of the TCR-CD3 
complex. (Biniyash etal, 1988 a) (Section 1.4.3). Thus CD4 or CD8 may 
play important role in regulating tyrosine phosphorylation in T cells.
It has also been suggested that CD4 and CD8 have influence in the 
selection of TCR repertoire in the thymus (Von Boehmer et a l, 1989).
Signals delivered via CD4 or CD8 in differentiating thymocytes may act 
together with some yet undefined thymic ligand to influence the negative or 
positive selection of T cells.
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Figure 1.7: Structure of the CD4 and CD8 molecules.
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Figure 1.8: Diagram illustrating the interaction
between CD4/CD8 with the TCR -CD3 
complex and the MHC Class II.
1.4.3 T Cell Antigen Receptor- CD3 Complex
The main recognition and activation element that acts during 
physiological T cell responses to antigen is a complex receptor. It consists of, 
first, clonally distributed, highly polymorphic subunits namely the T- cell 
antigen receptor (TCR) whose function is to recognise and specifically bind 
antagonistic peptides presented by MHC molecules (Section 1.4.1) and, 
second, a complex termed "CD3" (formerly T3). CD3 is composed of at least 
5 distinct invariant polypeptides some or all of which are believed to function
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as the signal transducing unit of the receptor complex. TCR and CD3 
associate non- covalendy to form the complete and functional receptor.
1.4.3.1 Structure of the CD3 Molecule
The CD3 complex was initially identified by the monoclonal antibody 
OKT3 (Kung et a l 1979), as a specific T cell marker on human T cells. To 
date 5 distinct polypeptides termed y,S,e,£ and rj have been identified in non- 
covalent association with the clonotypic a -  (3 TCR. These proteins range in 
size between molecular wieghts of 16,000 and Mr 28,000 . The y and 5 
subunits contain 1 to 3 extracellular N- glycosylated sites, while 8, £ and r\ 
are non- glycosylated (Samelson et al .,1985; Baniyash et al .,1988a). About 
90% of £ is found as a homodimer, and the rest forms a heterodimer with the 
rj subunit (Samelson et al ,1985; Weissman et al 1986). The r[ chain is not as 
well characterised as the other subunits. A CD3 subunit, termed p21, which 
becomes phosphorylated on tyrosine residues in response to antigen 
stimulation (Samelson et al ,1986) was found to represent the phosphorylated 
form of £ ( Baniyash et al 1988b). When T cells are activated by antigen, the y 
and 8 chains become phosphorylated on some residues and £ is 
phosphorylated on tyrosine residues, y,5,8,and £ components contain a 21 to 
22 amino acid signal peptide, and a hydrophobic transmembrane domain 
consisting of 21- 27 amino acids, in all cases , a centrally located acidic 
residue (glutamic acid in y and aspartic acid in 8, e and Q. This contrasts with 
the basic residues found in the corresponding domains of all clonotypic TCR 
subunits (Yanagi et al 1984; Hedrick et al 1984). These charged residues 
could form salt bridges between the TCR and CD3 and may stabilise the non- 
covalent association of the various components within the hydrophobicity of 
the T cell membrane, y, 8, and e polypeptides have large extracellular domains 
(79-104 amino acids) with a cytoplasmic domain of 44- 79 amino acids, while 
£ has a 9 amino acid extracellular domain and a much larger cytoplasmic
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domain of 112-113 amino acids. The cytoplasmic region of £ chain has 6 
(murine) or 7 (human) tyrosine residues that are potential substrates for 
tyrosine protein kinases and also possess a consensus ATP binding sequence 
(Kung etal .,1979; Weissman etal .,1988a).
Wiessman et al .,(1988b) have proposed 2 structural classes of 
receptor complexes displayed on T cells. One class, the majority, contains 
only homodimers while the other classes (10-20%) contains the ^-rj 
heterodimers. The two subclasses may represent 2 receptor classes coupled to 
2 distinct signalling pathways. The £ chain appears to be the limiting factor 
for assembly of the mature receptor complex, emphasising its crucial role in 
the synthesis and function of the complete receptor
1.4.3.2 Structure of the TCR
The TCR consists of 4 highly polymorphic proteins (cx,p,y and 8) that 
form two heterodimers (oc-p, and y - 8) similar to immunoglobulins in their 
overall primary structure gene organisation, and rearrangement patterns. Each 
of the polypeptides is similar in size (Mr 27,000- 34,000). The a -  P 
heterodimer mediates the specific recognition of antigenic peptides in the 
context of the MHC molecules. The exact function of the y - 8 TCR is largely 
unknown. Each of the 4 TCR polypeptides contains a single membrane- 
spanning region, and notably very short (up to 12 amino acids) cytoplasmic 
domains (Yanagi et al .,1984; Hedrick et al .,1984) suggesting that the 
polymorphic TCR does not play a direct role in signal transduction.
Because the different elements correspond very well to 
immunoglobulin domains and genes the same nomenclature has been adopted 
for TCR molecules. Each has a distinct variable (V), joining (J) and constant 
(C) region element and, in the case of P and 8 diversity (D) regions as well 
(Geliebter et al, 1986; Vega et al., 1985; Seeman et al., 1986; Van 
Schravendijk et al., 1985). It is interesting that polypeptides which contain D
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elements appear to pair only with those which do not (for example, TCR a  
/TCR p and TCR y / TCR 8).
The vast majority of T cells in normal mice and humans (including all 
functional Th and CTL lines) bear the cx/p type of receptor. Much less well 
expressed and less numerous is the y/S subset which appears early in the 
course of T cell differentiation (Mellor et al., 1983; Schulze et al., 1983). This 
subset normally constitutes only 1-5% of mature lymphocytes, but somewhat 
more in immunodeficient patients ( Hammering et al., 1985). Murine dendritic 
epithelial cells bear exclusively y/8 receptors (Koning et al., 1987; Kuziel et 
al., 1987), while the murine intraepithelial lymphocytes (IEL) not only have 
predominantly CD3- associated y/8 receptors but also express surface CD8 
(Goodman and Lefrancois, 1988). In contrast to murine IEL, human IEL 
have been reported to have low representations of the y/8 receptors in the 
normal individual, with raised levels being observed in coeliac disease 
(Raulet, 1989; Borst et al., 1988). The discovery that some y/8 T cells react 
with bacterial antigens and heat- shock proteins (Spencer et al., 1989) has led 
to the suggestion that y/8 T cells may play a role in cytolytic 
immunosurveillance for infected or transformed autologous cells.
Currently in humans, the V a  genomic sequence of the gene segments 
is estimated to contain approximately 100 members and the V p pool 
approximately 70 members which can be assembled with D,J, and C regions. 
The number of permutations created in mature a  and p chains by these 
events, and the association of the different a  and p chains into mature 
heterodimers leads to a considerable potential for diversity. For V y/8 TCRs, 
this potential for diversity also exists, but the pool of V y genes is smaller.
Based on similarities at the nucleic acid level, the V p pool of gene 
segment has been grouped into 18 "families". Likewise, the V a  pool of gene 
segments has been grouped into 19 "families" (Klein, et al .,1987; Toyonaga 
and Mak, 1987). Each family can contain between 1 and 10 members. Over
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the last few years, antibodies to V region determinants of murine and human 
TCRs have been developed. Some of these antibodies appear to recognise all 
members of a V region family, some a subset of V regions within a family, 
and some a particular V region only. These reagents have proven valuable in 
studying the repertoire of TCRs expressed under many in vivo and in vitro 
conditions.
1.4.3.3 Vp TCR region expression
The use of expanded populations of TILs for therapy (Section 1.5.7) 
appears promising in animal models of solid tumours and in human clinical 
trials of melanoma (Rosenberg et al., 1989), although the TCR genes 
expressed in tumour infiltrating lymphocytes (TILs) are not yet known. 
Recent evidence from studies in autoimmunity (Zamvil et al., 1985; 
Oksenborg et al., 1990) and allograft rejection (Miceli and Finn, 1989) 
indicates that effector cells may utilize a very limited range of TCR genes. 
Restricted gene expression has been demonstrated in encephalitogenic T cells 
mediating the autoimmune disease, experimental allergic encephalomyelitis 
(Acha- Qrbea et al., 1988), in T cells in demyelinating plaques from brains of 
patients with multiple sclerosis (Oksenberg et al., 1990), and on T cell 
populations on body surfaces such as skin, tongue, and vagina (Itohara et 
al., 1990). It has been reported that oligoclonality exists for TCR expression 
in bulk cultures of TILs analysed by southern (DNA) blots (Belldegrun et al.,
1989). Studies have also been undertaken to investigate the Vp product 
expression on chemically induced murine TIL containing tumours (Karpati et 
al., 1991). It was found that the TILs expressed all of the measured VP's and 
that TILs cultured in IL-2 initially expressed multiple VP product, but rapidly 
restricted their VP expression, frequently expressing a dominant Vp.
Populations of T cells expressing elevated levels of specific TCR V 
region epitopes (Section 1.4.3.2) have been identified in sarcoidosis (Moller 
et al., 1988), Crohn's disease (Schmelkin et al., 1989), cutaneous T cell 
lymphoma (Jack et a l , 1990) and also in human responses to "superantigens" 
(Kappler et al., 1989). Superantigens were proposed by White et al (1989) to 
describe several structures that stimulate T lymphocytes by novel 
mechanisms (Figure 1.9). They are distinguished from antigens by the high 
frequency of responding T cells (approximately 5%- 25%); they are also 
distinguished from polyclonal T cell mitogens, such as concanavalin A (Con 
A), by the fact that the stimulus activates the T cell by binding a specific site in 
the variable portion of the p chain of the specific TCR. At present there are 2 
main catagories of superantigens with closely similar properties: the toxin 
molecules produced by certain bacteria and recently characterised products of 
mouse MMTV virus (Choi et al., 1991; Reviewed by Acha- Orbea, H., and 
Palmer, E.,1991). These toxins, including the staphylococcal toxins, do not 
stimulate all T cells, and each toxin reacts mouse or with human T cells 
bearing particular VP sequences as part of their receptors. It has been 
suggested that CTLs isolated from tumour draining lymph nodes of pancreatic 
cancer patients express the oc/p heterodimer rather than the y/8 receptor, which 
is commonly associated with MHC- unrestricted killing (Borst et al., 1987). 
Further studies demonstrated that the specific epitope recognised by these 
CTLs was present on a mucin polypeptide core (Bamd et al., 1989). Thus 
perhaps these mucins are being recognised as tumour- associated antigen and 
eliciting a CTL response, and because of the association with oc/p TCR 
expression may be acting as a superantigen (Jerome et al., 1991). Previous 
work analysing Vp usage in numerous in vivo and in vitro systems has 
provided varying results. In a number of cases (Topalian and Rosenberg, 
1990; Weber and Rosenberg, 1990; Posnett et al., 1990; Moebius et al.,
1990) selective VP usage in response to antigen has been noted.
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Figure 1.9: Schematic representation of the trimolecular
complex of Superantigen- TCR VP - MHC 
Class II.
1.4.4 Antigen presentation
The TCR does not recognise free antigen but recognises small peptide 
fragments derived from proteins associated with products of the MHC. 
Fragmentation of viral, bacterial or parasitic polypeptides is carried out by 
proteases. The resulting fragments are associated with the MHC within the 
cell (Section 1.4.1) and the complex of peptide and MHC is displayed on the 
cell surface. MHC- restricted recognition of foreign antigen by T cells,
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reflects the specificty of the TCR (Section 1.4.3) for the complex of the MHC 
molecules and antigen fragments. MHC molecules interact with processed 
antigen independently of the TCR engagement (Babbitt et al, 1985). A peptide 
of 7-10 residues may normally occupy the MHC Class I cleft (Van Bleek and 
Nathensen, 1990; Ratzschke et al., 1990).
1.4.4.1 Class I MHC- antigen presentation
For MHC Class I (Section 1.4.1) it is likely that under physiological 
conditions most Class I molecules arrive at the cell surface complexed with 
processed antigen fragments. Evidence suggests that peptide charging occurs 
in the ER, and that peptide association is required for the physiological 
stabilisation of the Class I- p2- microglobulin complex and subsequent 
efficient transit out of the ER through the secretory pathway. There is 
evidence that in normal cells a small fraction of MHC Class I p2- 
microglobulin dimers do assemble and transit from the ER to the cell surface 
without peptide (Ljunggen et al., 1990), and it is possible that 'empty' MHC 
Class I (32- microglobulin dimers might encounter cytosolic peptides in post- 
ER compartments during transit to the cell surface. The inefficient recognition 
of endosomally- processed antigen is due to the fact that most Class I 
molecules that come into contact with this processed antigen are already 
associated with ER- derived peptide. Newly synthesised MHC Class I 
molecules do not join with the endocytic pathway on the exit to the cell 
surface (Neefjes et al., 1990). MHC molecules at the cell surface do not 
internalise and recycle through an endosomal compartment.
In the absence of peptide, the association of Class I heavy chain (la) 
and p2 microglobulin leads to an unstable complex, which is inefficiently 
transported out of the ER and empty la  heavy chains may be degraded in the 
ER. In the presence of peptide, la  and p2- microglobulin form stable 
complexes which are efficiently transported to the cell surface. At the cell
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surface empty Ia-p2 microglobulin complexes may dissociate and isolated 
heavy chains may be degraded. At the cell surface the full complexes 
dissociate releasing the weakly bound peptides. Empty unstable la  chains 
may be charged by exogenous peptide in the presence of exogenous P2- 
microglobulin and may form stable complexes (Braciale and Braciale 1991).
1.4.4.2 Class II MHC- antigen presentation
The structural constraints on MHC Class II (Section 1.4.1) molecule 
assembly, transport and stability appear to be less stringent that those of MHC 
Class I molecule assembly and transport. Cells lacking invariant chain 
assemble, transport and display normal levels of Class II ap heterodimers. 
There is dispute over whether Class II can be charged with peptide in the ER. 
Nuchtem (1990) reported the contribution to the pool of MHC class II antigen 
complexes supplied by pre- Golgi compartment processing. Jaraquemada et al 
(1990) have also reported the presence of an endosomal route of antigen 
presentation. When a gene encoding a pre-processed antigen site recognised 
by both CD4 and CD8 T cells existing in the form of exogenously added 
peptide was expressed in the cell cytoplasm, it was found only to charge 
Class I molecules (Sweetser et a/.,1989). Thus perhaps Class I, and not Class 
II molecules appear to be efficiently charged in the ER. Braciale et al (1990) 
have since proposed that newly synthesised glycoprotein antigens must enter 
a post- Golgi compartment in order to be processed/ presented in association 
with MHC Class II molecules.
The method of antigen presentation for Class II - antigen presentation 
may be as follows. The MHC Class Da (Da) and Class Dp (Dp) assemble in 
the ER along with the invariant chain (Ii) to form a stable trimolecular 
complex. Ii is thought to inhibit binding of peptide. Ii is then proteolytically 
cleaved when the complex is shuttled to the endosome. Loss of a portion of Ii 
may lead to peptide binding. Binding of peptide may lead to further cleavage
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of Ii resulting in exit of the peptide Ha- np  complex to the cell surface. Ha 
and Up complexes can assemble in the ER in the absence of Ii and transit to 
the cell surface.
1.4.5 Interleukin 2 Receptor
The idea that immune responsiveness and immune memory are 
influenced by interleukins was first introduced when the T cell growth factor, 
interleukin 2 (IL-2) (Gillis et al., 1978), was found to bind with high affinity 
to sites expressed only on antigen- or lectin- activated T lymphocytes (Robb et 
al., 1981).When cells are stimulated with a mitogenic lectin such as Con A, 
IL-2 appears in the culture medium during the first 24-48hrs but then declines 
rapidly, so that by 96 hr very low levels of activity are detectable. The decline 
in activity seemed to be due to some cellular consumption (Gillis, et al., 1978; 
Baker, et al., 1978). Confirmation of a cell associated removal of IL-2 from 
the culture medium was obtained when experiments were carried out in which 
the concentration of IL-2 was found to decrease progressively as the cell 
concentration increased (Smith, 1980). It has also been shown that only 
antigenI lectin -activated T- cells are capable of absorbing IL-2 activity (Smith 
et al., 1979), as lipopolysaccharide (LPS)- activated spleen cells, which are 
primarily proliferating B cells, absorb no IL-2 activity. The experiments that 
were carried out indicated that the disappearance of IL-2 was via its binding to 
cell surface receptors.
Radiolabelled IL-2 was first used to explore its binding parameters to 
various target cells. IL-2 seems to bind to a single mass of high affinity sites 
expressed on antigen- and lectin activated T cells (Robb, et al., 1981), and 
there was no difference when binding to whole cells is compared to binding to 
isolated plasma membranes (Smith, 1983). The availability of cloned IL-2- 
dependent cytolytic T lymphocyte lines (CTLL) (Baker et al., 1979), made it 
possible to compare the concentrations of IL-2 responsible for promoting T
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cell proliferation with those found to bind to high affinity IL-2 receptors. It 
was found that there was a linear relationship between occupancy of high 
affinity IL-2 receptors and the concentration of ligand required to effect a half- 
maximal response (EC 50). A maximal T cell growth response occurs at a 
concentration of IL-2 that yields 100% receptor occupancy, which indicates 
that there are no spare receptors.
The picture of the IL-2 receptor is however more complicated than 
this. A monoclonal antibody was found that was reactive with activated T 
cells (anti-Tac), and inhibited both radiolabeled IL-2 binding and IL-2 
dependent T cell proliferation (Leonard, et al., 1982). This antibody 
recognised about 10-20 fold more binding sites per cell than could be 
enumerated by IL-2 binding. A second class of IL-2 binding site was revealed 
by using 100- fold higher IL-2 concentrations, and this site was found to 
bind both the antibody and IL-2 (Robb et al., 1984). However this second 
class of binding sites was characterized by a 1000- fold lower binding than 
had been detected previously. It was found that a glycoprotein of Mr 55,000 
binds IL-2 with a low affinity only (Sabe et al., 1984), and the expression of 
two IL-2 binding proteins is required to form a high affinity IL-2 receptor 
(Tsudo et al., 1986; Teshigawara et al., 1987)). Thus high affinity IL-2 
receptors are constructed by cooperative binding of IL-2 to both the low 
affinity (p55 chain) and intermediate affinity (p75 chain) binding sites (Figure 
1.10).
Studies into the kinetic binding constants were performed in order to 
establish the method by which high affinity IL-2 receptors are formed from 
two distinct lower affinity binding sites (Wang and Smith, 1987)) It was 
found that IL-2 binds to and dissociates from p55 chains so rapidly that it is 
difficult to measure (half- times for dissociation t ^  = 2 seconds) compared to 
longer dissociation times for p75 and p55/p75.The combination of a rapid
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"on" rate and a slow "off' rate for the high affinity receptor makes for an 
affinity 100-1000-fold greater than IL-2 binding to either chain alone.
a75kD
Plasma membrane
Cytoplasm
Figure 1.10: Schematic representation of the IL-2 receptor
components
1.4.6 Adhesion m olecules
The interaction of lymphocytes with other cell types is critical for 
immune function and provides excellent opportunities to study the cell biology 
of dynamic cell- cell and cell- extracellular matrix interactions. Lymphocytes 
rapidly interconvert between a nonadherent state in the circulation and an 
adherent and highly motile state in lymphoid and other tissues. Mechanisms 
of lymphocytic adhesion may have a dual function: to provide a foothold for
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cell interactions and migration, and also to transmit information across the cell 
membrane. Rapid transition between adherent and non- adherent states is of 
key importance to the dual function of immune surveillance and 
responsiveness.
Three families of adhesion receptors mediate these interactions:
(1)the immunoglobulin superfamily, which include the 
antigen- specific receptors of T and B lymphocytes 
(Section 1.4.3),
(2)the integrin family, which is important in dynamic 
regulation of adhesion and migration, and
(3)the selectins which are prominent in lymphocyte and 
neutrophil interaction with vascular endothelium.
Among the cell- cell interactions relevant to this thesis are the interaction 
between 2 specific molecules: namely Lymphocyte function associated antigen 
(LFA-1), a member of the integrin family, and its counter receptor on the 
target cell intercellular adhesion molecule (ICAM-1) (Figure 1.11).
1.4.6.1 Structure o f LFA-1
LFA-1, like all members of its extended family, the integrins, is a 
heterodimer of two non- covalently associated transmembrane proteins. It has 
a unique a  chain (CD 11 a) and a p chain (CD 18) (Figure 1.11) which also 
constitutes part of the related molecules MAC-1 (CDllb) and pl50.95 
(CD1 lc). Both the CD18 and CD1 la chains are homologous to the chains of 
other integrins and share their distinctive features such as binding sites for 
divalent cations, including Ca^+. The most important difference is the 
inclusion in the CD 11 a, CDllb and CD 11c chains of an 'inserted (1)- 
domain' of about 200 amino acids near the amino terminus. Sites in this 1- 
domain might function as binding sites in cell- cell adhesion. The LFA-1
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molecule is widely expressed by cells of haematopoietic origin and is used in 
a variety of lymphocyte, monocyte, natural killer and granulocyte interactions 
with other cells (Springer et al., 1987; Mattz, 1987).
1.4.6.2 Structure o f ICAM-1 (CD54)
ICAM-1 is an integral membrane glycoprotein with 5 
immunoglobulin- like domains (Staunton et al., 1988), (Figure 1.11) and 
particularly strong homology to two immunoglobulin super gene family 
proteins important in neural cell adhesion: myelin associated glycoprotein 
(MAG) and neural cell adhesion molecule (NCAM). The possibility that 
carbohydrate may play a role in ICAM-1 function is highlighted by the 7 
possible N- linked oligosaccharides (at least Mr 20,000) and variations in 
glycosylation between different cell types.
Because it is an important ligand for LFA-1, ICAM-1 is fundamental 
to many immunologic reactions including antigen- specific recognition and 
lysis of certain target cells (Makgoba, et al., 1988). ICAM-1 has also been 
shown to be associated with the CD25 (Molecular weight 55,000) chain of the 
IL-2R (Ediden, et al., 1988) (Section 1.4.5) and is identical to a melanoma- 
associated antigen (Holzmann, et al., 1988; Vogetseder, et al., 1989; Matsui, 
etal., 1988) P3.58 (Section 1.5.5)
Inflammatory mediators, including LPS, y- interferon (y-INF), IL-1 
and tumour necrosis factor- a  (TNF- a) cause strong induction of ICAM-1 in 
a wide variety of tissues and greatly increase binding of lymphocytes and 
monocytes through their surface LFA-1 (Dustin and Springer, 1988). 
Endothelial, fibroblastic and epithelial cells vary as to which cytokines are 
capable of inducing ICAM-1 expression, and the types of mediators released 
may therefore help regulate differing patterns of cell localisation induced by 
inflammatory stimuli.
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1.4.6.3 Regulation of ICAM-1 expression
ICAM-1 is absent from most cells in normal, non lymphoid tissues, 
except for expression of low levels on endothelial cells. Local immune 
responses result in a rapid increase in ICAM-1 expression on endothelial cells 
and induction of ICAM-1 on epithelial cells (Wantzin etal., 1989; Munro et 
al., 1989). The increase of ICAM-1 expression on malignant melanomas and 
carcinomas may be secondary to local immune reactions generating cytokines 
(Temponi et al., 1989).
Plasma membrane
Tumour Cell 
or
Lymphocyte
ICAM-1
m LFA-1
t
e
Figure 1.11: Diagram illustrating the interactions between ICAM-
1 and LFA-1.
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1.5. TUMOUR IMMUNOLOGY
1.5.1 Im m unosurveillance theory
This theory states that malignancies express foreign determinants that 
can be potential targets of the immune system. (Burnet, 1964). T cell 
mediated immunity is thought to be present to eliminate cells as they arise due 
to the expression of novel epitopes. These new epitopes are consequently 
recognised as foreign. Lines of evidence available to support this theory 
include the increased occurence of malignant tumours in childhood and in old 
age. This can be explained by the fact that the immune system may not be 
fully functional at these times. It was found that due to the use of 
immunosuppressive drugs in transplantation studies in the 1960s, the 
incidence of malignancy, although only involving a few types of cancer,
, was ;,found to be higher in immunosuppressed patients. Recently the 
increased incidence of pathological immunosuppression associated with the 
human immunodeficiency virus (HTV) has also suggested a relationship 
between immunosuppression and the development of certain kinds of 
malignant disease.
There are two main criticisms of the theory:
(1) The first concerns the existence of tumour- specific antigens in human 
malignancy (Section 1.5.2). Studies in animal models have indicated that 
spontaneously arising tumours caused in the absence of known carcinogens 
display no detectable immunogenicity (Foley, 1953; Prehn, 1975). Hewitt 
(1976) also reported that spontaneously arising tumours when transplanted 
into syngeneic hosts elicit no detectable immunity. Because transplantation 
experiments cannot be performed on humans it is not known if human 
tumours express tumour- specific antigens analogous to experimentally 
induced animal tumours.
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It must be noted that epidemiological evidence clearly shows that the 
majority of human cancers are induced by physical and chemical carcinogens 
(Doll, 1980), including benz-a-pyrene in tobacco smoke, and radiation. With 
some viruses such as hepatitis B virus , the association is direct where as 
others it is indirect, for example HIV and Kaposi's sarcoma in AIDS 
patients,where the pathological immunodeficiency caused by the vims 
probably permits the reactivation of a latent cytomegalovirus infection.
(2) The second involves immunopotentiation of autologous tumour growth 
during carcinogenesis in vivo. Reduced latency of a tumour can be induced by 
immunostimulation (Prehn, 1977), thus enhancing tumour growth. This is 
not predicted by the immunosurveillance theory. Tumours with higher 
immunogenicity can have shorter latencies (Prehn and Bartlett, 1987).
Two mechanisms have been used to explain this phenomenon:
(a) T h cell subsets may stimulate tumours, followed by local release 
of lymphokines, promoting tumour cell growth.
(b) Certain antigenic epitopes on tumours might stimulate 
immunosuppression or tolerance in tumour- bearing hosts.
Consequently immune responses to tumours may not be deleterious toward 
the neoplastic disease development.
1.5.2 Tumour antigens
An immune response will be elicited in an immunocompetent host by 
any cell component that is new to the system. When a cell undergoes 
transformation it expresses molecules which, when recognised 
immunologically, not necessarily by the host of the tumour, are referred to as 
tumour- associated antigens. In theory these may be located within the cell or 
on the surface. The former is not a well studied idea since they are isolated
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from any specific antibody or cell-mediated reaction, by the cell membrane. 
Alternatively the expression of cell surface antigens may elicit some immune 
reaction, and it is with membrane- bound antigens that tumour immunology is 
principally concerned.
A method of classifying tumour associated antigens was originally 
introduced whereby antigens expressed solely by a single tumour were 
originally catagorised as class 1, those expressed by the same tumour type in 
different individuals as class 2, and those expressed by a wide range of 
normal and malignant cells, not necessarily of the human species, as class 3. 
(Old, 1981)
There is much inter- and intra- tumour heterogeneity (Miller, 1982; 
Natali et al., 1983; Heppner, 1984; Brstryn, 1985), which has obvious 
significance in the immunological diagnosis and therapy of cancer.
1.5.3.M elanom a associated antigens
Human cutaneous malignant melanoma is one of the best studied solid 
tumours. Specific Melanoma Associated Antigens (MAA) were originally 
identified on the surface of melanoma cells (Koprowski et al., 1978).
Various immunologically and biologically distinct antigenic structures have 
been identified along with a variety of less well defined antigens . Examples 
of these are reviewed by Herlyn and Koprowski (1988). Extracellular matrix 
proteins such as fibronectin are secreted in large quantities by melanoma cells 
but are not expressed on the cell surfaces (Herlyn et al., 1987). These 
extracellular proteins may be involved in adhesion (Section 1.4.6), motility 
and invasion of the tumours. Gangliosides and high -molecular -weight 
oncofeotal proteins are expressed on the cell surface and are shed. Cell 
surface receptors for growth factors and intracellular and extracellular cation 
transport and binding proteins are involved in the intracellular transport of 
biologically active material. Histocompatibility antigens (Section 1.4.1) are
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expressed and also shed by melanoma cells and they play a part in immune 
recognition. HLA DR is reported to be expressed on 75% of cultured 
melanoma lines (Reviewed by Taramelli et al., 1986) and primary tumour cell 
lesions expressing HLA DR are reported to have high metastatic potential, 
independent of tumour thickness (Brocker et al., 1985).
Several antigens on melanoma cells are associated with differentiation. 
Houghton et al (1986) and Real et al (1985) have proposed a differentiation 
pathway in melanoma based on morphological and antigenic studies of 
cultured melanocytes and metastatic melanoma cells.
1.5.4. MHC expression in malignancy
There is a vast literature covering the expression of HLA-A,B,C and 
D antigens (Section 1.4.1) in human malignancy (Doherty et al., 1984;
Tanaka etal., 1988; Bernards, 1987; Hammerling etal., 1987). Many studies 
have been performed using frozen sections stained by immunofluorescence 
and immunoperoxidase.
Analysis of MHC levels on certain tumours has suggested a decrease of 
MHC expression compared to normal tissues. Examples include infiltrating 
ductal carcinomas ( Natali et a l ., 1986), basal cell carcinomas (Turbitt and 
Mackie, 1981), colorectal carcinomas (Van den Ingh et al., 1987). Loss of 
Class I has been interpreted as the result of tumours escaping from T- cell 
immune attack, since a cell that does not express Class I determinants is 
protected from cytotoxic T- cell attack (Bodmer, 1987). There is a high 
frequency of individual Class I allele loss, most notably for HLA-A2 (Smith 
et al., 1989a). Perhaps loss of one individual allele may lead to a tumour 
having a major advantage in escaping from a particular T- cell immune 
response.
Locus- specific Class II (DR, DP, and DQ) molecules can be readily 
distinguished by monoclonal antibodies against non- polymorphic
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determinants. In certain cases, such as colorectal carcinomas (Momburg et al., 
1986) and lung carcinomas (Natali et al, 1986), de novo expression of Class 
II MHC antigens was observed. An extensive study of primary and metastatic 
melanomas cells was performed by Van Vreeswijk et al, (1988) who found 
differential expression of DR,DP, and DQ molecules in primary metastatic 
disease. HLA-DR and DP antigens were expressed in a higher percentage of 
metastatic than primary melanomas and there was no marked difference in 
HLA DQ antigens (Van Duinen et a l , 1988). Changes in the inducibility of 
HLA- class II determinants may be interpreted as the result of escape from T- 
cell immune recognition, either in connection with antigen presentation or 
Class II restricted cytotoxicity (Smith et al, 1989b). These changes in HLA 
expression identify those tumours which have definitely been subjected to T- 
cell attack, and thus express novel determinants that can be recognised by T 
cells.
Thus there are some changes in expression of MHC antigens in some 
malignancies, but there is no defined correlation between MHC expression on 
malignant transformed cells.
1.5.5 Theories on invasion and metastasis
Metastatic tumour cells (Section 1.2.3) disseminating through the 
blood stream must penetrate capillary basement membranes as they enter and 
exit the vascular compartment. However, this extracellular matrix (ECM) 
represents a significant mechanical barrier to invasion.
There is a 3 step hypothesis for invasion of ECM (Figure 1.12):
(1) The tumour cell attaches to the ECM through cell surface receptors that 
bind to specific adhesion molecules (Section 1.4.6) in the matrix, such as 
laminin, Type IV collagen, heparin sulphate, proteoglycan and fibronectin 
(Black and Horowitz, 1987; Hynes, 1987; Ruoslahti, 1988).
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(2) Next the ECM is locally digested by tumour cell associated or host 
associated hydrolases.
(3) Finally, the tumour cell migrates by active locomotion into the newly 
created void and forms new attachment sites.
The cycle is then repeated until the tumour cell has penetrated the entire 
thickness of the basement membrane.
Tumour 
Cell
1. AdhesionExtra- - 
Cellular' 
Matrix L
2.Migration BLOOD
3. Transendothelial 
migration 
>. 4 0 0 0 0 0 4
Basement 
Membrane
Figure 1.12: Diagram illustrating the invasion of a metastsising
tumour cell from the blood stream to the target 
tissue.
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Immunohistochemical analysis of in situ phenotypic changes 
correlating with tumour progression in human cutaneous melanoma has led to 
the identification of molecules potentially involved in metastasis (Holzmann, 
et al., 1987). One of these is the melanoma associated antigen P3.58. It is not 
detectable in quiescent melanocytes and only sporadically found in 
proliferating benign melanocytic lesions. On melanomas, the frequency with 
which this antigen is found increases with increasing tumour thickness. This 
P3.58 is found to be identical with ICAM-1 (Section 1.4.6).
It has been proposed by Johnson et al (1989) that the de novo 
expression of ICAM-1 by melanomas leads to heterotypic adhesion between 
melanoma cells and LFA-1 bearing lymphocytes and thereby causes the 
dissemination of cells from the primary tumour (Section 1.4.6)
The role of the mononuclear infiltrate in melanomas may be two sided:
(1) Infiltrating leucocytes have been shown to include cells specifically 
capable of killing tumour cells in vitro (Anachini, 1987).
However,
(2) By regulating gene expression in the tumour cells, the mononuclear cell 
infitrate may also play a direct role in the acquisition that contributes to the 
progression of the tumour toward metastatic disease (Johnson et al., 1989)
1.5.6 TILs as a prognostic indicator
The immunological role of lymphocytes and plasma cells in 
malignant neoplasms has been extensively studied in the past 2 decades. 
Speculations have been made on whether or not the presence of these 
mononuclear cells in tumours have an effect on patient survival.
Much work has been carried out to identify and characterise the 
presence of these tumour infiltrating lymphocytes (TILs) within malignant
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neoplasms. Such neoplasms include cutaneous malignant melanoma, lung 
carcinoma, breast carcinomas, lung cancer and medullary carcinomas. The 
presence of these TILs has been suggested to represent the cancer patient 
mounting an immune response to their tumours. This was suggested due to 
early studies carried out by Handley (1907) who reported the spontaneous 
regression of malignant skin melanomata that contained a "round cell 
infiltrate" and Da Fano (1912) who used animal models to illustrate that this 
infiltration might represent the host's tumour defence responding to the 
tumour. A better prognosis has been associated with lymphocytic infiltration 
in gastric cancers (MacCartey and Mahle, 1921), breast cancer (Sistrunk, and 
MacCartey, 1922), colon cancer (MacCartey, 1922) and medullary carcinoma 
(Moore and Foote, 1949; Cutler and Connelly, 1969; Bloom et al., 1970; 
Ridolfi et al., 1977). The positive correlation between the presence of 
infiltrate and prognosis illustrated in some of these early studies was rather 
weak, but interest into the presence of these TILs lasted with some 
contradictory consequences. In the case of breast carcinoma there have been 
reports indicating an improved survival rate due to inflammatory infiltrate 
(Ridolfi et a l , 1977; Black et al., 1975; Underwood, 1974), but there also 
exists reports that the infiltrate is associated with a poor prognosis (Rosen et 
al.y 1981; Fisher etal., 1983).
This controversy also extends into the field of not only malignant 
cutaneous melanoma but also malignant uveal melanoma. Some workers 
(Balch et a l ,1978; McGovern et al., 1981 and Bemengo, 1983) found that in 
malignant cutaneous melanoma there was a poor prognosis associated with 
the presence of lymphocytes. Lang et al (1977) also found that in malignant 
uveal melanoma that survival was better if the tumour contained lymphocytes. 
De La Cruz et al (1990) carried out a retrospective study of 1193 uveal 
melanomas, and performed histological examination to identify the presence 
of lymphocytes. It was found that 12.4% contained more that 100
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lymphocytes per 20 high power fields (HPF) and this was subsequently 
identified as the "high" lymphocytic infiltration group. The remaining were 
classified as containing "low" levels of lymphocytes. When these patients 
survival rates were followed through it was found that after 15 years 36.5% 
of the high lymphocyte containing group were alive, but 69.9% of the low 
lymphocyte group were still living. Thus it was concluded that an increase of 
lymphocytes per 20 HPF was significantly associated with decreased 
survival.
1.5.7 Adoptive immunotherapy of cancer
Alone or together, surgery, radiation and chemotherapy can cure or 
delay cancer in many of the people in whom it develops. However the 
incidence of cancer, and thus the number of deaths, remains high.
Recent strategies of immunotherapy of cancer patients involve what is 
termed as adoptive immunotherapy, or cell- transfer therapy. Lymphocytes 
are removed from a cancer patient and their native ability to kill tumour cells is 
enhanced by subsequent procedures. The cells are then returned to the 
patient's blood stream.
This adoptive immunotherapy has been studied by Rosenberg who 
since the late 1960's has studied over 700 patients with advanced cancer using 
variations of these methods.
Noting the presence of lymphocytes that invade a high number of 
tumours, Rosenberg studied methods of removing and expanding these 
lymphocytes that might have activity against the relevant tumour. The 
discovery of Interleukin 2 (IL-2) (Gillis et al., 1978)) (Section 1.4.5) and the 
introduction of methods of growing abundant quantities of T cells in culture 
with this cytokine provided a new approach. It was found that incubation of 
unseparated lymphocytes from a variety of sources, including peripheral 
blood lymphocytes (PBLs), spleen cells, thoracic duct lymphocytes in
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recombinant IL-2 for 3-4 days, generated cells referred to as lymphokine 
activated killer cells (LAK). These cells were capable of in vitro lysis of a 
variety of autologous and allogeneic fresh tumour targets but did not lyse 
normal tissue (Raynor et al., 1985). LAK cells are non- cytotoxic T cells and 
are derived from the "null" population that constitutes only 5% of the 
circulating lymphocytes. They are capable of mediating non- MHC restricted 
cytotoxicity (Grimm et al., 1985). These positive effector cells are CD3 
negative (Section 1.4.3), CD 16 negative, and derived from large granular 
lymphocytes or natural killer cells, together with a minor population of CD3 
positive, CD 16 positive/ negative cells also possessing MHC unrestricted 
cytotoxicity (Qrtaldo et al., 1986).
When adoptively transferred in conjunction with rIL-2, LAK cells 
were shown to mediate regression of established pulmonary and hepatic 
metastases in a variety of murine models (Mule et al, 1984), and were also 
thought to be effective in reducing metastatic tumours in clinical trials 
(Rosenberg et al, 1986). However, it was decided that the result showed 
limited antitumour activity in patients with malignant melanoma, renal cell and 
colorectal carcinoma, giving clinical responses rates of 35%, 21% and 17% 
respectively (Rosenberg et al., 1989)
In an attempt to improve the clinical response of cancer patients to 
immunotherapy, lymphocytes isolated from the tumour mass were assessed 
for the ability to promote tumour progression. Preliminary studies in murine 
systems indicated that these cells were 50-100 times more effective than LAK 
cells in mediating tumour regression (Rosenberg, 1986). This methodology 
was then applied to the human system whereby TILs were obtained by 
surgically removing a tumour nodule from patients resulting in about 50 x 10^ 
tumour cells which then were cultured in rhIL-2 until the tumour cells
9
regressed, giving extensive expansion of the TILs. Approximately 200 x 10 
of these cells were then re- administered intravenously, along with rhIL-2
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(Topalian et al.> 1987) TILs were successfully expanded on an experimental 
scale from 24 of 25 consecutive human tumours including 6 melanomas, 10 
sarcomas and 8 adenocarcinomas. In a clinical trial started in 1988, there was 
a 55% "response rate", twice as good than with LAK therapy.
Immunotherapy based on the administration of LAK cells plus IL-2 or 
in some cases IL-2 alone, can however produce some side- effects. The 
proliferation of lymphocytes in tissues can interfere with the function of vital 
organs. The administration of high doses of rhIL-2 leads to leakage of fluid 
from the blood into tissues, and weight gain from the fluid is common. Less 
commonly, the accumulating fluid impairs lung function and thereby impedes 
the delivery of oxygen to tissues. It is claimed that the mortality due to this 
treatment to be approximately 1% and in the remaining 99% the side effects 
disappear rapidly once treatment is completed.
Methods to optimise this treatment have been undertaken so as to define 
the in vivo distribution and survival of TILs. This involves using retroviral- 
mediated gene transduction to introduce the gene coding for resistance to 
neomycin into human TILs before their infusion into patients (Rosenberg et 
al., 1990). With the inserted gene as a stable component of the TIL genome, 
these cells and their offspring can be identified in long term studies even if 
they represent a tiny fraction of the total number of cells present. Using the 
polymerase chain reaction , gene modified cells were found to remain in the 
circulation of all the patients for 3 weeks and for as long as 2 months in 2 of 5 
patients. Cells were recovered from further tumour growth as long as 64 
days after the initial administration.
This particular study indicated the feasibility of using retroviral gene 
transduction for human gene therapy and there are consequent implications for
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the design of HL therapy with improved antitumour potency. Among the 
candidates are the gene for TNF and INF-a or perhaps for IL-2 itself.
1.6 GENETIC FACTORS IN MALIGNANCY
1.6.1 O ncogenes
Although it has long since been proposed that cancer is a disease 
associated with fundamental alterations of the cellular genome. However it is 
only within the last decade that it has been possible to identify growth 
regulating genes participating in the transformation process ( reviewed by 
Spandidos and Anderson, 1989). It appears that 2 classes of genes can be 
involved: (a) genetic elements which act dominantly to convert normal cells to 
transformed or malignant cells, termed oncogenes, (b) suppressor oncogenes 
which physiologically inhibit cell growth by inhibiting any of the cancer 
related phenotypes of the cell. Mutation leading to loss of function of these 
leads to loss of control. Such genes are termed "anti- oncogenes" and 
characterised by "loss of heterozygosity" in DNA blots.
Oncogenes are derived by genetic damage to proto-oncogenes which 
are normal constituents of cellular DNA. More than 59 oncogenes have been 
isolated and encode proteins with diverse functions. Some oncogene products 
are structurally similar to secreted growth factors such as platelet derived 
growth factor. Oncogene activation may lead to the production of growth 
factors by the tumours itself, for example TGF a  or p. Other oncoproteins are 
growth factor membrane receptors. Ras, src,fps and abl proteins are 
examples of oncopeptides located on the internal cytoplasmic membrane and 
are thought to act in a mitogenic pathway in the cytoplasm. The proto­
oncogene myc has been implicated in the pathogenesis of a wide range of 
neoplasms including breast, lung, stomach, colon carcinomas; leukaemias; 
neuroblastomas and glioblastomas. The biochemical function of myc remains 
unclear (Cole, 1986; Eisenman, 1989). A number of studies have suggested
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that myc might regulate transcription (Schweinfest et al., 1988), whereas 
others have suggested the role of myc in DNA replication (Hann et al.,
1988). This oncogene encodes a nuclear protein which shares sequence 
homology with a region of the adenovirus EIA protein and the simian virus 
SV 40 T antigen that is necessary for the interaction of the retinoblastoma 
locus, Rb (Figge et al., 1988).
Suppressor genes contribute to transformation only if both alleles are 
mutationally and functionally inactivated. This can be demonstrated in 
hereditary retinoblastoma which results from the loss of both alleles of the 
retinoblastoma gene (Rb-1) (Lee et al., 1987). Studies involving the 
adenovirus 2 EIA protein have suggested that the Rb-1 protein is a member of 
a signalling pathway that allows the cell to respond to environmental 
conditions, since it was found that EIA binds to several host proteins one of 
which was identified as the Rb-1 gene (Whyte et al., 1988). People with 
hereditary predisposition to retinoblastoma have a much increased risk of 
developing other non- ocular primary cancers such as osteosarcoma 
(Abramson, 1984). It was found that as with retinoblastoma, osteosarcoma 
also involves loss of heterozygosity of a gene on chromosome 13 that 
includes the Rb-1 locus (Hansen, et al., 1985). Thus, this Rb-1 gene may be 
more than merely a suppressor of retinoblastoma.
Although there have been several reports about the role of oncogenes 
in the pathogenesis of melanoma, virtually all such work has been performed 
on cutaneous melanoma (Albino, 1988; Albino et al., 1984; Price et 
a/,.,1989). The ras oncogene has been implicated in approximately 20% of 
cutaneous melanomas, and aberrations have been identified in chromosomes
1,6 and 7. The majority of mutations are found on the N- ras gene located on 
chromosome 1 (Bos, 1989). Ras gene products are known to comprise a 
family of proteins (Mr 21,000) designated as p21 ras. Due to the structural 
and functional resemblance of the ras proteins to the G-proteins controlling
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adenylate cyclase it has been proposed that in the normal cell, p21 ras 
proteins are involved in the transduction of external stimuli, most likely 
induced by growth factors. After transducing the signal to an effector 
molecule, normal ras proteins become inactivated. Thus mutated ras proteins 
lose the ability to become inactivated and growth and differentiation occur in 
an uncontrolled manner (Bos, 1989).
Another suppressor gene which has been found in association with 
colorectal carcinomas (Baker et al., 1989), lung cancer (Takahashi et 
al., 1989), brain (James et al., 1989) and breast tumours (Mackay et al.,
1988) is the p53 gene located on the short arm of chromosome 17 (Reviewed 
by Levine et al., 1991).
It has been realised that colon cancer, apparendy develops by a 
stepwise accumulation of several mutations including ras gene mutations, loss 
of chromosome 18 involving the DCC gene (deleted in colonic carcinomas 
gene) and the previously mentioned suppressor gene p53. It has been reported 
(Kinzler and Vogelstein, 1991) that loss of a chromosome 5 gene seems to 
appear early in development of colonic cancer, with the normal gene product 
having tumour suppressive effects functioning via a cytoplasmic signalling 
pathway involving interaction with a G protein.
It is now apparent that some of the changes that are part of the 
progression of a tumour toward malignancy give rise to mutations in proteins 
that are potential targets for the immune system, even when they are internal 
cellular products such as p53 and ras. As mentioned previously (Section 
1.5.4) some tumour cells can lack HLA Class I and thus are no longer 
susceptible to immune T cell cytotoxicity. If a tumour is thought to have lost 
expression of one or more HLA Class I determinants, this is suggested to be 
evidence that the tumour has been subjected to immune T cell attack and 
carries a genetic change that has been recognised by immune T cell (reviewed 
by Bodmer, 1991). This genetic change may involve such oncogenes or
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tumour suppressor genes as ras and p53 and these may be used as potential 
targets for immunodiagnosis.
The role of oncogenes and suppressor genes in the development of 
uveal melanomas is completely unknown, although, there is evidence for a 
role of immune surveillance in the control of growth of uveal melanomas 
(Section 1.5.1). The malignant transformation of cutaneous melanocytes and 
further neoplastic progression has been shown to be inversely related to the 
levels of HLA Class 1 antigen on their surface and the amount of Class 1 
antigen on the cell surface has been found to be controlled by the c- fos 
proto- oncogene (Feldman, 1988; D' Alessandro etal., 1987). The oncogene 
c- myc has also been implicated in the down regulation of HLA class 1 
antigens in cutaneous melanoma (Versloog, 1988).
The involvement of oncogenes in carcinogenesis is well established, 
but it is only fairly recently that the importance of onco- suppressor genes in 
this process has been appreciated. The limiting factor at present has been the 
lack of appropriate systems for identification of as yet unknown 
oncogenes.and tumour suppressor elements.
1.6.2 Ploidy analysis
1.6.2.1 Cell cycle analysis as an indicator for prognosis.
DNA cell cycle analysis of primary tumour cells gives information on 
both the nuclear DNA content (DNA ploidy), which is frequently abnormal in 
major subsets of cells within primary tumours* and the G2/M+S phase 
fractions of the cell cycle (Figure 1.13), which are considered to be a measure 
of the proliferative rate of a growing cell population. A number of studies 
have now suggested that DNA ploidy and cell cycle analysis are of prognostic 
relevance and predictive value in patients with epithelial tumours of the breast
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and colon. Aneuploidy has also been reported in bladder cancer (Murphy et 
al., 1986; Gustafson et al., 1982) and in stem cell malignancies such as 
ovarian tumours (Iversen and Skaarland, 1987; Friedlander et al., 1984). 
Aneuploidy has also been found in pre- malignant disease such as chronic 
atrophic gastritis (Teodori et al., 1984), and pre- malignant skin lesions such 
as solar keratoses,(Newton et al., 1987). Normal or reactive tissue is not 
associated with DNA aneuploidy (Barlogie et al., 1980) and thus DNA 
aneuploidy may be held to be implicit of neoplasia. Within this group, by far 
the most extensively studied is breast cancer where 65-74% of excised 
tumours contain a substantial aneuploid population and very large numbers 
(>1000 in some studies) of patient samples have been available for statistically 
relevant analysis. The aneuploid profile of breast tumours differs between any 
two patients, but is generally similar between primary and secondary growths 
within the same patient (Auer et al 1980a,b; Remvikos et al., 1988). Studies 
on both recurrences and overall survival, have suggested that patients with 
diploid, low S-phase tumour DNA profiles have a good prognosis (Eskelinen 
et al., 1989; Clark etal., 1989; Toikkanen et al., 1989; Comelisse et al.,
1987; Hedley et al, 1987; Kallioniemi et al., 1988; Olsz et al .1981; Moran et 
al., 1984). Similar data have been presented for colon carcinoma (Armitage et 
al., 1985).
Tumour ploidy cannot be used to differentiate between benign and 
malignant tumours as the latter are frequently diploid but many attempts have 
been made to correlate the degree of histopathologically defined tumour 
differentiation with tumour ploidy. In breast and ovarian cancer, these studies 
have found DNA aneuploidy to be significantly associated with axillary lymph 
node involvement (Eskelinen et al., 1989; Toikkanen et al., 1989),and 
histological grade/ steroid receptor status (Toikkanen et al., 1989; O’Reilly et 
al., 1990; Thorud et al., 1986; Moran et al., 1984; Kute et al., 1985; 
Kallioniemi et al., 1984; Feichter et al., 1988; Dowle et al., 1987; Thorud et
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al, 1986;Friedlander, 1984). It is suggested that the bulk of early tumours 
tend to be diploid while more advanced tumours contain significant 
populations of aneuploid cells (Iversen and Skaarland, 1987).
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Figure 1.13: Diagram illustrating stages of the cell cycle.
1.6.2 2 The DNA content of cutaneous melanoma
Newton et al (1988) performed DNA flow cytometry on formalin fixed, 
paraffin embedded melanocytic naevi. They reported aneuploidy especially in 
those naevi accepted as precursors of malignancy: that is, dysplastic and 
congenital pigmented hairy naevi. Congenital pigmented hairy naevi (CPHN) 
present even more of a management problem than do the dysplastic naevi.
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They may be small (less than 20 cm in diameter) or large. The giant CPHN 
can cover large areas of the body, especially the limbs, head and neck 
regions. All CPHN probably carry a risk of malignant change although the 
precise risk for the small naevi remains controversial. It has been estimated 
that for small CPHN a cumulative lifetime risk of 2.6% to 4.9% exists 
(Rhodes et al., 1985 ). The lifetime risk of melanoma for large lesions is 
probably at least 6.3% (Stenzinger et al., 1984). Excision of the majority of 
moderate to large CPNH in order to prevent malignant change is not a 
practical proposition because of the area of skin involved and also the 
considerable depth to which the melanocytes extend. Management is further 
complicated by the apparent lack of any correlation between histological 
degree of atypia and the risk of malignant change (Reed et al., 1965; Borges 
and Lineberger, 1984). A marker of malignancy would therefore be of 
considerable practical value to physicians who manage these cases.
In the study of Newton et al (1988), DNA aneuploidy was found to be 
higher in the giant CPHN than the small CPHN. This suggests that the risk of 
malignant melanoma could be higher in the giant naevi and thus the presence 
of aneuploidy indicates a higher risk of malignant change.
Previous studies, one of fresh tissue and one of formalin fixed tissue, 
have reported that a small percentage of benign naevi were aneuploid 
(Sondergaard et al., 1983; Von Roenn et al., 1986). One study of fresh tissue 
found no aneuploidy in 62 naevi (Stenzinger et al, 1984). Thus it is unclear if 
this indicates that DNA aneuploidy in naevi is not always associated with 
neoplasia potential or whether some apparent benign naevi do have a 
possibility of malignant transformation.
52
1.6.2.3 The DNA content of uveal melanoma
To date, flow cytometric studies of uveal melanomas have been limited 
to analysis of histological material recovered from paraffin embedded 
specimens (Meecham and Char, 1986; Shapiro et al., 1986), but many 
technical difficulties have been encountered including possible formalin 
induced artefacts, reduced fluorescent intensity and high levels of cellular 
debris which makes histogram interpretation difficult, (Shapiro et al., 1986) 
Meecham and Char et al (1986)demonstrated aneuploidy in 37% of tumour 
samples measured and also strong correlation of the DNA index with higher 
tumour- related mortality. Greatest tumour diameter and cell type also 
correlated with survival, but less strongly than did the DNA index. Thus it 
appeared that those patients in this particular study with elevated DNA indices 
were at greater risk of developing metastatic disease. In contrast, Shapiro et al 
.,1986) found the incidence of aneuploidy to be 77% and there was found to 
be no correlation between DNA (ploidy) index and death from metastatic 
disease.
Char et al (1989) made a histological study of uveal melanomas treated 
with surgery, low dose (20Gy) pre-enucleation radiation followed by 
enucleation, or enucleated melanomas after high- dose(50-80Gy) charged 
particle beam therapy. In this study the cells were labelled with 
bromodeoxyuridine (BdUR) (Section 5.1.1.3), stained with an anti- BdUR 
monoclonal antibody and analysed using the fluorescence microscope. There 
were more melanoma cells in the DNA synthesis phase in tumours that were 
not treated with ionising radiation than in irradiated uveal melanomas. Two 
colour flow cytometry was also employed and gave generally similar results. 
Samples with few or no cells in S phase had low counts with both methods, 
and higher BdUR uptake was noted with greater numbers of cells in S phase
53
by both methods. The lesser BdUR uptake in irradiated versus untreated 
melanomas, and the reduced ability of irradiated tumours to grow in tissue 
culture demonstrated that the helium ion irradiated melanomas had lost their 
reproductive integrity. Although the microscopic data showed little deviation 
from the flow cytometric data the authors were obliged to rely on the 
microscopic data since it allowed them to eliminate artefacts caused either by 
staining of debris or non- tumour cells infiltrating the melanomas (Guntuz, 
1985).
In a more recent report Rennie et al (1989) used flow cytometry in a 
study of the cellular DNA content of fresh tumour tissue from 19 uveal 
melanomas. It was found that 84% of the tumour samples were diploid and 
15.8% (3 out of 19) were aneuploid. This was low compared to previous 
studies (Meecham and Char, 1986; Shapiro et al, 1986) and could perhaps be 
result of sample number. An index of proliferation was also obtained 
(summation of G2M/S) and was found to be 5.96% (range 2.2-9.8%). It 
was concluded that spindle neoplasms appeared to have lower rates of 
proliferation than epithelial cell tumours, as has also been found in an earlier 
study by Augsberger et al (1984). There was also reported to be no 
correlation between cell turnover and either tumour size or anatomical 
location, although it is probable that tumour growth is not uniform with times 
of relative quiescence and increased activity (Char et al., 1983).
54
1.7 OBJECTIVES
1.7.1 Uveal melanoma
Uveal melanoma is a tumour which has several interesting features. 
Firstly its location in the eye, a site of immunological privilege, makes the 
nature of its interaction with the immune system an area of interest. Secondly, 
probably the most studied malignancy in tumour immunology is cutaneous 
melanoma and the relationship between this, and the parallel eye neoplasm, is 
a relevant area of study. Thirdly, Glasgow has been unusual in having unique 
access to uveal melanoma tissue via the Tennent Institute of Ophthalmology 
which a centre noted for its ability to remove the tumour leaving the vision 
functional.
1.7.2 Flow cytom etry
Flow cytometry is a technique which has been extensively used in the 
study of the immune response, particularly in cells of the blood. The 
advantages are many in comparison to a single individual making a subjective 
analysis down a microscope. Flow cytometry can analyse several thousand 
cells in a short period of time. It is not subjective and small changes within a 
population can be assessed. In the case of tumour cells, it has largely been 
used only for retrospective ploidy analysis. It is obviously of interest to 
extend the application of this technique to analyse fresh, living cells of the 
tumour and its associated lymphocytes in order to further elucidate the nature 
of the autologous immune response in uveal melanoma patients.
CHAPTER 2
MATERIALS AND METHODS
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2.1 MATERIALS
All routine chemicals are of the highest grade available and were 
supplied by Sigma Chemical Company or BDH Chemicals, both of Poole, 
Dorset, England, except for the following:
2.1.1 Human Tissue
Peripheral blood
Tumour samples
2.1.2 Tumour cell preparations
RPMI-1640 Gibco Ltd., Paisley, Scotland
DMSO BDH Chemicals Ltd., Poole
Foetal calf serum Imperial Laboratories, Andover, Hants.
2.1.3 Peripheral blood lymphocyte preparations
Ficoll- Hypaque Pharmacia Fine Chemicals
Uppsala, Sweden
Male and female patients with uveal 
melanoma, breast carcinoma (female 
only) or retinitis pigmentosa.
Patients with either uveal melanoma 
(provided by Dr B Damato) or breast 
carcinoma (courtesy of Professor W.D. 
George, Department of Surgery, 
Western Infirmary, Glasgow)
Plasticware Sterilin Ltd., Feltham, England
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2.1.4 DNA analysis solutions
as stated in section 2.222  
Nonidet P40 BDH Chemicals
Trypsin Sigma Chemical Co.
Trypsin Inhibitor "
Ribonuclease A "
Propidium Iodide "
2.1.5 A ntibodies
All antibodies were obtained from Becton Dickinson, Cowley, 
Oxford (Table 3.1) with the following exceptions:
Sheep anti- mouse Ig, (whole antibody)
FITC conjugated.
Mouse anti- human Vb region TCR 
FITC conjugated (Screening panel)
Mouse anti- human ICAM-1 (CD54) 
and LFA-1 (CD1 la)
2.1.6 R adiochem icals
Sodium Chromate (^^Cr) Solution (lmCi/ml) was obtained from 
Amersham International pic. Amersham, Bucks.
Amersham International pic., 
Amersham, Bucks.
T Cell Sciences, Inc. 
Cambridge, MA, USA
Generous gift from Dr D. 
Haskard, Dept. Medicine, 
Hammersmith Hospital
2.1.7 B uffers
Phosphate Buffered Saline (PBS) pH 7.4 
170mM NaCl 
3.4mM KC1 
lOmM Na2HP04 
1.8mM KH2PO
Citrate buffer pH 7.6 
250mM sucrose 
40mM trisodium citrate 
5% DMSO (v/v)
Sheath fluid pH 7.2 (FACScan fluid)
1.3mMNaCl 
0.02 mM KC1 
20mM LiCl 
15mMKH2P04 
lOmM Na2HP04 
lOmMEDTA
2.1.8 M iscellaneous
FACScan tubes (Falcon 2052) were purchased from Becton 
Dickinson, Cowley, Oxford.
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2.2 METHODS
2.2.1 Preparation and storage of tumour derived samples
2.2.1.1 Collection and storage of uveal melanoma tissue
Tumour tissue was obtained from uveal melanomas which were 
treated at the Tennent Institute of Ophthalmology either by local surgical 
resection or by enucleation. The tumour was first transported in saline to the 
Pathology laboratory. Triangular blocks (2-4 mm) were excised from the 
apical part of the tumour in such a way that the anatomy of the apex and the 
clearance margins were unaffected. These specimens were then taken to the 
Biochemistry laboratory, in a sterile container containing RPMI1640 tissue 
culture medium, where further processing was undertaken within 30 minutes 
of their excision.
2.2.1.2 Preparation of spilled cells
Tumour pieces were transferred into a 60 mm sterile petri dish 
containing RPMI 1640 tissue culture media. Spilled cells were teased out 
using a sterile needle and scalpel. The cells were then harvested, washed by 
centrifugation at 150g for 5 minutes, counted and adjusted to lxlO^/ml in 
RPMI 1640 medium. If these cells were not being used immediately, they 
were cryopreserved until use (Section 2.2.1.3).
2.2.1.3 Cryopreservation of tumour cell samples
The number of cells available for storage was determined by counting 
with a Neubauer Haemocytometer. The cell suspension was centrifuged 150g 
for 5 minutes at room temperature and the pellet was re-suspended in a 10% 
solution of DMSO in 90% PBS to achieve a final concentration of 
0.5-1 x lO^cells /ml. This cell suspension was transferred in 1ml aliquots to 
freezing vials which were placed in a -70°C freezer overnight prior to storage 
in a liquid nitrogen freezer.
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On removal from liquid nitrogen, each ampoule of cells was thawed 
rapidly in a 37°C water bath and immediately transferred to a universal 
container containing 15 ml of RPMI 1640 medium. This was centrifuged at 
150g for 5 minutes and resuspended at the required cell concentration in 
filtered PBS pH 7.4 ready for FACScan analysis.
2.2.1.4 Preparation of lymphocytes from human peripheral
b lood
Blood (10ml) was obtained by venipuncture from normal donors, 
patients with uveal melanoma, or patients with other eye conditions. The 
blood was stored in potassium - EDTA anti-coagulant until ready for 
processing, usually within 1 Hour of removal from the patient *
10 ml of blood was layered on top of an equal volume of Ficoll- Hypaque 
density gradient The tubes were centrifuged at 1400g for 20 minutes, and the 
lymphocyte layer pipetted off and added to a clean tube. The plasma, ficoll 
and red blood cells were discarded. The lymphocytes were then centrifuged at 
150g for 5 minutes and the supernatant was removed. The pellet was 
resuspended in 10 ml RPMI and the cells were washed once again.The 
subsequent lymphocytes were then either used fresh or frozen I for later analysis.
2.2.2 Preparation of FACScan Samples
2.2.2.1 General FACS procedures
Cell suspensions of TIL, tumour cell, and PBL were washed and 
resuspended in PBS at a final cell density of 10*7 m l. Cells (50|il) were 
incubated on ice with the appropriate antibody, for 20 minutes. All samples 
were maintained in the dark to prevent bleaching of the fluorochrome. If a 
double staining procedure was required then after the initial 20 minute 
incubation the cells were washed in 1ml of PBS for 5 minutes, the
6 0
supernatant was gently removed, and the cells were incubated in the 
appropriate antibody for 20 minutes. After the final incubation the cells were 
centrifuged at 150g for 5 minutes, the supernatant was again removed and the 
cells were resuspended in 0.5 ml of PBS and gently vortexed. Propidium 
Iodide (PI) was added to each tube to a final concentration of 2ug/ml, so that a 
live dead discrimination gate could be set (Section 2.2.4.1)
2.2.2.2 Preparation of nuclei for Flow Cytometric DNA  
analysis
This was performed by the detergent- trypsin method of Vindelpv et al 
(1983). Nuclei were prepared from lymphocyte and tumour cells using the 
detergent- Trypsin method. The following solutions were used in the 
preparation:
Citrate buffer:
sucrose 85.5g (250mM)
trisodium citrate 2 H2O 11.76g (40mM)
These were dissolved in approximately 800 ml CIH2O. 50ml of 
dimethylsulphoxide were added and then distilled water added to a 
final volume of 1000ml with the pH adjusted to 7.6.
Stock solution:
Trisodium citrate, 2 H2O 2000mg (3.4 mM)
NonidetP40 2000|il (0.1% v/v)
Spermine tetrahydrochloride 1044 mg (1.5mM)
Tris (Hydroxymethyl)- aminomethane 121mg (0.5mM)
These were dissolved in (IH2O to make a final volume of 2000ml. 
The pH was adjusted to 7.6.
This stock solution was used as the basis for the preparation of the 
staining solutions.
Staining solutions:
Solution A:
15mg trypsin dissolved in 500ml of stock solution and pH adjusted to
7.6.
Solution B:
250mg trypsin inhibitor 
50mg Ribonuclease A
Both were added to 500 ml of stock solution and the pH adjusted to
7.6.
Solution C:
208mg Propidium iodide 
580mg Spermine tetrahydrochloride
Both were added to 500 ml of stock solution and the pH was adjusted 
to 7.6. This solution was protected from light with tinfoil during 
preparation, storage and staining procedures.
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Long term storage of staining solutions:
The solutions were stored in 5ml aliquots in plastic tubes at -70°C. Before 
use the solutions were thawed in a water bath at 37°C (but not heated to 
37°C). Solutions A and B were kept at room temperature until use. Solution 
C was kept in an ice bath.
Staining procedure:
Solution A (900pl) was added to 200pl of the cell (10^) suspension in 
citrate buffer and the tube was inverted to mix the contents gently. After 10 
minutes at room temperature, during which time the tubes were inverted 5 or 
6  times, 750jil of solution B was added. The tubes were again inverted and 
after a further 10 minutes at room temperature 750pl of solution C was added. 
At this stage the samples were stored at 4°C and protected from light. The 
samples were analysed between 15 minutes and 3 hours after the addition of 
solution C.
2.2.2.3 Preparation of single cell suspensions from paraffin 
fixed tissue sections
This was performed by the method described by Hedley et al (1983). 
Tissue sections were dewaxed in xylene for 10 minutes, following which 
they were rehydrated by sequential immersion in 100%, 95%, 70% and 50% 
ethanol for 1 0  minutes each at room temperature and then finally washed 
twice in distilled water. The tissue was then resuspended in 0.5% pepsin, in 
0.9% NaCl, with the pH adjusted to 1.5 with 2N HC1 in a water bath at 
37°C. During this 30 minutes incubation the cell suspensions were frequently 
vortexed.
The nuclei were then prepared using the method described in Section 
2 .2 .2 .2 .
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2.2.3 Flow Cytometry
PBLs, TILs and tumour cells themselves were studied for the 
expression of specific cell surface markers by flow cytometry. The flow 
cytometer used was a Becton- Dickinson designed FACScan (Fluorescence 
Activated Cell Scanner), which is a laser - driven, automated cell analyser 
capable of detecting and analysing cells using 5 optical detectors, consisting 
of 2 physical parameters and 3 different spectral regions of fluorescence. The 
machine is dependent on the ability of the immunologist to provide high 
affinity fluorescently labelled monoclonal antibodies.
The FACScan can also detect 2 physical parameters: the amount of 
incident light scattered in the forward direction (FSC or forward scatter) 
which is a measure of the cell volume, and the amount of incident light 
scattered at 90 degrees. (SSC or side scatter) which gives an indication of the 
granularity of the cell. Cells can be identified by their specific size and 
granularity, and it is possible to utilise these parameters to place a gate round a 
particular cell population so as to distinguish it from other cell types present 
(Section 2.2.4.2)
2.2.3.1 Fluorochrom es used
Such fluorescent dyes include fluorescein-5- isothiocyanate (FITC) 
(C1 2H1 1NO5 S) which is a commonly preferred conjugate because it reacts in
a covalent manner with immunoglobulin and thus no coupling reagents are 
required. It produces stable conjugates and gives bright distinctive 
fluorescence (FL1 channel) absorbing light at 488nm and emitting a strong 
green fluorescence signal at 525 nm.
A second dye, R- phycoerythrin (PE) is a member of the 
phycobiliproteins which is a family of highly fluorescent macromolecules (Mr 
240,000). Coupling of PE to immunoglobulin requires thiolated 
phycoerythrin (FL2 channel) which reacts with a cross- linking reagent such
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as N-succinimidyl 3-(2-pyridylthio)- propronate (SPDP) conjugated to the 
immunoglobulin. PE also absorbs at 488 nm but emits at a wavelength of 575 
nm with a strong orange coloured signal.
The third dye is propidium iodide (PI) which is used to perform live / 
dead discriminations (Section 2.2.4.1). This again absorbs at 488nm and 
emits light at greater than 650 nm detected in the red part of the spectrum.
Thus the 15mW Argon laser with a fixed wavelength of 488nm 
excites the cells labelled with these mentioned fluorochromes which then emit 
in the red - green part of the spectrum.
2.2.3.2 FACScan optical system s
The optical system is based on an air cooled, 15 mW Argon laser set 
at 488nm. The output beam is transformed into an elliptical shape using a 
refracting beam expander. This is focused on a stream of cells in the flow 
chamber by a steering plate, and the behaviour of the cells within the laser 
beam is recorded (Figure 2.1).
65
Side Scatter 
PMT
FL1
PMTFL2 PMT
Photo- multiplier 
tube for FL3
J Orange/ Red 
Filter FL2 Green ruiei 
FL1
strong Red 
Filter FL3
Dichroic 1
Dichroic 2
/  Forward 
f  Scatter f  
Photodiode /CondenserLaser'
Prismatic 
Beam Expander
Steering Plate
Minor’
Figure 2.1: Diagram illustrating the optical system of the FACScan
The long wavelength is spectrally filtered from scatter and green 
fluorescence by a dichroic mirror (dichroic 1). The edge efficiently reflects 
longer wavelengths and efficiently transmits shorter wavelengths.
The transmitted path scatter is further split from the green fluorescence 
by a Brewster- angle beam splitter which takes advantage of the polarised 
nature of 90 degree scatter and the mostly unpolarised state of fluorescence. 
Meanwhile a 45 degree dichroic mirror (dichroic 2) with a 640nm edge further 
splits off the orange/ red fluorescence (FL2) from the red (FL3) fluorescence.
Forward scatter light is collected using lenses with makes use of a 
silicon photodiode with a sensitive area of 11.3 mm diameter. The side scatter 
channel does not require a filter, but the red fluorescence (FL3) channel uses a 
emission filter which transmits long wavelength light beams above 650 nm
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The filter in front of the the FL1 photomultiplier transmits 525 nm light and 
has a band width of 30nm, optimised for FITC detection. The filter used in 
the FL2 channel is optimised for the detection of PE. It transmits at 575nm 
and has a bandwidth of 42 nm.
Spectral overlap of fluorochrome emission
The FITC emission extends from 500nm to about 600nm with 
maximum emission at the 525nm The RPE emission bandwidth begins at the 
550nm and extends to about 640nm with maximum at 575nm, while the PI 
emission covers the range from 550nm to over 700nm, and has maximum at 
approximately 650nm. Thus it can be seen that there exists some spectral 
overlap between FITC and PE across the region 550nm to 600nm, while PE 
and PI emission overlap across the region from 550nm to 650 nm. Emission 
filters in each of the detector channels are selected to minimise this, although 
there is still some overlap between the FITC and the PE spectra. This is 
important when considering that these are the fluorochromes conjugated to the 
monoclonal antibodies being used. This overlap can be compensated for 
electronically (Figure 2.2)
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Figure 2.2: Diagram illustrating the spectral overlap of the
three fluorochromes used (FITC, PE, PI)
2.2.3.3 The FACScan fluidics system
The function of the fluidics system is to provide a laminar, single file 
flow of cells through a sensory region, contained within a rectangular volume 
inside a quartz viewing orifice (Figure 2.3). The air pump is provided with a 
regulator for the air pressure which drives the isotonic sheath fluid from a 
reservoir through the viewing orifice. Once a single cell suspension is 
prepared, the sample is placed into a sample test tube that specifically fits over 
the sample capillary tube so as to form a tight seal. The sample is driven into 
the capillary tube by a differential pressure. The flow rate of the sample can be 
either high (60fil/ min) or low (12}il/min). The high flow rate is suitable for 
immune monitoring applications, whereas the low flow rate allows more 
precise cell positioning providing higher resolution in applications such as 
DNA cell- cycle analysis.
In the flow cell assembly the cells are then exposed to the argon laser 
beam. To avoid blockage by cell clumps or debris the flow cell of the
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FACScan analyser consists of a regulator quartz cuvette with a large internal 
cross- section of 180|im by 480|im.
The cell sample is then carried to the waste reservoir by the sheath
fluid.
Air Pump
Waste resevoir
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\ /
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Filter
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Figure 2.3: A box diagram of the FACScan fluidics system.
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2.2.3.4 FACScan associated computer systems
The FACScan computer module consists of the Hewlett- Packard 
Model 310 computer, a 20 Mbyte hard disk, floppy disk, keyboard, mouse, 
printer, and monitor. This system displays, stores, gates and statistically 
analyses data collected.
The software program utilised in this study was FACScan research 
which allows the collection and storage of raw data from all 5 parameters.
The limit of sensitivity is 1000 FITC equivalent molecules per cell and 
as the amount of fluorescence on the surface of the cell varies widely.
2.2.4 Analysis o f cell surface antigen expression
Once the cells have been prepared and the data collected, the 
information can be analysed in several ways. There are problems in analysing 
the data thus a few techniques either prior to the collection of the data, or 
during the analysis of the data must be put into operation.
2.2.4.1 Discrim ination o f live from dead cells
When the cells are being prepared for flow cytometric analysis, either 
during primary tissue cell isolation or antibody staining procedures, 1 0 0 % 
viability is never obtained. Cells die during incubation periods, centrifugation 
steps and more practically while waiting to be collected on the FACScan. 
Dead cells than lead to high non- specific staining of the antibodies and this 
must be removed before a reliable result can be obtained. To remove dead, 
nucleated material from the collection data, a DNA stain called propidium 
iodide (PI) is employed(Section 2.2.3.1). PI enters a permeable, non- viable 
cell and intercollates with the DNA and RNA. PI staining of cells can then be 
negated by setting a gate that excludes cells that stain highly on a FL3 
channel(Figure 2.4) This particular gating system however only removes 
nucleated, non- viable cellular debris. Cells that have disintegrated thus
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leaving membranous material, are not included in this gate and must be 
removed using the FSC versus SSC plot system. This debris will be 
positioned in the lower left hand portion of the scatter plot (Figure 2.5)
Cells mcluded
DEAD CELLSLIVE CELLS
( PI incorporated)
FL3 FLUORESCENCE (LOG)
Figure 2.4: Diagram illustrating cells staining with PI,
which can be excluded by applying the 
appropriate gate.
2.2.4.2 Discrim ination o f individual cell populations
Cells show specific size and granularity, and thus can be identified by 
viewing a FSC versus SSC plot of the collection data (Figure 2.6). By 
making use of fluorescently labelled antibodies it is possible to gate the 
material under examination so as to exclude any unwanted cells. Also with 
Becton Dickinson software package called "Paint-a-Gate" it is possible to 
identify a populations of cells in one parameter and then identify the same
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cells in another parameter. Gates cannot be set using this program but it can 
be used to check the validity of the gate applied (Figure 2.6)
This technique was applied when looking at the phenotypic expression 
of tumour infiltrating lymphocytes within a mixed tumour cell 
population.(Section 3.1 and 3.2)
2.2.5 DNA Cell cycle analysis
DNA Cell- Cycle Analysis Software provides a quantitative analysis 
of cell cycle distribution from flow cytometric files (Section 1.6.2). There are 
many programmes available for this type of study and they often give 
disturbingly different results. For this work, only two were available although 
it was also possible to use operator directed measurement on the Lysys 
software programme. Once the nuclei were stained (Vindelpv et al 1983), the 
data was collected and analysed using one of these two main available DNA 
Cell- Cycle Analysis Software programs.
(a) The Polynomial Model
(b) The Sum of Broadened Rectangles Model
Both models calculate the percentages, total cells, and other parameters for the 
G l, G2+M, and S phases of the cell cycle (Figure 2.7)
2.2.5.1 The Polynomial Model (SFIT)
This model is an automated model that searches for the highest peak 
between channels 60 and 1 2 0  in the histogram and assumes this peak is the 
Gl peak (Dean, 1980). the model then searches for the G2+M peak. After 
locating the G2+M peak, The model determines a region of "pure" S phase 
(no Gl, G2, or M phase cell present). "Pure" S phase is the region from 3.5 
standard deviations to the right of the Gl peak to 2.5 standard deviations to
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the left of the G2+M peak. Next, the Polynomial Model divides the 
calculation region into two equal subregions and sums the number of events, 
or nuclei, in each subregion. It assumes that the total S phase region runs 
from the mean of the Gl peak to the mean of the G2+M peak. Using the 
polynomial equation, the model computes the number of cells in each half of 
the S phase. The polynomial model then determines the number of cells in the 
Gl phase by subtracting the number of cells in the first half of the S phase 
from the total number of cells in the first subregion. A similar operation 
determines the number of cells in the G2+ M regions. This means that if the 
Gl or G2/M peaks are slightly broadened, an abnormal s phase figure may be 
obtained.
2.2.5.2 Sum o f Broadened Rectangles Model (SOBR)
This model uses successive approximations to match a computed 
DNA distribution to the actual cell analysis data. The model uses Gaussian 
curves to model the Gl and G2+M peaks. It then approximates the S phase 
region by dividing it into a number of compartments, each are referred to as 
broadened rectangles, and the computer forms these by summing a series of 
Gaussian curves, contained within the rectangles.
Unlike the Polynomial model, the SOBR uses initial parameters that 
the operator specifies. The initial parameters used in this SOBR are the Gl 
and G2+M peak positions. The model computes a DNA distribution based on 
the initial estimation of these parameters. It then compares the computed and 
actual distribution and calculates the goodness- of fit. The model then 
determines the number of cells within the Gl and the G2+M regions from 
their respective Gaussian curves. It determines the number of cells in S phase 
by summing the number of cells in each of the S phase compartments.
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Which is the Best Model?
The following criteria must apply when deciding to use the Polynomial 
Model:
(1) The cell population is nearly asynchronous in growth.
(2) Very little debris is present in the sample
(3) The Gl peak occurs within the channel range of 60 to 120 on the 
histogram.
(4) The reference peak, if present, occurs in a channel greater than or equal to 
10 (CRBC are used because they contain approximately 35% the amount of 
human DNA.)
Use of the SOBR for cell cycle analysis is appropriate the data meets these 
criteria:
(1) When an error message appears after an attempt has been made to analyse 
the data with the Polynomial model.
(2) When it is suspected that the cell population may be partially 
synchronised.
(3) When the Gl peak is not in the channels that the Polynomial Model 
requires.
These models can only really be applied if the cells under examination 
are diploid.(Figure 2.7) The percentage of cells in the S phase of an diploid 
tumour, that also contains some aneuploid cells, cannot be measured because 
the G0/G1 peak of the aneuploid tumour is situated in the area corresponding 
to the S phase of the diploid tumour (Figure 2.8).
Certain profiles are also unintelligable because they contain too much debris 
In this situation the sample must be discarded.
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Figure 2.5: FSC versus SSC plot for the identification of non­
nucleated debris. This material is contained within 
the box shown and is excluded form any analysis 
peformed.
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FL1 FSC
Figure 2.6: Becton Dickinson "Paint- a- Gate" software used to
identify lymphocytes (red) and monocytes 
(blue) on FL1/FL2 (using the "Leucogate" antibody: 
anti -leucocyte FITC (FL1) and anti- Leu M3 PE 
(FL2)). These cells then show a distinctive pattern on 
the FSC and SSC plot.
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Figure 2.7: DNA showing diploid characteristics. Peaks indicate
the G0/G1 (Gap 0 and 1) and G2M (Gap 2 and 
Mitosis) phases of the cell cycle. The position of 
chick red blood cell (CRBC) DNA is also identified.
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Figure 2.8: DNA showing aneuploid characteristics. Peaks
indicate the position of G0/G1 and G2M of the 
aneuploid peaks.
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2.2.6 4-Hour 51 Cr release cytotoxicity assay
Effector cells were prepared, washed in RPMI1640 medium 
supplemented with 10 % FCS, resuspended in appropriate concentrations 
(effector: target ratios of 20:1 to 1:1) and added in lOOjil aliquots to microtitre 
wells( serially diluted across the plate in triplicate wells). Target cells were 
incubated in 0.7 ml PBS with 200jiCi Na2 51 Cr O4 for 90 minutes at 37°C in 
a water bath. After this time the cells were washed 3 times with complete 
medium. Cells were counted and the cell count adjusted to the appropriate 
number (lxlO5 per well). Aliquots of lOOjil were added to the wells 
containing the effector cells. For each target, additional wells were also 
prepared, containing lOOjil of target cell suspension with lOOjil of complete 
medium, and lOOpl of target cells with lOOjil of 3N HC1, corresponding to 
spontaneous and maximal release respectively. The culture plate was then 
centrifuged at 150g for 5 minutes and incubated at 4 hours at 37°C, 5 % CO2 
and 95% O2. After this incubation period the plate was centrifuged at 150g for 
5 minutes, and lOOjil of supernatant was carefully removed, without 
disturbing the cells, and added to gamma counter tubes . The tubes were then 
counted on an LKB Wallac 1275 Minigamma counter on isotope selection 
mode fro ^C r. Results were analysed by calculating the % lysis of the target 
cells. The following formula was applied:
experimental cpm - spontaneous cpm 
maximum cpm - spontaneous cpm
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3 FLOW CYTOMETRIC ANALYSIS OF TUMOUR
INFILTRATING LYMPHOCYTES AND PERIPHERAL  
BLOOD LYMPHOCYTES OF UVEAL MELANOMA  
PATIENTS
3.1 Phenotypic analysis of tumour infiltrating lymphocytes
3.1.1 Aims of the Study
Approximately 5-12% of uveal melanomas contain TILs. This section 
examines the differences between these TILs and the parallel PBLs from such 
individuals. The lymphocytes were analysed with respect to the relative 
proportions of lymphocyte subsets and the markers of activation expressed on 
their cell surface.
3.1.1.1 Activation markers
Activation markers used in this study included 2 well known antigens 
on the surface of T cells that are reported to be upregulated when the cell is 
stimulated by antigen or mitogen.
(1) HLA DR
HLA DR has been demonstrated as a T cell activation marker which is 
absent on resting T cells (Reinherz et al., 1979) but is present on T cells 
stimulated by antigen, in mixed lymphocyte cultures (Pawelec et al., 1982). 
This antigen is thought to be associated with antigen presentation (Section
1.4.4.2).
(2) IL-2 Receptor (Tac, CD25)
On antigen stimulated T cells the expression of the low affinity p chain (p55) 
is 5 to 10 fold greater than that of the intermediate affinity chain. IL-2 binding 
to high affinity receptors decreases their expression by 50%, but increases the
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expression of the p chain 10 to 20 fold (Smith, 1989a) (Section 1.4.5). This 
increase in the P chain makes their presence a good guide to the increase in 
IL-2 receptors after activation, antigen stimulation or the presence of IL-2.
3.1.2 R esults
Phenotypic analysis of TILs and appropriate PBLs from 5 uveal 
melanoma patients, was performed by applying 2  colour flow cytometric 
analysis. TILs and PBLs were characterised according to their expression of 
CD3, CD 19, CD4 and CD8 on the cell surface. The CD4+ and CD8 + T cells 
were then analysed for their expression of the activation markers (i) HLADR 
and (ii) IL-2 receptor (Tac or CD25). The antibodies were murine antibodies 
to human cell surface markers and directly conjugated to either PE or FTTC. 
(Table 3.1).
Antibodv CD Coniueate Reactivitv
Anti- leu 2(a) CD8 PE Suppressor/
Cytotoxic
Anti- leu 3(a) CD4 PE Helper T cell
Anti- leu 4 CD3 FITC T lymphocytes
Anti- leu 12 CD 19 PE B lymphocytes
HLADR NA FITC Class IIMHC
antigen
IL-2R CD25 FITC Interleukin 2
receptor
Table 3.1: Antibodies used to detect lymphocyte
populations and activation markers (CD 
nomenclature for HLA DR not available (NA)
Spilled cells from 27 tumour samples were prepared (Section
2 .2 .1 .2 ), and then incubated with the relevant antibodies for 2 0  minutes, at 
4°C and washed ready for FACscan analysis (Section 2.2.2.1). Similarly, 
PBLs from each patient that contained sufficient TILs, were isolated from 
whole blood, using a ficoll- density gradient (Section 2.2.1.4), and stained as 
before. Lymphocytes were identified in 5 out of the 27 tumour samples by 
the use of the Leucogate antibody (Becton Dickinson) (Figure 3.1) which is a 
prepared antibody mixture containing a FITC conjugated anti- leucocyte 
marker and a PE conjugated monocyte/ macrophage marker (anti- leu 3M). 
This antibody identified an extensive infiltrate in 4 of the tumours. The 5th did 
contain analysable lymphocytes but to a much lesser extent. This 5th tumour 
sample was included to investigate the possibility that this lymphocytic 
infiltrate was perhaps a reflection of hemorrhage in the tumour. This antibody 
preparation allows lymphocytes, and this situation TILs, to be identified 
according to their position on a FL1 versus FL2 plot (Figure 3.1). It also 
allows an approximate gate to be placed on the FSC versus SSC scatter plot 
so that TILs could be collected within the tumour cell suspension. Live cells 
were also identified by using PI, detected on the FL3 fluorescence channel 
(Section 2.2.4.1). Simultest reagent (Becton Dickinson) kits for the 
identification of T and B cells and also for the identification of CD4+ and 
CD8 + cells were used.
FSCF5_l
Figure 3.1: Identification of TILs (red) on the FL1/FL2 plot and
the corresponding FFC/SSC plot. These cells are 
stained with the "Leucogate" antibody and analysed 
using the "Paint- a- Gate" software (Becton 
Dickinson).
Figure 3.2 indicates data obtained from flow cytometric analysis of (a) 
TIL and (b) PBL samples showing the classification of the cells into the 
individual lymphocyte subpopulations. Quadrants were set according to the 
fluorescence profile of cells incubated with an irrelevant antibody (FITC- 
IgGi and PE- IgG 2 a) >so as to allow approximately 99% of the cells to be
within the lower left (LL) quadrant. When the cells were incubated with the 
appropriate PE and FITC labelled antibody, any spread of fluorescence along 
the FL1 channel to the right of the vertical marker indicated a positive result. 
Statistical analysis identified the percentages of each lymphocyte sub­
population and expressed it as a percentage of the cells within the lymphocyte 
gate. The actual percentage of each T lymphocyte sub-population expressing 
the particular marker to be calculated.
% Positive =  % in UR  X 100
% in UL + % in UR 
In Figure 3.3, the data was obtained in a manner similar to that 
demonstrated in Figure 3.2. All 5 tumour samples are presented with the 
corresponding data from the PBL of four of the patients. Table 3.2 and 3.3 
indicates the actual data obtained for the PBLs and TILs respectively. For all 
patients it can be seen that T cells predominate in the TILs (Figure 3.3(a)) 
with insignificant levels of B cells. The CD8 + T cells predominate in the TILs 
whereas CD4+ T cells generally predominate in the PBL samples (Figure 
3.3(b)) When considering the activation markers Figure 3.3(c) indicates that 
the TILs express substantially more HLA DR than the PBLs even in patient 5. 
Table 3.3 indicates the mean values for the PBL and TIL samples. It shows 
the increased expression of the HLA DR on the TTLs compared to the PBLs 
samples.
Figure 3.2(a): Data from the analysis of TILs of uveal melanomas.
TILs were identified using the previously mentioned 
“Leucogate" antibody and then the CD4+ and CD8+ 
T cells were identified and analysed for the 
expression of HLA DR and CD25.
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Figure 3.2(b): Data obtained form the analysis of PBLs from uveal 
melanoma patients. PBLs were identified using the 
previously mentioned "Leucogate" antibody and then 
the CD4+ and CD8 + T cells were identified and 
analysed for the expression of HLA DR and CD25.
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HLADR+ CD25+
Patient T cell BceU CD4+ CD8+ CD4+ CD8 + CD4+ CD8+
1 56.6 13.4 31.6 29.6 7.6 20.7 18.6 2.7
2 81.7 10 42.5 35.9 2 2 .6 36.3 32.3 5.4
3 NA NA NA NA NA NA NA NA
4 50.1 10.5 30.3 29.4 1 0 .1 16.0 28.3 4.2
5 59.7 11.4 33.9 34.8 14.4 43.6 7.6 3.3
Table 3.2: Percentage of PBLs positive for the indicated
phenotype.
HLADR+ CD25+
Patient T cell BceU CD4+ CD8 + CD4+ CD8 + CD4+ CD8 +
1 54.1 0.3 5.4 43.9 37.1 93.6 16.5 3.5
2 50.3 0.3 1 1 .6 31.9 64.0 73.0 11 3.3
3 85.6 2.4 18.4 73.9 83.0 55.0 26.0 3.4
4 73.1 1 .2 8 .2 77.3 80.0 8 8 .2 30.0 8 .1
5 6.7 0 . 0 3.0 5.0 87.8 55.5 7.9 4.0
Table 3.3: Percentage of TILs positive for the
indicated phenotype
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The CD4+ are consistently more positive for the CD25 marker than 
the CD8 + T cells (Figure 3.3 (d) and Table 3.4) not only in the TIL but also 
in the PBL samples available.
PBL TIL
T cell Marker mean mean
CD4+ HLADR+ 13.7 70.3
CD8 + HLADR+ 29.1 73.0
CD4+ CD25+ 21.6 18.2
CD8 + CD25+ 3.9 4.4
Table 3.4: Mean data for the expression of HLA DR and
CD25 on the T cell subsets.
Figure 3.3: Histograms indicating the percentage of (a) T and B 
cell populations, (b) CD4+ and CD8 + T cells 
populations, (c) HLA DR+ CD4+/CD8+ populations 
and (d) CD25+ CD4+/CD8+ populations, in the 
TILs and PBLs of uveal melanoma patients.
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3.1.3 Discussion
In this particular study dominant populations of T cells as opposed to 
B cells were identified within the tumour infiltrate. This is in agreement with 
other workers (Whitford et al., 1990; Itoh et al., 1985; Ralfkiiaer et al., 1987; 
Muul et al., 1987; Belldegrun et al., Topalian et al .,1987; Kumick etal., 
1886) who have performed similar studies in other neoplasms. Within the T 
cells identified, we also found the predominance of CD8 + T cells and this is 
also reported by other workers (Topalian et al., 1987; Kumick et al., 1986; 
Giomo, 1983; Naukkarinen and Syijanen, 1983; Bilik etal., 1989), although 
some studies do disagree with these results, finding the predominance of 
CD4+ T cells (Muul et al .,1987; Belldegrun et al., 1986; Kradin et al., 1987; 
Whitwell et al., 1984; Gottlinger et al., 1985). These conflicting results may 
be due to the methods used on the cell populations. Most groups study tissue 
sections stained with enzyme or fluorochrome conjugated antibodies and thus 
the question of intra -sample variation occurs. This is important in view of 
tumour heterogeneity (Heppner, 1984; Edwards et al., 1985), the effect of 
which is reduced by analysing larger amounts of tumour.
The activation of CD4+ T cells marks the beginning of an effective 
immune response, and the successful completion of antigen presentation by 
the antigen presenting cell (Section 1.4.4). As mentioned, during this 
activation process, the surface of the T cell acquires the HLA DR antigens and 
receptors for IL-2.
The presence of high levels of HLA DR on the surface of the CD8 + 
ULs may be indicative of the cells presenting some foreign antigen. It is 
possible that after recognition of the tumour antigen combined to the Class I 
MHC complex and destruction of the tumour cell, the CD8 + cytotoxic cells 
present part of the antigenic structure of the foreign cell within the groove of 
their HLA DR complex to signal to other cells of the immune system. The 
CD4+ T cells also seem to express high levels of the HLA DR and this again
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could be indicative of the antigen presenting capabilities of these T cells to 
other T cells to augment the immune response. Several groups have found 
HLA DR to be expressed by an increased number of T cell that infiltrate breast 
tumours (Rotstein et al., 1988; Ben- Ezra and Sherbari, 1987) ovarian 
tumours (Heo et al., 1988) and liver tumours (Takagi etal., 1989).There is 
great variation in results with those studies involving long preparation times 
or fixing of cells. Whiteside et al (1986) performed a study on breast 
carcinomas, whereby the tumours were collagenase digested, and then 
exposed to a long incubation period prior to the staining of the lymphocytes 
that were consequently released. It was found that there were few 
lymphocytes bearing any activation markers and it is likely that these were 
cleaved during the enzymatic digestion and incubation period.
Very little difference is evident between the expression of CD25 on the 
surface of the T cells between the TILs and the PBLs, but there is still 
significantly more CD25 on the CD4+ T cells than the CD8 + T cells. This 
receptor only increases on cells after they have been stimulated by antigen and 
so its presence again signifies that these cells may have possibly recognised 
some tumour antigen alongside the Class IMHC complex. This marker is 
also a marker of cell division, and since it seems to be expressed on high 
percentages of the CD4+ cells, then these cells have an increased turnover and 
possible expansion within the tumour. The CD8 + T cells show little evidence 
of division thus this may be due to the existence of a terminal differentiation 
point into functional cytotoxic cells.
These finding may be relevant when considering TIL immunotherapy 
(Section 1.5.7). The rationale for this treatment is that the cytotoxic T cells 
have already been primed with antigen within the tumour mass, and thus will 
greatly increase in numbers within the IL-2 culture. Consequently, upon 
returning the cells to the patient, they will destroy metastatic deposits 
(Rosenberg et al., 1986). Measurements of IL-2 receptor on the surface of the
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T cell subsets in melanomas have been performed by other workers (Lotze et 
al., 1987; Balch et al., 1990) and they also found that the CD4+ cells seemed 
to express higher levels of this activation marker. Although some groups who 
phenotyped the cells after IL-2 culture, found CD8 + T cells to predominate 
(Kumick et al., 1986; Topalian et al., 1988), others found that the greatest 
expansion to be in the CD4+ T cell population, with the CD8 + T cells dying 
away after 2 or 3 weeks. This indicated that the cells being returned to the 
patient were actually cells expressing the CD4 phenotype (Belldegrun et al., 
1989; Muul et a l, 1987; Heo et a l, 1988; Kradin et al., 1987; Skomick et al., 
1990). It is evident that this treatment has been partially successful in 
malignant melanoma (Rosenberg et al., 1990), it thus seems likely that these 
results have actually been mediated via the CD4 cells . How these responses 
have been mediated must be clarified to allow further development of this 
therapeutic approach.
Little work has been performed on uveal melanoma involving 
culturing of the TILs in IL-2, perhaps due to the low levels of lymphocytic 
infiltrate within the tumours in general. The problem arises when isolating the 
lymphocytes from the tumour cell suspensions, due to the predominance of 
tumour cells. Consequently these TILs cannot be readily phenotyped, after 
IL-2 stimulation, to determine if it is indeed the CD4+ population that will 
predominate.
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3.2 v p  TCR REGION ANALYSIS OF TUMOUR  
INFILTRATING LYMPHOCYTES
3.2.1 Aims of the study
It was decided to investigate the origin of the TILs. Among many other 
possibilites these could have expanded and located in the tumour site or, 
alternatively, have been attracted to the tumour by selective expression of 
adherence molecules (Section 4.1) by the tumour cells. In attempt to 
investigate this question of clonality it was decided to study the VP TCR 
region expression on TILs of uveal melanoma and also breast carcinoma 
another type of cancer readily available to studying. This was performed to 
assess whether the TILs were clonal or polyclonal, in their Vp TCR 
expression, and if so, which Vps were preferentially expressed. If a restricted 
usage of a particular Vp TCR region in the TILs is present then this may be 
indicative of a specific antigen or superantigen that is being targeted in these 
malignant neoplasms. It also gives information as to whether TILs can expand 
into a clonal population at the site of the tumour.
3.2.2 Results
Vp TCR region expression on TILs and associated PBLs, from 4 
breast carcinomas (patient 1-4) and 6  uveal melanoma tumour samples 
(patients 5-10) was performed by simultaneous two colour flow cytometric 
analysis. CD3+ lymphocytes were identified using a PE labelled CD3 
antibody (detected on FL2) and the expression of the Vp TCR region 
associated with these cells was also identified by using a panel of murine 
FTTC labelled monoclonal antibodies (detected on FL1), specific for a 
selected number of sub-families of human TCR Vp regions (Table 3.5).
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Name Specificity
Vp5(a)
Vp5(b)
Vp5(c)
VP8 (a)
Vpl2(a)
Vp6 (a)
VP5 subfamily 
Vp5 subfamily
Vp5.1 (not a subset of 5(a))
VP8  subfamily 
VP12 subfamily 
VP6  subfamily
(allotype Vp6.7 epitope)
Table 3.5: Subfamilies of the human TCR VP regions
Spilled cells from both the breast carcinoma and uveal melanoma 
tumour samples were prepared (Section 2.2.1.2), and then incubated with the 
relevant antibodies for 20 minutes, at 4°C and washed ready for FACScan 
analysis (Section 2.2.2.1). Similarly PBLs from each patient were isolated 
from whole blood, using a ficoll- density gradient (Section 2.2.1.4) and 
stained as before (Section 2.2.2.1). Once the cell suspensions were prepared, 
the relevant information was collected by the flow cytometer. Each sample 
was collected with a live /dead discrimination gate present (Section 2.2.4.1) 
and in the case of the TILs an approximate lymphocyte scatter gate was also 
present. This lymphocyte gate was placed according to the position of 
isolated PBLs on a FSC versus SSC plot (Section 2.2.4.2).
Figures 3.4 and 3.5 represent the data obtained from the relevant 
analysis of the CD3+ Vp+ populations for the uveal melanoma and the breast 
carcinoma respectively. Quadrants were placed so as to maintain the CD3"
VP" population in the lower left quadrant (LL), the CD3+ VP" population in 
the upper left quadrant (UL) and the CD3+ Vp+ population in the upper right 
quadrant (UR). Statistics were then derived by calculating the population of
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the CD3+ VP+ cells as a percentage of the total CD3 population. This 
information constitutes analysis using the gating method 1 (Rl).
% positive (Rl) = % in UR X 100
% in UL + % in UR
Methods of analysis were complicated by the fact that the antibodies 
appeared to bind in a non specific manner to some of the TIL samples, 
especially the uveal melanoma samples. This was indicated by a high 
fluorescence obtained at the 3rd or 4th log position of the FL1 scale and also 
leaking through of non-lymphoid cells on the FL2 scale (Figure 3.6). To 
overcome this the samples were analysed using a different gate setting that 
would remove any detected non -specific binding. The PBL cell preparations 
seemed to identify relatively uniform patterns of expression of the VP TCR 
regions, and thus a second gating method (R2) was put into operation. This 
gating system involved placing a "gate" round the PBLs considered to be 
positive for the specific VP expression and thus maintained to analyse the TIL 
samples (Figure 3.7 and 3.8). The percentage positive was that determined by 
calculating the percentage within this gate and stating it as a percentage of the 
whole CD3+ population.
% positive (R2) = % in "gate" X 100
% in UL + % in UR
To identify the TILs in the analysis the CD3+ population was 
identified and using the "Paint-a-Gate" software (Becton Dickinson), the 
corresponding population of cells in the FSC versus SSc plot is identified 
(Figure 3.9).
Figure 3.4: Flow cytometric analysis of (a) PBLs and (b) TILs
of uveal melanoma patients in terms of their VP TCR 
expression. Quadrants represent the gating 1 method 
of analysis (Rl).
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Figure 3.6: Non- specific staining of V(3 TCR region antibodies.
(a) indicates high fluorescence in the 3rd and 4th log 
position, (b) Indicates leaking of non- lymphoid cells 
on the FL2 scale.
Figure 3.7: Gating method 2 (R2) used to analyse (a) PBLs and 
(b) TILs of uveal melanoma patients for the analysis 
of V(3 TCR region expression.
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Figure 3.8: Gating method 2 (R2) used to analyse (a) PBLs and
(b) TILs of breast carcinoma patients for the analysis 
of Vp TCR region expression.
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Figure 3.9: Identification of CD3+ TILs (red) on the FL1/ FL2
plot and the corresponding position of these cells on 
the FSC/ SSC plot These cells were identified using 
the "Paint- a- Gate" software (Becton Dickinson).
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Tables 3.6 and 3.7 express the CD3+ Vp+ populations for the PBLs 
and the TILs respectively, and compares the percentages obtained using the 
different gating methods described earlier. Tables 3.8 expresses the mean 
percentages of the specific Vp for the PBL and the TILs. For the PBLs the 
analysis using gating method 1 (Rl) always gave a slightly higher value but 
the deviation was not great, the largest difference in mean being a value of 
0.3% for Vp5(a). The mean percentage for the TDLs indicates the importance 
of setting the correct gate, since the percentages vary considerably. It was 
decided to include the gating method 2 (R2) for analysis for these particular 
samples since it seemed to be more representative of the actual Vp positive 
population and thus removed any possibility of non- specific binding of the 
antibodies.
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Patient Gate Vp5(a) Vp5(b)
1 Rl 3.2 1 .8
R2 2.7 1 . 6
2 Rl 3.0 1.4
R2 2.9 1.3
3 Rl 2.9 0.4
R2 2.9 0.4
4 Rl 2 . 8 3.9
R2 2 . 8 3.9
5 Rl 3.2 1.7
R2 2 . 8 1.5
6 Rl 15.0 12.5
R2 14.2 1 2 .1
7 Rl 2 . 8 0 . 8
R2 2.7 0 . 8
8 Rl 4.2 2 . 0
R2 3.9 1.7
9 Rl 4.6 1 .8
R2 4.6 1 .8
1 0 Rl 6.3 2 . 6
R2 6.3 2.3
Vp5(c) Vp8 (a) VP 1 2 (a) Vp6 (a)
2.9 4.5 1 .8 3.8
3.0 4.2 1 . 6 3.5
5.7 5.2 1 .1 2 . 6
5.7 5.2 1 .1 2.3
6.5 5.2 3.1 6.9
5.6 4.7 3.1 5.1
3.4 7.9 2 . 1 3.2
3.4 7.9 2 . 1 3.2
4.3 3.6 2 . 1 0.92
4.0 3.4 2 . 0 0.7
1 0 .1 7.1 4.6 5.3
9.8 6 . 8 4.1 5.0
3.5 4.3 1.4 4.2
3.5 4.2 1.3 3.7
6 . 6 5.5 3.0 5.1
6 . 6 5.9 3.3 4.1
3.9 3.4 2 . 2 4.5
3.9 3.4 2 . 2 4.5
3.8 1 . 6 2.7 7.4
3.8 1.3 2.5 7.4
Table 3.6: Data corresponding to CD3+ Vp+ PBLs obtained with
gating method 1 (Rl) and 2 (R2).
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Patient Gate VP5(a) Vp5(b)
1 Rl 3.0 4.0
R2 2.9 3.4
2 Rl 7.3 6.4
R2 7.7 6.4
3 Rl 1.5 0.9
R2 1.5 0.9
4 Rl 8 .1 8 . 1
R2 7.2 7.4
5 Rl 29.1 14.6
R2 8.5 7.1
6 Rl 9.3 3.8
R2 7.8 1.3
7 Rl 5.4 2 . 6
R2 2.7 1.4
8 Rl 19.1 25.7
R2 2 . 6 5.5
9 Rl 2 . 6 3.0
R2 2 . 2 2.7
1 0 Rl 32.2 18.5
R2 8 . 0 4.2
Vp5(c) Vp8 (a) Vpl2(a) VP6 (a)
4.4 6.3 4.1 7.1
4.3 6 . 0 3.7 6.5
3.3 6 . 6 2 . 8 8.4
3.3 6 . 6 1.9 6 . 0
3.3 5.5 3.3 6 .1
3.1 5.0 3.3 4.8
2 . 8 7.3 7.3 3.7
2.5 6 . 2 6.9 3.0
17.1 17.7 15.1 18.7
9.6 8.9 5.7 6.4
3.5 1 . 6 2 . 8 9.9
1 . 2 1 . 6 0 4.4
4.1 11.4 18.2 16.5
3.0 6.5 10.9 7.8
8 . 6 31.9 33.6 19.1
2.7 1 0 .1 6 . 6 2.9
2 . 8 0 . 2 2.9 5.4
2.5 0 . 1 2.9 5.4
27.1 23.9 2 0 . 0 33.3
9.8 9.8 3.4 4.0
Table 3.7: Data corresponding to CD3+ VP+ TILs obtained using
gating methods 1 (Rl) and 2 (R2).
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PBL TIL
Specific VP R i R2 Rl R2
VP5(a) 4.8 4.5 11.7 5.1
Vp5(b) 2 . 8 2.7 8.7 4.0
Vp5(c) 5.0 4.9 7.7 4.2
Vp8 (a) 4.8 4.7 1 1 . 2 6 . 0
Vp 12(a) 2.4 2.3 1 1 . 0 4.5
VP6 (a) 4.3 4.1 1 2 . 8 5.1
Table 3.8: Mean data corresponding to CD3+ VP+ PBLs and
TILs using gating method 1 (Rl) and 2 (R2).
Figure 3.10 represents the comparison between the individual VP 
TCR region expression on the PBL and TIL samples for the 10 tumour 
samples. There is much variation between the different Vps, but generally Vp 
expression is higher on the TILs than on the PBLs with the exception of 
patient 6  who seems to express more of VP 5(a) on the PBLs than on the 
TILs. Indeed it would seem this occurs for all the VPs for this particular 
patient. There does not seem to be one particular Vp that is present on any one 
tumour sample to the exclusion of the other tumour samples.
Table 3.9 shows the mean values for the individual tumour types of 
the PBLs and the TILs, respectively, and this information is graphically 
illustrated in Figure 3.11. Generally that the PBLs from patients with breast 
carcinoma and uveal melanoma have lower Vp expression than the TIL from 
these patients, except for Vp5(c) which seems to be expressed to a slightly 
higher extent in the PBLs than the TILs from the corresponding sample. In 
general, the expression of VPs in the breast carcinoma PBL samples is lower
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than that of the uveal melanoma patient PBLs, except for, Vp8 (a) where the 
change is very slight (5.5% and 4.7%, respectively). In uveal melanoma the 
expression of the TCR Vp regions shows a general trend of being greater than 
the breast carcinoma, except for Vp5(b), where there is a slight reduction.
Tumour Cell tvpe Vp5(a) vp„5(b) Yp5(c) Vp8 (a) Vpl2(al Vp6 (a)
Breast PBL 2 . 8 1 .8 4.4 5.5 1.9 3.5
TIL 4.8 4.5 3.3 5.9 3.9 5.0
Uveal PBL 6 . 2 3.3 5.2 4.7 2.5 4.2
TEL 5.3 3.7 4.8 6 . 1 4.9 5.1
Table 3.9: Comparison of mean data for CD3+ VP+ PBLs and
TILs for breast carcinoma and uveal melanoma (gating 
method 2 (R2) used).
These changes in expression are not large and therefore may not be 
significant but taken as an entity the change is significant when one considers 
that only 1-5% of the PBLs are positive for any specific Vp. This seems 
reasonable since other workers (Kappler et al., 1989; Karpati et aL, 1991) 
have also shown similar Vp expression statistics in other VP induction 
systems.
Figure 3.10: Comparison of each of the individual Vp TCR 
regions analysed on the 10 tumour samples Data 
obtained by analysis using gating method 2 (R2).
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Figure 3.11: Mean data corresponding to the VP TCR region
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compared to the uveal melanoma PBLs and TILs.
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3.2.3 Discussion
Very few studies have been concerned with the expression of Vp TCR 
regions in TILs, although much work has been done on the association of VP 
expression with reactivity to exotoxins which are produced by bacteria.(Choi 
et al., 1989; White et al., 1989; Kappler et al., 1989) and superantigens 
produced by the recently characterised products of mouse MMTV virus (Choi 
et al., 1991).However there has been one report on the V a TCR gene 
expression in uveal melanoma (Nitta et al., 1990), where it was found that 
Va7 was found in 7 of the 8 uveal melanomas studied. This was done by 
using PCR techniques with V a primers. Thus it was suggested that TILs may 
have a restricted TCR repertoire. Va genes are seldom analysed in diversity 
studies because they are dominated by the VP regions in monoclonal antibody 
production, and consequently few antibody probes to Va products on the 
surface of the cells under study, are available.
The present study was performed on 6  uveal melanoma tumour 
samples and 4 breast carcinomas by the technique of flow cytometry using 
fluorescendy labelled murine antibodies to the VP regions of the human 
TCR. These antibodies identify minor populations of PBLs ( approximately 
1-5%).
It can be seen from Figure 3.4 and 3.5 that all the VPs seem to be 
expressed on the TILs and PBLs analysed and no one VP is preferentially 
expressed. This indicates that the TILs are polyclonal for the Vp TCR region 
measured. In addition it should be noted that Ja  genes and Dp and jp  genes 
may add to the diversity of any one expressing specific Vp or V a genes.
Thus the lack of clonal diversity observed may indicate a difference between 
the a  and P chains of the TCR in an oligoclonal response. Belldegrun et al 
(1989) reported oligoclonality in bulk IL-2 generated cultures of TILs derived 
from human tumours. However, the same laboratory, studying transplanted 
chemically- induced murine tumours, in inbred strains of mice, has more
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recently reported that freshly excised TILs are polyclonal in their VP 
repertoire and that oligoclonality is only observed after culture in IL-2 
(Karpati et al., 1991). However, some restriction in the TCR expression 
might still exist, although this restriction might or might not be reflected in 
restricted Vp usage because TCR-a and TCR-p regions other than Vp 
contributed to the determination of antigen specificity*.Also the panel of 
antibodies used included a limited number of the possible Vp repertoire, thus 
the question of clonality cannot be completely addressed. In addition, 
lymphocytes may not only enter the tumour but may also leave the tumour, 
thus the TILs are only being measured at one specific moment in time. The 
expression of the VP on a particular population of TILs may change during 
the course of time. Finally, the TIL population may contain only a limited 
number of tumour- specific T cells and a larger number of "passenger" T 
cells, making it difficult to detect selective TCR expression in the response to 
tumours.
There are slight differences between the expression of the Vp on the 
TILs compared to the PBLs, the TILs generally expressing more of any given 
Vp. This may be due to practical problems in the analysis since activated cells 
are larger and thus more fluorescent. Differences may also be due to the TILs 
recognising a particular antigen that is not Vp specific. For example, as 
mentioned, the recognition of an epitope on the mucin polypeptide core in the 
case of pancreatic and breast adenocarcinoma (Jerome et al., 1990). In the 
case of superantigen involvement, any direct parallel to murine Mis model 
(Dyson et al., 1991; Marrack et al., 1991) would be expected to be observed 
as an absence of a particular Vp clone in both PBLs and tumour cells and we 
do not observe this within the panel studied. Likewise, any equivalent to a 
bacterial superantigen in the tumour would be expected to be observed as a 
non- MHC restricted selective accumulation of a particular VP clone in all 
patients bearing the same tumour (Herman et al., 1991; Kappler et al., 1989).
94
In the data of Nitta et al (1990) there is a clear suggestion of superantigen 
involvement for V a chains of the TCR. Within the limitations of the available 
panel of antibodies, there is no evidence of this in the presented data.
It is relatively simple to collect 10,000 events for both the PBLs and 
the TILs of the breast carcinoma samples, due to the abundance of cells 
present Unfortunately, the uveal melanomas do not contain high levels of 
TELs (Table 3.10) even in the small number of a relatively highly infiltrated 
tumours. Only 10-12% of the uveal melanoma tumour samples contain 
lymphocytes and of these approximately 1-6 % of the cell suspension obtained 
will represent lymphocytes. It is therefore impossible to isolate these 
lymphocytes from the tumour cells and consequently the cell suspension that 
is incubated with the antibodies will invariably contain mosdy tumour or non­
lymphoid cells. For example patient samples 6  and 9 contained high levels of 
lymphocytes whereas patients samples 5,7,8 ,and 10 only contained 
1.1%, 1.3% 1.1% and 1.6% lymphocytes, respectively (Table 3.10). The 
high levels of non specific binding occuring in these patients may be due to 
the antibodies binding to the tumour cells present within the gate placed round 
the lymphocytes.
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Patient no. Tumour %TTL
1 Breast 30
2 29
3 11
4 20
5 Uveal 1.1
6  4.6
7 1.3
8 1.1
9 5.3
10 1.6
Table 3.10: Percentage of cell suspension containing TILs
The breast carcinoma samples were included in the study, since they 
are readily available and act as a different cell type to compare with the uveal 
melanoma TILs. Breast carcinomas exhibit TILs in approximately 70% of 
tumours and the levels of TILs are significantly higher than in uveal 
melanoma (Whitford et al., 1990) (Table 3.10). Thus it is interesting to see 
the same pattern occuring in the increased level of expression of the VP in the 
TILs compared to the PBLs.
The conclusion from this study is that TILs may be oligoclonal or 
polyclonal with the capacity for selective homing. They are not, however, 
monoclonal. Thus therapeutic strategies for TIL expansion in IL-2 culture 
must accommodate selective alterations in the recognition profile of the T 
cells.
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3.3 INVESTIGATION INTO THE SYSTEMIC IMMUNE 
RESPONSE TO UVEAL MELANOMA
3.3.1 Aims
In consequence of the controversy over the role of enucleation in the 
management of patients with uveal melanoma (Section 1.3), it was decided to 
determine the immune status of patients prior to and after the operation to 
remove the tumour. This would (1) identify whether or not the operation had 
altered the immune status of the patient in general (so far as it is reflected in 
these parameters) and (2) test the hypothesis of Zimmerman et al (1978) that 
the primary tumour was generating a protective response and thus should be 
left intact. In the first case, an earlier report (Flynn et al., 1986) had suggested 
that the tumour had a significant effect on the phenotypic population in the 
systemic circulation.
Initially, the proposal was to look at the lymphocytes in the systemic 
circulation prior to the operation and then 1 week, 4 weeks and 6  months 
after. However this was seldom practical as patients did not always return for 
check- ups at the expected times and, there were strategic problems in 
obtaining the samples from the medical staff. Thus the data collected was 
eventually only 8  patients pre- operatively and 1 week post- operatively. In 
addition, the control samples were intended to include uveitis patients as there 
is strong evidence for an immune response (although not necessarily 
systemic) in this condition. However the only samples available were retinitis 
pigmentosa (RP) patients who have an eye disease which shows little 
evidence of any, let alone systemic, autoimmunity. A series of control 
samples from "normal" individuals were collected but the data was 
subsequently discovered to be improperly analysed.
The analysis was by the methods described previously (Section 3.1.1)
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3.2.2 R esults
Blood samples (10ml) were obtained from 8 uveal melanoma patients 
immediately prior to the operation to remove the tumour, and also 1 week post 
operatively. Blood was also obtained from 4 RP patients. PBL were isolated 
using a ficoll- density gradient (Section 2.2.1.4) and cells were then classified 
into T or B cells or either CD4+ or CD8 + by using directly labelled 
antibodies to the T cell subsets (Table 3.1). The individual markers were 
identified by using the previously described FTTC labelled murine antibodies 
to HLA DR and CD25 (Table 3.1). Data was analysed as before (Section 3.1) 
where the percentage of cells positive for the marker were calculated.
Tables 3.11,3.12 and 3.13 indicate the percentage of the relevant 
phenotypes in pre- operative PBLs, post- operative and control patients 
respectively. The mean data are also indicated on the relevant table and then 
graphically represented on Figures 3.12 to 3.15. It can be seen from Figure 
3.12 that the levels of T cells and B cells do not change between the pre- and 
post- operative blood samples and indeed the control patients also seem to 
have similar levels of the different lymphocyte cell types (Table 3.14). This is
also true not only for the levels of CD4 and CD8 positive cells but also for the
j
expression of HLA DR and CD25 on the CD4+ and CD8 + T cells. Table 3.14 
shows the significance values between the pre- operative, post- operative and 
control samples and indicated that no significant differences exist.
98
HLADR+ CD25+
Patient 1 B CD4+ CD8+ CD4+ CD8 + CD4+ CD8 +
1 74.2 10.7 58.5 19.0 7.9 55.5 39.1 49.2
2 69.2 9.8 44.5 23.5 4.6 21.9 47.3 38.0
3 71.1 3.6 30.9 43.7 30.9 78.9 64.3 51.1
4 54.3 30.5 32.7 24.0 14.0 65.0 46.1 41.8
5 63.4 25.3 33.1 30.3 12.5 37.1 2 2 . 8 52.0
6 44.2 44.8 20.3 19.9 32.6 62.7 70.6 51.2
7 67.7 6 . 8 30.9 37.8 24.3 56.8 61.1 46.2
8 47.7 18.5 33.0 25.6 14.4 25.5 49.1 36.9
mean 61.6 18.8 35.5 28.0 17.7 50.4 50.1 45.9
±SD ±11.4 ±14.0 ±11.3 ± 8 . 8 ±10.4 ±2 0 . 2 ±15.5 ± 6 . 0
Table 3.11: Percentage of pre- operative PBL positive for the
specific cell markers.
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HLADR+ CD25+
Patient T B CD4+ CD8 + CD4+ CD8 + CD4+ CD8+
1 57.3 13.9 48.3 20.4 12.4 23.1 66.5 66.3
2 37.7 43.7 19.8 28.1 9.8 36.9 40.4 32.1
3 60.1 7.5 35.0 33.0 35.7 49.7 60.1 39.6
4 46.2 4.0 21.4 11.9 25.4 45.0 73.1 32.3
5 67.7 22.5 28.5 35.9 21.3 74.7 57.1 66.3
6 70.6 18.0 32.3 26.7 20.4 44.0 55.4 25.7
7 58.6 10.7 29.1 26.3 17.8 55.3 67.6 38.8
8 67.9 1 1 . 0 56.2 21.3 1 0 . 2 27.4 37.1 37.6
mean 58.2 16.4 33.9 25.5 19.1 44.5 57.2 42.4
±SD ±11.3 ±12.4 ± 1 2 . 6 ±7.6 ±8.7 ±16.3 ± 1 2 . 8 ±15.
Table 3.12: Percentage of Post- operative PBL positive for the
specific cell markers.
1 0 0
Patient ! B CD4+ CD8 +
HLADR+ 
CD4+ CD8 +
CD25+ 
CD4+ CD8 H
1 64.7 1 0 .1 40.5 26.3 2 0 . 0 73.4 45.5 43.4
2 53.7 1 1 . 8 41.7 15.9 23.8 61.0 59.0 45.7
3 43.5 15.6 27.0 25.7 43.7 61.7 73.7 39.8
4 74.3 14.4 56.0 2 0 . 1 34.0 34.7 69.7 48.1
mean 59 12.9 41.3 2 2 30.3 57.7 61.9 44.2
±SD ±13.5 ±2.4 ± 1 1 . 8 ±4.9 ± 1 0 . 6 ±16.3 ± 1 2 . 6 ±3.5
Table 3.13: Percentages of control patient PBL positive for
the specific cell markers.
1 0 1
Correlation
Marker Pre/Post Pre/Control Post/Control
TceH p<0.288 p<0.477 p<0.500
B cell p<0.440 p<0.488 p<0.500
CD4+ p<0.337 p<0.452 p<0.443
CD8 + p<0.242 p<0.454 p<0.414
CD4+HLA DR+ p<0.288 p<0.386 p<0.398
CD8 +HLA DR+ p<0.242 p<0.466 p<0.420
CD4+CD25+ p<0.242 p<0.431 p<0.443
CD8+CD25+ p<0.288 p<0.454 p<0.409
Table 3.14: The significance values for the correlation between
the activation markers on the pre- operative and post­
operative T cells (using the Wilcoxon Signed Rank 
correlation) and between the pre-/ post- operative T 
cells with the control samples (using the Mann- 
Whitney test). A p<0.05 is considered to be 
significant.
Figure 3.12:
Figure 3.13:
Mean data obtained for T and B cell populations in 
pre- operative, post- operative and control (RP) PBL 
samples.
Mean data obtained for CD4+ and CD8+ T cell 
populations in pre- operative, post- operative and 
control (RP) PBL samples.
POST CONTROL
SAMPLE
POST
SAMPLE
■  CD4 
E2 CD8
CONTROL
Figure 3.14:
Figure 3.15:
Mean data obtained for HLA DR+ CD4+/CD8+ T 
cell populations in pre- operative, post- operative and 
control (RP) PBL samples.
Mean data obtained for CD25+ CD4+/CD8+ T cell 
populations in pre- operative, post- operative and 
control (RP) PBL samples.
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3.3.3 Discussion
During the 1970's much work was carried out into tumour antigen and 
tumour- host relationships which was reviewed by Baldwin and Price (1976) 
and also HoUstrome (1976). The latter established that lymphoid cells from 
tumour- bearing as well as tumour- free donors were cytotoxic in vitro for the 
appropriate target cells, but that tumour- bearing serum specifically inhibited 
these effects. This phenomenon was rationalised in terms of circulating 
humoral factors. In addition, the effects of tumour- bearer serum were 
demonstrated using other in vitro procedures to monitor cell mediated 
immunity to tumour cells including inhibition of leucocyte adherence (Maluish 
and Halliday, 1974) and lymphocyte stimulation (Vanky et al., 1974). Such 
immune responses were identified in patients with colonic cancer (Nind et al., 
1975) and also in malignant melanoma where experiments showed that PBLs 
initially exhibited litde cytotoxicity for melanoma cells in vitro, but reactivity 
was detected after repeated washing. Furthermore, the cytotoxicity of washed 
PBLs could apparently be inhibited again by addition of the patient's serum 
(Currie and Basham, 1973). At this time the circulating tumour antigens or 
immune complexes were implicated in this type of inhibitory response, since 
semm activity decreased in animals rendered tumour- free by local resection 
of their tumour grafts (Robins and Baldwin, 1974; Baldwin et al., 1973). 
There have been reports that uveal melanoma are susceptible to dissemination 
into the venous circulation by manipulation of the tumour (Zimmerman et al., 
1978; Zimmerman and McLean, 1979) although others are in disagreement 
with this idea (Manschot et al., 1979; Seigal et al., 1979). Zimmerman et al 
(1978) concluded that enucleation of a melanoma- containing eye led to a 
significant increase in the, metastasis of the tumour, by removal of a systemic 
response elicited by the primary tumour.
A more recent study by Flynn et al (1986) indicated an increase in the 
level of Tc, Th and the level of B cells in the PBLs of patients with uveal
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melanoma compared to control patients, it was decided to determine whether 
PBLs from patients with uveal melanoma displayed any alteration in the cell 
activation status when the tumour was removed. There is wide patient 
variability (Table 3.11 to 3.13) as is common with clinical studies, and 
consequently mean values were used for comparisons. Control patients with a 
condition RP, a term used to describe a heterogeneous group of progressive 
retinal dystrophies affecting pigment epithelium function (Reviewed by 
Forrester et al., 1987) were used in this study to act as another eye condition, 
although non- neoplastic, in case disease induced changes in the eye itself 
may elicit an immune response.
It was found that there was little difference between the levels of T 
cells and B cells between the PBL samples taken at different time intervals and 
indeed between the control patients (Figure 3.12). The levels of cytotoxic T 
cells within the PBL did not seem to change significantly when the tumour 
was removed, and indeed the activation status of the T cells did not seem to be 
impaired or accentuated (Figure 3.14 and 3.15). Previous reports indicated 
the inhibition of the activation of T cells (Vanky et al., 1974). It must be noted 
that the blood samples were only 1 week post- operative and perhaps a greater 
time lapse may have given a better indication if the tumour was inducing some 
immunosuppressive activity upon the PBLs. It must also be noted that as 
previously mentioned (Section 1.1.4) the eye is classically referred to as an 
immunologically privileged site, being isolated from cells of the immune 
system. Thus perhaps no systemic immune response would be expected. 
There also appears to be little difference between the sample T cells and the 
control cells which is in disagreement with the findings of Flynn et al (1986) 
who did however, include a greater number of patients and unlike our study, 
included normal control PBL samples.
In retrospect, the view of the immune response in the 1970's was 
oversimplified and is now greatly altered by knowledge of the nature of T cell 
recognition and function (Section 1.4.1) and also of the largely self nature of 
oncogene products (Section 1.6.1). In addition experimental methods were of 
limited accuracy in comparison to those now available. It is likely, in outbred 
patients with many and variable recent and past immunological stimuli, that 
analysis of simple markers such as those used here will be so dominated by 
other environmental stimuli as to make any anti- tumour response 
undetectable.
CHAPTER 4
CELL SURFACE ANALYSIS OF 
ADHESION MOLECULES ON TUMOUR 
CELLS AND TILS
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4 CELL SURFACE ANALYSIS OF ADHESION
MOLECULES ON TUMOUR CELLS AND TILS
4.1 Background and Aims
Section 3.2 shows that there is no evidence of clonal expansion of 
TTLs due to site post recognition. An alternative hypothesis is that they 
migrate to and accumulate at the tumour site in response to molecules 
expressed on the tumour cells. Adhesion molecules are reported to be 
involved in the metastasis of primary tumour cells (Section 1.5.5). The 
surface markers measured in this study, on 2 0  uveal melanoma tumour 
samples, included HLA DR and ICAM-1 (CD54) which have been shown to 
have expression patterns correlating with the probability of metastasis in 
cutaneous melanoma. In addition, two further markers were studied: LFA-1 
(CD1 la), the relevant ligand for ICAM-1, particularly on the TIL samples, 
and also Class IMHC antigen. The TILs were also studied for the expression 
of these molecules to investigate the possibility that there may be differences 
between the CD4+ and CD8 + T cell populations within the tumour. The 
expression of these molecules and also of the MHC antigens were 
investigated for possible correlations with differing tumour cell types.
4.2 Results
4.2.1 Tumour cell surface antigen analysis
Primary cell suspensions were prepared (Section 2.2.1.2 ) and 
stained for FACScan analysis using the secondary antibody method (Section
2.2.2.1), except in the case of HLA DR expression where the antibody was 
already directly conjugated to FITC. The relevant unconjugated antibodies 
used in this particular study included W6/32 (anti- Class I), 6.5B5 (anti- 
ICAM-1, CD54), TS1/22 (anti- LFA-1, CDlla) (Table 4.1).
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Antibody Isotvpe
W6/32 IgG2 HLAA/B/C
Reactivity
ECAC
Cell Source
6.5B5 IgGl CD54
(Barnstable et al, 
1978)
(Wellicome et al,
TS1/22 IgGl CD 11a
1990)
ATCC
Table 4.1: Antibodies used in this study
The antibodies 6.5B5 and TS1/22 were supplied as cell supernatants, 
containing 0.05% sodium azide, and 10}il of each was added to the cell 
suspension (50|il). W6/32 was purified in the laboratory to a concentration of 
20|ig/ml and diluted 1:5 with 0.1% sodium azide. Again lOfil of this antibody 
was added to a 50|il cell suspension. After the primary incubation the cells 
were washed as usual and then stained with the FITC conjugated secondary 
antibody (sheep anti mouse IgG whole antibody (Section 2.1)). Once the 
unbound antibody had been washed from the cell suspension, PI was added 
to allow a live/ dead discrimination gate to be applied upon collection (Section
2.2.4.1).
Two gates were placed on the final collection of the tumour cells. 
These included the live/ dead discrimination gate, as described previously 
(Section 2.2.4.1), and also a scatter gate (Figure 4.1) to remove the 
possibility of any lymphocytes present influencing the results obtained for the 
tumour cells. Prior to the analysis the cells were analysed for the presence of 
any infiltrate using the previously defined Leucogate antibody (Section 3.1.2) 
(Figure 3.1). Once the position of the lymphocytes was determined on the
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scatter plot, an exclusion gate for the lymphocytes was applied (Figure 4.1). 
Figure 4.2 gives an illustration of the histograms obtained on analysis of the 
cell surface expression of each individual antigen on a representative tumour 
sample.
Table 4.2 shows the percentages of the cells within the tumour cell 
suspensions expressing each of the individual surface markers and also the 
percentage of the suspension that contained lymphocytes. There is much 
patient variability for all of the antigens studied. This can be seen from the 
mean data and appropriate standard deviations presented. The percentages of 
cells bearing Class I and Class II (HLA DR) antigens vary considerably 
between patients and Figure 4.3 shows that Class II (HLA DR) gain does not 
correlate with Class I loss. There is a trend toward a high percentage of 
ICAM-1 expressing cells and a negative correlation between percent ICAM-1 
positive cells and percent Class II(HLA DR) +ve cells (p< 0.012) (Table 4.3 
and Figure 4.4). The levels of TILs present in the tumour suspensions does 
not correlate with Class I or ICAM-1 (Figures 4.5 and 4.6). The statistics for 
this data are shown in Table 4.3. There is a correlation between the levels of 
TILs present and the expression of Class II present (p<0.001) (Figure 4.7)
Pathological reports for the tumours were analysed to investigate 
possible correlations between the expression of these markers and the cell 
type. The cell types are pure epithelioid cells (EP, n=2), pure spindle cells 
(SP, n=9) and mixed spindle and epithelioid (EP/SP, n=9) cells (Section 
1.3.3). Figures 4.8 to 4.10 show the levels of the individual cell surface 
antigens and the appropriate cell type and Table 4.4 indicates the mean values. 
Class I is expressed on a higher percentage of the mixed cell population with a 
mean value of 34.5% and both epithelioid cell samples have a lower 
percentage of cells expressing this MHC antigen (mean value of 16.3%).
HLA DR is expressed on a slightly higher percent of the pure spindle cells 
than the mixed cell population with mean values of 8.9% and 7.6%
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respectively. Again the two pure epithelioid tumours have a lower percentage 
of cells bearing this MHC antigen. ICAM-1 is present on similar percentages 
of all the 3 cell types.
Patient No. %TILs Class I HLA DR ICAM-1
1 2 . 2 13.1 2.3 82.3
2 0 . 8 3.1 8 . 0 65.5
3 0 . 6 2 2 . 0 6.3 89.5
4 4.2 34.4 26.3 55.4
5 0.4 2 2 . 1 1 . 2 83.4
6 7.3 19.5 9.1 67.4
7 3.8 33.3 16.0 61.5
8 3.2 79.8 7.4 94.9
9 6 . 1 8 .1 9.6 84.0
1 0 2.4 4.9 5.1 88.3
11 0 . 1 1 2 .8 0 95.3
1 2 0 . 6 31.3 1.5 93.9
13 6 . 0 7.7 3.0 91.1
14 0.3 13.4 0.7 92.9
15 1 .1 30.7 4.0 91.1
16 4.6 18.2 10.3 54.7
17 0 . 2 9.2 0 . 8 46.1
18 1 .1 23.5 27.9 57.6
19 5.3 8 8 . 6 1 1 . 6 84.5
2 0 1 .6 59.9 8.5 74.9
mean
±SD
2.1 ±2.2 26.7± 23.6 7.9± 7.8 77.7±5.9
Table 4.2: Percentages of tumour cells expressing antigens
thought to be involved in metastasis.
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Variable 1 Variable 2 Significance Correlation Eau
ICAM-1 HLA DR p<0 . 0 1 2 y=87.0-1.16x
% TILs Class I p<0.67 y=80.1-0.89x
% TILs Class II p<0 . 0 0 1 y=5.16+1.08x
% TILs ICAM-1 p<0.316 y=80.1-0.89x
Table 4.3: Statistical analysis on the tumour cell surface marker
expression data represented in Table 4.2. Significance 
values were calculated using the Spearman Rank 
correlation model. It is considered that a p value of less 
than 0.05 (p<0.05) indicates a significant correlation.
1 1 0
Antigen EP SP EP/SP
Class I 16.3 22.3 34.5
HLA DR 5.7 8.9 7.6
ICAM-1 74.9 71.5 84.6
Table 4.4: Mean values of the cell surface antigen expression on
the different cell types (epithelioid (EP), spindle (SP) 
and mixed epithelioid/ spindle (EP/SP)) of uveal 
melanoma.
Gate to exclude lymphocytes 
Gate to include lymphocytes
Figure 4.1: Scatter plot indicating gates applied when analysing
the cell surface expression of the relevant adhesion 
molecules on the uveal melanoma tumour cells 
(excluding TBLs) and TILs
CLASS 1+ TUMOUR CELLS CLASS 11+ TUMOUR CELLS
control
#15? FHD229004\FL1nF1uoresc enc © 1 #15? FHD229006\FL1\F 1uorescenc e 1
control
#15? FHD2290O3\FL1\F1uorescenc® 1 b b  
ICAM-1+ TUMOUR CELLS
control
Figure 4.2: Histograms obtained when analysing the expression
of individual antigens on the surface of the uveal 
melanoma tumour cells.
Figure 4.3: Graph indicating the correlation of Class I MHC 
expression with the level of HLA DR expression.on 
the uveal melanoma tumour cells.
Figure 4.4: Graph indicating the correlation of HLA DR with
ICAM-1 being expressed on the uveal melanoma
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Figure 4.5: Graph indicating the correlation of Class I MHC
being expressed on the tumour cells with the level of 
TILs present within the tumour cell suspension.
Figure 4.6: Graph indicating the correlation of ICAM-1 being
expressed on the tumour cells with the levels of TILS 
present within the tumour cell suspension.
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Figure 4.7: Graph indicating the correlation of HLA DR (Class n
MHC) being expressed on the tumour cells with the 
level of TILs present within the tumour cell 
suspension.
Figure 4.8:
Figure 4.9:
Class I expressed on the epithelioid (E), spindle (SP) 
and the mixed epithelioid/spindle (EP/SP) tumour 
cell populations.
HLA DR (Class IIMHC) expressed on the 
epithelioid (E), spindle (SP) and the mixed 
epithelioid/spindle (EP/SP) tumour cell populations.
Figure 4.10: ICAM-1 expressed on the epithelioid (E),spindle
(SP) and the mixed epithelioid/spindle (EP/SP) 
tumour cell populations.
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4.2.2 Cell surface antigen analysis of TIL subpopulations
Five uveal melanoma tumour samples that contained sufficient levels 
of TILs were used in this study to measure the percentage expressing cell 
surface markers relevant to adhesion (Section 4.2.1) i.e. Class I, HLA DR, 
ICAM-1 and LFA-1. These molecules were also measured on 4 of the 5 
corresponding patient PBL samples. The cells were stained as described 
before (Section 4.2.1). Before the PE conjugated antibody could be added to 
the cell, any free binding sites of the FITC labelled secondary antibody were 
blocked with 10% mouse serum. Three of the TIL samples were those 
obtained from the previous study (Section 4.2.1), namely samples 16,19 and 
20, and an additional 2 TIL samples not included in the previous study. For 
the purpose of this study these samples will be referred to as TIL and PBL 
samples 1, 2 ,3 ,4 , and 5. Figures 4.11 and 4.12 illustrate FACScan analysis 
diagrams obtained for (a) PBLs and (b) TILs. Percentages were calculated as 
in Section 3.1.2.
Table 4.5 shows the percentage positive cells measured in the TIL and 
PBL samples for each marker. It was decided not to continue measure the 
levels of LFA-1 on the lymphocytes since preliminary data indicated that it 
was present on >97% of the cells. This provided more cells to measure the 
other perhaps more variable cell surface markers.
Figure 4.11: Illustrative FACSan diagrams obtained for the 
analysis of CD4+ (A) and CD8 +(B) PBL subsets. 
Each diagram indicates the staining for (a) CD4+(A)/ 
CD8+(B) PBL in the UL quadrant, (b) Class I 
MHC+ staining PBL subsets in the UR quadrant,
(c) HLA DR+ staining PBL subsets in the UR 
quadrant and (d) ICAM-1+ staining PBL subsets in 
the UR quadrant. In each case the percentage non­
specific staining of the CD4+/CD8+ T cells present 
in the UR quadrant of panel (a) was subtracted from 
the positive staining for the other antigens.
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Table 4.6 and Figure 4.13 indicate the mean percentages of cells 
positive for the measured markers. The Class IMHC antigen is present on a 
high percent of the each of the lymphocyte subpopulations in the TILs and the 
PBLs (Figure 4.14) ( although it should be noted that the average data may be 
influenced by the low percentage of CD8+ Class I+ PBL on patient 2 
(24.7%)). It can be seen that HLA DR is present to greater extent on the TILs 
than the PBL samples (Figure 4.15). This is similar to the previous study 
(Section 3.2), with a higher percentage of CD8+HLA DR+ cells than the 
CD4+ HLA DR+ cells. In both the PBL and TIL samples ICAM-1 is present 
on a higher percentage of CD8 + T cells than CD4+ T cells (Figure 4.16).
As a consequence of the observation of Whitford et al (1991) of a 
strong correlation between HLA DR expression on CD8 + TILs and both 
Class I and Class II MHC antigens on breast carcinoma cells, it was relevant 
to inspect the more limited uveal melanoma data for any such trends. For 3 of 
the TIL samples, data for the matching tumour cell sample was available 
(Section 4.2.1). Although there is a very small sample number there does 
appear to be a trend towards correlation between HLA DR bearing CD4+ cells 
(Figure 4.17) and also between HLA DR expressing tumour cells and HLA 
DR bearing CD8 + TILs (Figure 4.18). Figures 4.19 and 4.20 indicate that a 
similar correlation does not exist between HLA DR expression on the tumour 
cells and HLA DR bearing CD4+ TILs (p<0.667), or the expression of Class 
I on the tumour cells with HLA DR bearing CD8 + TILs (p<0.667).
However, with only three patients such an analysis obviously has limited 
validity.
CD4±
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CD8±
Sample no C te . i HLA DR ICAM-1 Class I HLA DR ICA1V
1TIL 96.6 67.2 29.0 92.5 74.0 47.8
2 PBL 90.9 16.7 24.7 24.7 28.2 38.3
2 TIL 94.5 53.8 36.8 92.0 73.6 72.4
3 PBL 98.6 13.5 27.9 97.0 97.0 67.1
3 TIL 95.2 42.3 70.0 96.3 61.5 82.4
4 PBL 98.5 1 .8 14.0 98.9 39.5 32.9
4TIL 91.2 55.5 68.9 98.4 81.5 63.0
5 PBL 94.0 9.9 5.0 97.9 28.4 28.2
5 TIL 81.4 2 2 .0 19.8 94.0 70.7 48.2
Table 4.5: Data obtained from the analysis of cell surface
expression of Class I, HLA DR and ICAM-1 by uveal 
melanoma containing TIL and relevant PBL samples.
Antigen 
Class 1+ 
HLADR+ 
ICAM-1+
PBL
CD4+
95.5± 3.7 
10.4± 6.4 
17.9+ 10.4
CD8+ 
79.6± 36.5 
48.2+ 32.8 
41.6+ 17.4
TIL
CD4+
91.7± 6.1 
48.1± 17 
44.9+ 23.2
CD8 + 
94.6+_2.6 
72.2± 7.2 
62.7+ 15.1
Table 4.6: Mean data obtained from the expression of Class I,
HLA DR and ICAM-1 on the surface of CD4+ and 
CD8+ PBL and TIL samples.
Figure 4.13: Mean percentage of the expression of each of the
individual cell surface markers on the PBLs and 
TILs.
Figure 4.14: Expression of MHC Class I on the CD4+ and CD8 + 
PBL and TIL subsets.
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Figure 4.15:
Figure 4.16:
Expression of HLA DR (MHC Class II) on the 
CD4+ and CD8 + PBL and TIL subsets.
Expression of ICAM-1 on the CD4+ and CD8 + PBL 
and TIL subsets.
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Figure 4.17:
Figure 4.18:
Correlation of the expression of CD4+ TILs bearing
HLA DR with Class IMHC+ tumour cells.
Correlation of the expression of CDS+TILs bearing 
HLA DR with HLA DR+ tumour cells.
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Figure 4.19: Correlation of the expression of CD4+ TILs bearing
HLA DR with HLA DR+ tumour cells.
Figure 4.20: Correlation of the expression of CD8 + TILs bearing 
HLA DR with Class I+ tumour cells.
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4.2.3 Involvement of ICAM-1 and LFA-1 in cell killing
4-hour chromium release cytotoxicity assays (Section 2.2.6) were 
performed, initially, to investigate the possibility that ICAM-1: LFA-1 
interactions, between uveal melanoma cells and the tumour infiltrating 
lymphocytes, may be involved in the killing of the autologous tumour cells 
(Anachini et al, 1987)). For this study to be performed it was essential that the 
primary tumour cells could incorporate the 51 Cr to a sufficient extent to allow 
a difference to be detected in the release of the isotope due to the selective 
inhibition of cytotoxicity by the presence of the adhesion molecules.
Initially the assay was performed using the natural killer sensitive 
erythroleukemia cell line K562 (targets) ( Lozzio and Lozzio, 1975) and 
normal PBLs (effector). Figure 4.21 shows the % lysis by each effector: 
target ratio tested. The mean maximum incorporation was 7700cpm and the 
mean spontaneous incorporation was 800cpm. It can be seen that increased 
killing occurs with increased E:T ratio, and thus the assay system functioned 
as expected. A cutaneous melanoma target cell line, B8 , was then used but 
there was no obvious killing by the PBLs even although the cells were 
incorporating the 5 lCr to reasonable levels (Figure 4.22). This could have 
been due to the lack of MHC compatibility between the targets and the 
effectors. When fresh primary tumour cells were used it was observed that 
little of the 51 Cr was being incorporated (Figure 4.23) and this was shown by 
simply incubating the cells with the isotope and than measuring the 
spontaneous release over the time period and also the maximum release due to 
treatment with 3N HC1. The levels of incorporation of the 51 Cr (400cpm) 
were similar to the spontaneous release levels of the K562 control cell line. 
However, the cell were incorporating some , albeit low, levels of the isotope 
since the incorporation was above the background of the gamma counter,
Figure 4.21:
Figure 4.22:
Percent lysis obtained using different effector
(E):target (T) ratios indicated. The target cells in
these experiments were an erytheroleukemic cell line 
(K562) and the effectors were normal PBLs.
Standard deviations are a result of triplicate
experiments (n=3).
Incorporation of 51Cr in the human cutaneous cell 
line (B008) and subsequent release due to killing at 
varying E:T ratios by normal human PBLs.
Figure 4.23: Maximum and spontaneous release of
51q - by different primary uveal melanoma cell 
populations.
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4.3 Discussion
4.3.1 Tumour cell surface antigen analysis
The development of the fully metastatic cell is a complex process 
which can be divided into several different stages often denoted as initiation, 
promotion and progression (Farber and Cameron, 1980; Weinstein, 1988; 
Yuspa and Priorier, 1988). Progression to a more malignant phenotype 
occurs as the tumour cells acquire new characteristics which may represent 
normal functions in other cell lineages or stages of differentiation (Nicholson,
1988). These new characteristics may also be involved in the adhesive 
properties of the metastasising cell to the target tissue. Much work has been 
performed on cutaneous melanoma to study these melanoma- specific antigens 
(Holzmann et al., 1987; Wilson et al., 1981) and their relevance in metastasis. 
It is thought that many of the melanoma- associated antigens which have been 
examined indicate that these molecules are associated with cell activation and 
proliferation rather than with malignant transformation (Herlyn and 
Koprowski, 1988; Johnston et <z/, 1989).
This particular study involved analysing the phenotypic expression of 
defined cell surface markers on 20 uveal melanoma tumours, including Class 
I and II MHC (HLA DR) antigens, and the adhesion molecule ICAM-1. It 
can be seen from Table 4.2 that much patient variation exists for the 
expression of these markers.
There appears to be no correlation between the loss of Class I and the 
gain of Class II antigen. HLA DR expression is generally low (7.9%) 
although there are some tumour cells that express much higher percentages of 
positive cells. The HLA D region products have a restricted tissue 
distribution, and are expressed primarily by B lymphocytes and monocytes, 
and present in higher levels on activated lymphocytes and other lymphokine 
activated cells. In melanomas it has been reported that HLA DR antigens are 
frequently expressed on malignant cells which are derived from Class II
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negative cells (Carrel et al., 1986). The expression of HLA DR molecules by 
primary melanomas has been suggested to be a feature of advanced malignant 
melanomas independent of tumour thickness (Brocker et al., 1985). A 
prognostic significance of HLA DR expression raises the possibility that the 
immune system is playing an active role in the control of tumour growth and 
progression in melanoma. The measure of metastasis of the tumours in this 
study will of course involve a long term follow- up study of the patients and 
their survival.
Approximately 70% of primary cutaneous melanomas greater than 
1mm in thickness express the glycoprotein defined by monoclonal antibody 
P.3.58 (ICAM-1) (Holzmann et al., 1985, 1987). In vitro ,the expression of 
P3.58 can be modulated both on lymphocytes and melanoma cells by 
lymphokines such as IFN and TNF- a  (Holzmann et al., 1987). Our studies 
indicate the presence of ICAM-1 on a high percentage of all cells (77.7%).
The flow cytometric data presented here show a negative correlation with the 
expression of HLA DR (p<0.012) (Figure 4.4) and this may indicate the 
phenotypic changes that take place during the development of the tumour. The 
TILs in this system seem to lack the potential to potentiate the expression of 
ICAM-1 (Figure 4.7) but to perhaps increase the level of HLA DR- expression 
(Figure 4.6 and Table 4.3).Brocker et al (1988) have observed a positive 
correlation between the leukocytes containing IFN-y and the expression of 
HLA DR and specific melanoma associated antigens, such as gp 89, on the 
tumour cells and suggested changes in the phenotype of the tumour cells 
were in part being determined by the infiltrate. In this study there does not 
seem to be any positive correlation between the expression of Class I or 
ICAM-1 on the tumour cells with the levels of TILs within the tumour 
suspension (Figures 4.5 and 4.6), although a correlation (p<0.001) between 
the levels of TILs and the expression of HLA DR is evident (Figure 4.7 and 
Table 4.3) as mentioned previously. This could be due to the antigen
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presenting capabilities of the tumour cells or, as in the study by Brocker et al 
(1988), the HLA DR could be induced by certain factors being released by the 
lymphocytes present.
An attempt was made to correlate the presence of the cell surface 
antigens with the particular cell type of the tumour (Figure 4.8 to 4.10). The 
purely epithelioid cells seemed to express less Class I (5.7%), HLA DR 
(16.3%) and LFA-1(1.3%) than the other cell types but with only 2 
epithelioid tumours in the study group, no conclusions can be drawn. There is 
little difference in the expression of ICAM-1 between the different cell groups 
and thus it is not, at this stage, a suitable marker for prognosis or the cell 
type, even although it is thought that epithelial cells are thought to have a 
worse prognosis (Section 1.3.3).
4.3.2. Cell Surface Antigen Analysis of TIL Subpopulations
The various cell types within the immune system communicate with 
each other via membrane contact and soluble factors. Cytotoxic T cells have 
received much attention since it was originally shown that effector- target 
contact is essential for lysis (Zaguiy et al., 1975; Martz 1975). The peptide in 
the groove serves to allow recognition, and effector function requires 
additional contact between CD8  and the non-polymorphic regions of MHC 
Class I( or CD4 and non-polymorphic regions of Class II) (Section 1.4.2). 
Finally, additional adhesion molecules are also necessary for effector 
function. Studies have been performed that show that activated lymphocytes 
can attach to cells within the same species in a process termed "natural 
attachment" (Galili et al., 1978). It has been suggested that this contact 
represents the first step in the immunological recognition and that it is the 
prerequisite for subsequent detection of fine structural deviations on the target 
cell membranes by the lymphocytes (Klein, 1980).
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As shown earlier lymphocytes infiltrate, albeit to small extents, into 
uveal melanomas, and it is mainly the CD8 + T cells that constitute this 
infiltrate. When the expression of LFA-1 was studied on these lymphocytes it 
was found that >97% expressed this marker. Section 4.3.1 shows that high 
percentages of the tumour cells express the ligand for this particular adhesion 
molecule, ICAM-1. Attachment of the lymphocytes to the target cell thus may 
be via this ligand- receptor complex. ICAM-1 has been identified as the ligand 
of the LFA-1 molecule, by attachment of the LFA-1 positive cells to the 
ICAM-1 in artificial membranes, to ICAM-1- coated surfaces, and to human 
malignant and non-malignant cell lines on which ICAM-1 expression has been 
induced by cytokines (Makgoba et al., 1988; Rotlein et al., 1988). Vanky et al 
(1990) found that human tumours that were lysed by autologous lymphocytes 
all expressed ICAM-1 and MHC Class I antigens. Figure 4.13 and 4.16 
shows that there is a higher level of ICAM-1 expression on the TIL samples, 
which may be due to the activation state of the lymphocytes, and also that the 
CD8 + T cells preferentially express this molecule not only in the TEL but also 
the PBL samples. ICAM -1 can be detected on approximately 40 % of the 
resting T cell population (Buckle and Hogg, 1990). It has been suggested that 
these ICAM-1+ T cells have the phenotypic markers of memory cells 
CD45", which can be distinguished functionally from naive T cells, CD45+ 
by their ability to respond to previously experienced antigen. These cells 
appear to be in a state of marginal activation in that they also have been 
reported to express low levels of CD25 (Buckle and Hogg, 1990). Wang et al 
(1990) have suggested that the requirement of ICAM-1 on cytotoxic T cells, 
as well as on the targets, indicates that the contact between the two molecules 
can be bi- directional. It has also been shown that on activated lymphocytes 
the avidity of the LFA-1 molecule is transiently elevated (Van Kooyk et al 
1989; Dustin and Springer et al 1989). This prompt and short- lived change 
in the avidity of LFA-1, together with the activation- dependant expression of
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ICAM-1, is thought to provide the dynamics of regulation of cell interactions, 
i.e. attachment and detachment to and from the targets, allowing recirculation 
of the effectors. Within this study, the high levels of ICAM-1 found on TILs 
compared to PBLs may be indicative of the functionally active lymphocytes, 
and these cell may interact via their high avidity LFA-1 with the ICAM-1 on 
the uveal melanomas cell targets and deliver the "lethal hit". Alternatively they 
could interact through their ICAM-1, with the LFA-1 of the resting 
lymphocytes and deliver activation signals. Indeed Wang et al (1990) found 
that incubation of lymphocytes with an anti- ICAM-1 antibody did not affect 
the lytic interaction with target cells, but did abrogate the activation of the 
resting lymphocytes.
Thus contact between the effector and target cells may be a result of 
the infiltration of lymphocytes into the tumour, and the consequent 
dissemination or lytic activity due to the lymphocytes. There also may be the 
possibility of contacts between the effector cell populations which may be 
required for the cytotoxic function.
As was also shown in Section 3.1 the TILs have much higher levels 
of HLA DR compared to the PBLs and as is expected Class IMHC antigen is 
present on very high levels of the lymphocytes.
Correlations between the expression of both MHC antigens on the 
tumour cells and HLA DR present on the CD4+ and CD8+ T cells were also 
investigated in three cases. The positive correlation found in breast cancer by 
Whitford et al (1991) may represent the ability of the tumour cells to present 
antigens such as oncogene derived peptides. In this particular study there was 
found to be a strong correlation between the expression of Class I on the 
tumour cells and HLA DR on the CD4+> and HL ADR expression on the 
tumour cells with CD8 + T cells expressing HLA DR (Figure 4.17 and 4.18). 
Perhaps the uveal melanoma cells are also capable of presenting antigen to the
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T cells, but obviously a greater sample number is required to make any 
definite conclusions.
4.3.3 Cytotoxicity Assays
Cytotoxicity assays were performed due to the report of Wang et al 
(1990) that events occurring in 51Q- cytotoxicity assays required ICAM-1 
expression on the effector cells. The study was intended to determine the lytic 
activity of the TILs compared to the resting PBLs. The effects of incubation 
of the effector or targets with the relevant adhesion molecule antibodies might 
have indicated the importance of these molecules in the lytic activity or 
activation abilities of the lymphocytes.
The study was not pursued because of the problems associated with 
the uptake of the 51 Cr by the tumour cells. Primary uveal melanoma cells 
will adhere to the plastic once in an in vitro situation but will not proliferate 
and consequently will not incorporate the 51Cr to an adequate level. Thus 
comparative studies involving the inhibition of the release of the isotope due 
to incubation of either the lymphocytes or the tumour cells with the antibodies 
to the relevant adhesion molecules cannot be performed.
CHAPTER 5
DNA ANALYSIS OF UVEAL MELANOMA
TUMOUR CELLS
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5 . DNA ANALYSIS OF UVEAL MELANOMA TUMOUR
CELLS
5.1. Methods of Cell Cycle Analysis
There are several states that proliferating cells can assume besides mitosis. 
After completing mitosis (M), the daughter cells enter the Gapl (G) phase and 
they spend a period of time in this phase depending upon the tissue type. The cell 
then enters the DNA synthetic (S) phase where the genetic material of the cell is 
doubled. Before the cells undergo division again there is a second Gap phase 
(G2) (Figure 1.13).
There are defined genes that are crucial for yeast cells to pass specific 
points of the cell cycle. These crucial genes are collectively known as cell- 
division cycle (cdc) genes and there are indications that other eukaryotic cells may 
use similar mechanisms. One of these genes, cdc 2 (Nurse, 1981) is particularly 
intriguing because its correct activity seems crucial for entry into mitosis. It is also 
required earlier in the cell cycle at the onset of S phase (Mendenhall et al., 1987). 
Control of the mitotic mechanisms is present universally in all eukaryotic cells, 
and involves the cdc 2  gene product which is a protein kinase 
p3 4  cdc2 jt js activated at both the mitotic and the meiotic M- phase 
(Reviewed by Nurse, 1990). Activation requires changes in the phosphorylation 
state of the kinase and its interaction with cyclins, which are proteins that vary in 
level during the cell cycle and are degraded as the cells exit the M phase.
There are various methods for the study of the various aspects of the cell 
cycle and much work has been done to correlate the variables that reflect tumour 
proliferation with metastatic potential, tumour recurrence and overall mortality.
Discussed below are six methods for cell cycle analysis, with the 
advantages and disadvantages of using such methods.
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5.1.1.Mitotic Count
This is defined as the number of mitoses per designated high-power field 
(HPFs). The mitotic count has long been employed by histopathologists as a 
diagnostic and prognostic indicator, but mitotic count as a marker of tumour 
proliferation activity remains controversial, due to inter- observer variation in 
mitosis counting. Wide variation between observers in mitosis counting have 
been reported by Silverberg (1976), who expressed concern about the use of the 
mitotic count as the sole indicator of malignancy.
5.1.2 Thymidine Labelling Index (TLI)
This is a measure of the percentage of tumour cells in the DNA synthetic 
(S) phase of the cell cycle. TLI is measured in vitro by incubating freshly excised 
tissue in a medium containing tritiated thymidine, which is incorporated into 
DNA. Autoradiographs are then prepared, and the labelled cells counted and 
compared with the non- labelled population. This method was first reported in 
1961 on a study on breast tissue (Johnson and Bond, 1961). Since then attention 
has focused on the role of TLI as a prognostic indicator in human cancer. 
Increased TLI levels have also been observed in colonic mucosa of patients with 
familial polyopsis coli and familial colonic cancer leading to the suggestion that 
TLI may be useful as a marker for hereditary disposition to colonic cancer 
(Maasken and Deschner, 1977).
The use of TLI as an indicator of tumour proliferation has several 
limitations. TLI documents the number of cells in the S phase, but does not 
measure the duration of the S phase. Thus a tumour could have a slow rate of cell 
proliferation but a high TLI. The method also relies upon a sample from one part 
of the tumour assuming that that no heterogeneous growth patterns exist. In
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addition, human inter-observer variation, reproducibility error and small sample 
size may lead to misleading results.
5.1.3 Brom odeoxyuridine
The S phase cell population can also be measured using BdUR (Section 
1.6.2.4). BdUR is a pyrimidine analogue of thymidine which is readily 
incorporated into cells during the DNA synthetic phase. Recently, various 
monoclonal antibodies to BdUR have been developed (Gratzner 1982; Morstyne 
et al .,1983; Roberts et al .,1985). Tumours which have been exposed to BdUR, 
in vivo or in vitro, are stained with the antibody using an immunoperoxidase 
technique after DNA denaturation. The stained cells are counted using microscopy 
and expressed as a percentage of 500 or 1000 tumour cells to yield the labelling 
index. BdUR has obvious advantages over thymidine labelling, since it is 
sometimes employed as a therapeutic agent and, in consequence, in vivo kinetic 
studies can be conducted without introducing additional procedures or exposing 
the patient to radioactivity.
5.1.4 Nucleolar Organiser Regions (NORs)
These are loops of DNA which code for ribosomal RNA (Alberts 
et al .,1983). NORs are so called because of j their ability to associate into 
nucleoli. They are located on acrocentric chromosomes, of which man has five 
pairs located on chromosomes 13,14,15,21and 22 (Lewin 1980). Each 
acrocentric chromosome bears two NORs: thus, a normal i diploid'cell should 
contain 20 NORs. NORs can be demonstrated using in situ hybridisation to 
localised ribosomal genes (Warburton and Henderson 1979). NORs are 
associated with certain proteins, including RNA polymerase 1. These proteins are 
known as AgNORs and are thought to play an important role in RNA
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transcription. In 1975, it was discovered that NORs could be demonstrated using 
a simple silver staining method (Goodpasture and Bloom, 1975), and the method 
could be applied to paraffin- embedded tissue sections (Ploton et al .,1986). 
AgNORs are visualised as black dots within the nucleolus and the mean AgNOR 
count for 50 or 100 cells is usually calculated. It has been shown that there is a 
significant difference in AgNOR count between benign and malignant melanocytic 
(Crocker and Skilbeck, 1987) and breast (Smith and Crocker, 1988) lesions and 
between low grade and high grade lymphomas (Crocker and Nar, 1987).
Discrepancies have been shown with this technique. Chromosomes fuse 
during interphase, so that only a single silver positive structure is seen in resting 
cells, but disperse during metaphase when individual chromosomes and 
consequently individual AgNORs can be identified (Jan- Mahammed et a l,
1989). Thus, the AgNOR count may depend on the stage of the cell cycle. It 
has been suggested the AgNOR count is not a true count but rather a measure of 
the degree of dispersal of NOR associated proteins (Underwood and Giri, 1988). 
Another problem arises in the affinity of the nucleolus itself for silver ( Tandler, 
1954). This may lead to dificulties in precise counting and consequently to inter­
observer variation and reproducibility error. Many of the current disputes about 
AgNORs, if the inter-observer variation and recognition differences are ignored, 
could well be failure to obtain properly randomised samples and to minimise 
sample error related to tumour heterogeneity.
5.1.5 Ki67
Ki67 is a mouse monoclonal antibody which was produced in 1983 
(Gerdes et al., 1983). This antibody is reported to recognise a nuclear antigen 
which is present only in proliferating cells. It appears to be expressed only at 
certain stages of the cell cycle (Gerdes et al .,1984; Barsch and Gerdes, 1987).
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The antibody is applied to sections obtained from frozen tissue using 
conventional immunocytochemistry. The number of cells staining with Ki67 is 
said to represent the number of cells cycling at any one time (i.e the growth 
fraction). Results are expressed as the number of positive cells per total number 
of tumour cells counted. Various workers have reported a good correlation 
between Ki67 positivity and cell proliferation data obtained using other 
techniques. (Schrape et a/.,1987; Sasaki et al., 1988).
As a marker of cell proliferation activitiy, Ki67 positivity may provide an 
indication of the number of cells cycling at any one time. It appears to begin 
expression in mid-Gl; GO and early G1 cells are negative. Expression then 
increases through the cycle, and G2 and M cells are very heavily positive. 
Drawbacks include the need for fresh tissue as opposed to paraffin embedded 
tissue sections, and the possibility of observer error. Moreover, sections must be 
stained immediately after cutting with short acetone fixation.
5.1.6 Flow Cytometry
The final and perhaps the most important method of studying tumour cell 
cycle is the flow cytometer. Flow cytometry is an automated technique which 
quantifies cellular DNA content and analyses cell cycle distribution (Quirke and 
Dyson, 1986; Coon et al., 1987). A sample of tissue is prepared and the cells are 
stained using DNA specific- fluorochrome dyes. The suspension flows through a 
light beam 'past stationary fluorescence detectors, at a rate of about 1 0 0  cells per 
second. The light scatter by the cells is registered by the detectors and converted 
into electronic signals which are analysed by the computer (Section 2.2.5). The 
computer produces DNA histograms, and the available software can then analyse 
the results and derive information on the cell cycle (Figure 2.7). Ploidy status is 
concerned with expressing the DNA content as a DNA index value. This is the
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ratio of the G0/G1 cells of the population being studied to that of an internal or 
external standard diploid cell population. Diploid cells have a DNA index of 1.00. 
Cells with an index of 2.00 are tetraploid. Cells that contain abnormal quantities 
of DNA are referred to as being aneuploid and thus have a DNA index less than 
or greater than l.The DNA histogram also can determine the S phase content and 
the proliferation activity (S+ G2/M phases) of the sample although in a mixed 
population of diploid and aneuploid cells the profile is difficult to analyse with 
accuracy.
5.2 Aims of the study
The aims of this study were to analyse the cell cycle distribution of the 
DNA of the uveal melanoma tumour samples by flow cytometry. Correlations 
between the cell type, level of cellular infiltrate and other pathological features 
were investigated so as to obtain a better understanding of these tumours at a 
genomic level.
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5.3 Results
Ploidy analysis of 32 uveal melanoma tumours, and the appropriate 
patient PBL, was performed using the method of Vindelpv et al (1983) (Section 
2.2.2.2). From this study it was found that only one of the tumours contained 
abnormal (aneuploid) DNA (Figure 1.5(a)), and the DNA index for this tumour 
was calculated to be 1.8. This tumour was of epithelial origin, contained no 
infiltrate and had a mitotic count of 1 per 40 high power field.
From the remaining 31 diploid tumours (Figure 5.1(b)), 18 were of pure 
spindle cell type (58%), 10 were mixed spindle and epithelioid cell type (32.2%) 
and the remaining 3 were purely epithelioid cells (9.6%). The cells in each part of 
the cell cycle ( Gl, S, and G2M) were calculated using the Becton Dickinson 
Software Sum of Broadened Rectangles (Section 2.2.5.2). This model was used 
since it was preferable to use one method of analysis throughout and under certain 
circumstances the model would not allow the data to fit the Polynomial model, 
perhaps due to the presence of debris or due to the presence of too small an S 
phase. Since this model was used, a reference control was necessary to establish 
the position of the G0/G1 peak. Chick red blood cells (CRBC) were used since 
they contain approximately 35% of the DNA content of normal human cells. The 
proliferation index for each tumour was also determined. This flow cytometric 
data was then correlated with other pathological features such as the cell type, 
mitotic count, and the presence or absence of tumour infiltrating 
lymphocytes.(Table 5.1). It was found that, of the tumours sampled for the 
study, the mean percentage of cells that were found to be in the G0/G1 phase was
87.3 ± 6.5 with a minimum of 67% and a maximum of 95%. The range of cells 
in this S phase was from 3% to 27% with a mean S phase presentation of 7.9% ± 
5.6%. Similarly, 4.7% + 2.9% of the cells were in the G2M phase of the cycle 
with values ranging from 1% to 14%. The summation of the G2,M and S phases
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gives the proliferation index, and the range of this index was between 5 and 32 
with a mean of 13.0± 7.0.
Patient G1 S G2M G2MS C.T Op. MI LI
1 89 7 4 11 B LR 4 X
2 89 7 4 11 B LR 0 X
3 93 3 4 7 B LR 1 X
4 76 1 0 14 24 EP/B EN 3 X
5 82 14 4 18 EP/B LR/EN 2 2 ++
6 89 4 7 11 B LR 7 X
7 87 5 9 14 B LR 6 X
8 93 4 3 7 B LR 0 X
9 78 16 6 24 B LR 0 X
1 0 92 5 3 8 EP/B LR 3 +
11 93 4 3 7 AB LR 2 X
1 2 85 1 0 5 15 EP LR/EN 5 X
13 95 3 2 5 AB EN 0 X
14 93 4 3 7 EP LR/EN 5 +
15 85 6 9 15 EP/B EN 1 X
16 89 9 2 11 B LR 1 0 X
17 91 5 4 9 B LR 2 X
18 8 6 11 3 14 EP/SP EN 2 0 +
19 92 5 3 8 B LR 1 +.+
2 0 92 5 3 8 B LR 5 X
2 1 77 2 0 3 23 B LR 2 X
2 2 94 3 3 6 EP/B EN 4 X
23 92 5 3 8 B LR 5 X
24 90 6 4 1 0 B LR 3 X
25 67 27 5 32 EP/B EN 5 +
26 78 17 5 2 2 EP LR 24 ++
27 91 9 1 10 EP/B LR 5 ++
28 82 6 1 2 18 EP/B EN 8 ++
29 85 7 8 15 AB EN 0 +
30 93 4 2 6 AB EN 0 X
31 90 5 6 11 EP/B LR 2 +
Table 5.1: Patient data concerning percentage of tumour cells in each stage of the 
cell cycle (obtained by FACScan analysis) and also pathological features. Cell 
types (CT) include spindle cells (AB), pure epithelioid (EP) and mixed spindle/ 
epithelioid (EP/B). Operations (Op.) performed were either local resection (LR) 
and/ or enucleation (EN). Mitotic index (MI) stated per 40 high power fields and 
lymphocytic infiltration (LI) consisted of no lymphocytes (X), low levels (+) or 
high levels (++)
(a)
#14:FHD114B007\FL2\ #14:FHD114B008SFL2\
DNA p r o file  of aneuploid tumour DNA PROFILE OF PATIENT PBL
G0/G1 aneup
GO/G1 dip.
G2M aneuploid
#14;FHD1!4B010\FL2\
DNA P R O F IL E  OF D IP L O ID  TUMOUR o l DNA P R O F IL E  OF P A T IE N T  PBL
G0/G1
Figure 5.1: DNA histogram of (a) abnormal DNA (aneuploid)
containing tumour. G0/G1 of diploid peak and 
G0/G1 of aneuploid peak are represented. 
Corresponding patient's diploid PBLs are shown, 
(b) Diploid tumour and PBL DNA.
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When the cells were classified into cell type and correlated with the 
proliferation index it was found that pure spindle cells exhibited an index of 
10.9± 5.3, pure epithelioid cells and the mixed cell type had an index of 14 ±7.5 
and 15.6±7.8 respectively (Figure 5.2). A similar correlation was performed 
with the mitotic index (MI) and the cell type. Pure spindle cells appeared to have a 
mean MI of 2.66 with a wide range of 0 to 10. Similarly, the epithelial and mixed 
cells had mean MI of 11.3 and 7.3 with ranges of 5 to 24 and 1 to 22, 
respectively (Fig 5.3)
When the mitotic index and its relationship with the presence or absence 
of tumour infiltrating lymphocytes defined by the pathology reports were 
compared, it was found that tumours containing no TILs had a mitotic index of 
between 0  and 1 0 , whereas tumours with low lymphocytic infiltration had a range 
of 0 to 20 and the highly infiltrated group exhibited levels of 1 to 24 (Figure 5.4).
When the flow cytometry data for the determination of the S phase and the 
pathology data for the mitotic count were compared, it was found that the tumour 
cells with mitotic counts less than 10 also had low levels of cells in the S phase of 
the cell cycle- less than 10%. There were also 3 tumours with mitotic indices of 
20, 22 and 24 with SPF of 11, 14, and 17, respectively. However, there were 3 
tumours with high S phase fractions cells but exceptionally low mitotic counts 
(Figure 5.5)
As might be expected there is a good correlation with the percentage of 
cells in S phase and the proliferation index of each individual tumour (Figure 
5.6), since, by definition, one of the variables of the proliferation index is the 
percentage of cells in the S phase.
Several attempts were made to perform flow cytometric analysis of fixed 
paraffin embedded samples sections of archival tissues. It would obviously be of 
value to be able to carry out a long term study of pathological material and
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correlate this with the treatment and survival of the patient, which would already 
be known by this time.
This was attempted by deparaffinising the tissue in xylene and rehydrating 
the sections in a sequence of decreasing concentrations of ethanol and finally 
washing the cells in distilled water (Section 2.2.2.3). The cells were then pepsin 
digested using the method of Hedley (1983), and then stained as before 
(Vindelpv, 1983) for cell cycle analysis of the tumour nucleii. After several 
attempts at this rehydration and digestion protocol, it was decided to terminate this 
study since the material being obtained at the end of the experiment appeared to be 
composed largely of debris which could not be analysed using the DNA software 
package. Since one of the benefits of flow cytometry is the ability to perform 
analysis of fresh tumour samples it seemed appropriate to concentrate the study to 
such material in the hope that it might form part of a long term follow- up study in 
the future.
Figure 5.2:
Figure 5.3:
Correlation of proliferation index with individual cell 
type populations; epithelioid (EP), spindle (SP) and 
mixed epithelioid/ spindle (EP/SP).
Correlation of mitotic index with individual cell type 
populations; epithelioid (EP), spindle (SP) and 
mixed epithelioid/ spindle (EP/SP).
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Figure 5.4: Correlation of mitotic index with levels of 
lymphocytic infiltration (none, + (minimal) and ++ 
(moderate/ extensive)).
Figure 5.5: Mitotic index correlation with S phase fraction.
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5.4 Discussion
Several technical points have emerged from this study. The first indicates 
the benefits of using flow cytometry for DNA analysis since it makes use of 
modem technology involving lasers and refined analytical computer software. It 
has the advantage of being entirely objective in data collection, and the 
subjectivity only occurs when deciding upon the best method of analysis. It also 
has the ability to collect 5000 to 10000 nuclei in a few minutes. This number of 
nuclei would not be able to be analysed using frozen sections and applying other 
immunohistochemical techniques of cell cycle analysis. Unfortunately, FACscan 
analysis does not give the position of the actively dividing cells within the 
architecture of the whole tumour. It does however indicate the relative numbers of 
cells in each phase of the cell cycle of the available tumour piece. Paraffin 
embedded sections of tissue may be unrepresentative of the whole tumour.
For epithelial tumours and uveal melanomas, reports in the last decade 
have had a strong bias toward the use of paraffin embedded tissue sections 
(section 1.6.2.2 and 1.6.2.3) since the survival of the patient is known. The data 
have not been in concordance with recent findings from fresh tissue, and it 
appears that fresh samples give a much better set of results to analyse, removing 
the problems presented by debris that occurs when deparaffinising, and 
rehydrating tissue samples. Paraffin fixation involves extensive formaldehyde 
cross- linking, and this makes it difficult to obtain "clean" nuclei not associated 
with the endoplasmic reticulum containing ribosomal RNA. In the preparation of 
the nuclei for the DNA analysis, RNAase is added to remove any RNA present, 
but it may not be completely effective due to the high level of formaldehyde 
fixation. Storage of paraffin embedded sections, particularly in acid conditions, 
may break down the phosphodiester bonds in DNA. Paraffin fixed tissue, 
provided for an attempt at studying DNA analysis of archival tissue. It was found that
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analysis on a modem FACS system, and personal communications with other 
laboratories suggested that this method is recognised as having limited 
value. In this context, it may be relevant to note that the manufacturers of the 
FACScan, Becton Dickinson, no longer advise that relevant results can be 
obtained from paraffin fixed tissue sections.
The data in this section are closer in agreement with Rennie et al (1989) 
than with Shapiro et al (1986) and suggest that, when fresh tissue is used, 
aneuploidy is a comparatively rare event in uveal melanoma. However, the data 
do not support the suggestion of Rennie et al (1989) that epithelial tumours have a 
higher rate of proliferation than spindle cell tumours. The most likely explanation 
for this is the small number of epithelial tumours available for study. It does 
illustrate the lower rate of proliferation of the spindle cells suggesting that perhaps 
in a mixed spindle, epithelioid tumour it is the epithelioid cells that give the 
tumour the high proliferation index. Spindle cells seem to have the lowest mitotic 
index, defined by pathology reports, which would be in concordance with the 
low proliferation index. It is important to mention that the 3 tumours with the 
highest mitotic index, all contain epithelioid cells either existing as pure epithelioid 
tumours or mixed spindle/ epithelioid tumours, and all 3 contain lymphocytes a 
varying levels. All tumours that do not contain TILs have a low mitotic index.
The high mitotic index of the TIL containing tumours is not due to the 
lymphocytes because they do not exist in high enough quantities to over- shadow 
the tumour cell nuclei present within the suspension.
Epithelial tumours are known to have a poor prognosis and it seems unlikely that 
flow cytometric analysis of the cell cycle can have a significant impact on clinical 
management.
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Finally, there is the question as to how the tumour cell cycle is related to 
tumour aggression and tumour metastasis. Within this question lies the 
supplementary question as to whether a preponderance of cells in S phase 
necessarily indicates tumour aggression. Modem molecular biological research 
has shown that the cell cycle is under a complex series of control mechanisms, 
many being related to oncogene functions (Section 1.6.1) and that no single index 
of proliferation, including flow cytometry is likely to give an indication of clinical 
outcome. Metastasis itself is a complex process involving the ability of the cells 
to escape from the primary tumour and to establish the secondary growth 
eslewhere. For this process, the possession of cell surface molecules such as 
adhesion molecules or of secretory functions such as collagenase, may be more 
relevant than the cell cycle status of the primary tumour.
CHAPTER 6
DISCUSSION
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6 DISCUSSION
6.1 General
The work described in this thesis was initiated to determine if there 
was any immune response to tumours of the eye, especially uveal melanoma, 
compared to other tumours that exist outwith this immunologically privileged 
site of the body (Section 1.1.4). Much work has been performed on 
cutaneous melanoma, but uveal melanoma is a less studied tumour due to its 
rarity. A major problem in the research was the availability of tumour samples 
due to the previously mentioned rarity. The degree of lymphocytic infiltration 
is also small in comparison to other tumours such as breast and colonic 
cancer.
6.2 Flow cytometry
Flow cytometry is a method of analysing the cell surface antigen 
expression of tumour cells with the ability of discriminating live from dead 
cells. It can quantitate the degree of expression non- subjectively. Other 
classical methods of phenotyping cells include basic immunohistological 
techniques that involve staining of fixed tissue sections or cell suspensions 
with either fluorescent or enzyme linked monoclonal antibodies. This 
introduces problems because of the nature of the procedures. The cells are 
fixed and thus perforated, introducing a high degree of non- specific staining 
of the cells. The quantititive analysis of the cells also becomes very subjective 
due to the nature of the counting procedures used, and very dependent on the 
person analysing the results. The individual tissue sections used also 
introduce an element of inaccuracy, since no two sections will be the same, 
and if a particular cell population congregates in a particular area of the tumour 
in preference to another site, then different sections will give different results. 
Alternatively, flow cytometry can be performed on live cells and any 
particular cell population can be detected and preferentially analysed
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depending on certain physical characteristics that the cells possess. When 
analysing the tumour it is also important to remember that ideally whole 
tumours should be analysed and thus removes any possibility preferential 
screening of individual cell populations, although in this study only apical 
pieces of the tumour were obtained and thus this problem is not completely 
removed. Data can also be stored on tapes so that it can be analysed by 
various methods at a later date.
The accuracy of the machine is also important since it was found that 
when comparing the levels of TILs from the pathology reports with those 
found in the tumours determined by FACScan, flow cytometry always 
revealed an element of infiltration, whereas the pathology reports frequently 
indicated that there was no infiltrate in the section studied.
6.3 Relevance of Tumour Infiltrating Lymphocytes
Much work has been carried out on the infiltration of human tumours 
by lymphocytes, and consequently it is an area of great interest with respect to 
methods of immunotherapy of cancer. The levels of TELs within any tumour 
type can vary. For example, breast carcinoma has an average of 12% of the 
tumour containing TILs (Whitford et al., 1990) whereas uveal melanoma can 
often contain 1-2% TILs. This is an important and relevant finding of this 
thesis since it illustrates the basic principle that not all tumours have the same 
immunological features. The levels of TILs may also be indicative of whether 
the patient will be responsive to therapy involving rhIL-2 (Rosenberg 1986: 
Topalian et al., 1987; Rosenberg et al., 1990). Most of the work so far has 
been carried out on malignant cutaneous melanoma which contains sufficient 
levels of TILs to enable them to be expanded and re- administered to the 
patient. However uveal melanoma contains such low levels that these TILs 
will not grow to sufficient quantities.
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Another problem exists when analysing the tumours for 
lymphocytes. This involves the anatomy of the tumour and the location of the 
test samples obtained. As mentioned previously (Section 6.2) only the apical 
pieces are obtained, prompting the questions; are these pieces representative 
of the tumour as a whole? This problem is unavoidable for obvious clinical 
and pathological reasons.Previous studies involving identification of uveal 
melanoma TILs have been involved with classical immunohistological or 
microscopical techniques (De La Cruz et al., 1990) introducing the problems 
listed above (Section 6.2). Results of phenotyping of TILs represented in 
this thesis indicate that the TILs are markedly different than the PBLs, not 
only in the relative proportions of the lymphocytes subsets present, but also in 
the activation status of the T cells (Section 3.1). Thus the lymphocytes are 
located within the tumour either because they possess some mechanism 
contributing to their migration and activation, or the tumour in some way 
attracts the lymphocytes consequently activating them. In both cases the cells 
are being selected to infiltrate the tumour for whatever function.
As mentioned (Section 1.5.7), therapeutic strategies have involved 
culturing of TILs with rhIL-2 and re- administering these to the patient in the 
hope that the TDLs will be more cytotoxic to the tumour cell present. Clonal 
phenotyping of these cells, in terms of their ability to express specific VP 
regions of the TCR (Section 3.2), has indicated that the TILs, in uveal 
melanoma, are of polyclonal nature, but also have ability to home into the 
tumour. Reports of oligoclonality in humans (Belldegrun et al., 1989) and 
murine (Karparti et al., 1991) IL-2 treated TILs, indicated that expression of 
these TILs may lead to selective alterations in the recognition profiles of the T 
cells. Such recognition may be patient specific due to the MHC restriction 
present within an outbred population.
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It would be interesting to elucidate whether the uveal melanoma TILs 
would be polyclonal or oligoclonal for the Vp TCR repertoire expression after 
culturing in IL-2, and also to determine what particular subset of T cell, CD4+ 
or CD8+, would predominantly be expressed within the culture.
Phenotyping of the PBL samples at different time points (Section 3.3) 
identified the lack of systemic immune response to uveal melanoma. In the 
1970's it was assumed that an immune response was detected due to the 
identification of a response at the level of serum antibody. It is now apparent 
that the nature of the response to a small, local and weakly antigenic tumour 
will not be the same as that detected in bacterial or viral infections.
6.4 Tumour cell surface antigen analysis and relevance in 
metastasis.
The study of the expression of cell surface antigens (Section 4.1) on 
the uveal melanomas has revealed some interesting points. The tumours show 
a high degree of variability in their expression of Class I and Class II (HLA 
DR) MHC antigen which is in agreement with other studies involving MHC 
antigen analysis of tumour cell (Whitford et al., 1991). Reports have indicated 
that HLA DR is preferentially expressed on advanced and metastatic 
cutaneous melanoma (Johnson et al., 1989). This thesis reports that there is 
an inverse correlation between the expression of the adhesion molecule, 
ICAM-1, perhaps involved in the metastasis of tumours, and the HLA DR 
MHC antigen on the malignant melanoma studied. Perhaps since HLA DR is 
present on more advanced tumours and the ICAM-1 may not be, then it could 
be the less aggressive tumours that disseminate and result in metastasis.
The fact that all the tumours expressed a high level of ICAM-1 
suggests that this molecule may be involved in the progression of tumours. 
ICAM-1 is also thought to be absent on normal non- lymphoid tissue and thus
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may be regarded, in the case of uveal melanoma, to be a tumour specific 
antigen.
The TILs, especially the CD8+ T cells, also seem to express ICAM-1 
and also its ligand LFA-1. This could indicate three possibilities:
(1) tumour cells adhere to the TILs and it is this attachment that 
promotes dissemination of the tumour cells into the blood stream, via 
recirculating lymphocytes, and causes the eventual metastasis of the 
tumour.
(2) The TILs have the ability to bind to each other via the ICAM-1: 
LFA-1 interaction, and by some mechanism transmitting the activating 
signals to the resting lymphocytes.
Finally (3) The binding of LFA-1 on the lymphocytes to the ICAM-1 on the 
tumours targets, may bring the effector and target cell closer together such that 
the cytolytic activities of the T cells can come into operation.
The first proposal is of poor prognosis to the patient, whereas the 
others are of detrimental value to the existing tumour. All three ideas are 
possible since lymphocytes lacking ICAM-1 expression may still be involved 
in the dissemination of the tumour cells, allowing the ICAM-1+ T cells to 
perform their cytotoxic functions.
6.5 DNA content of uveal melanoma tumour cells and relevance 
in prognosis.
Tumours are generally associated with an abnormal (aneuploid) DNA 
content, as in breast carcinoma (Alam et al., 1991) and these tumours are 
found to be of epithelial origin. Few uveal melanoma tumours are found to be 
aneuploid which indicates a difference in the characteristics of different 
neoplasms. Although there is a wealth of ploidy data involved on the analysis 
of breast and colonic cancer there are few articles on cutaneous melanoma.
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This suggests that, like its uveal melanoma counterpart, aneuploidy is not a 
feature of this type of cancer (Sondergaard et al., 1983; Stenzinger et al., 
1984)
The cell cycle parameters also give little information, except that the 
epithelioid cells, that are already established to give the poorer prognosis in 
uveal melanoma, may also contribute to the population of cells with the 
highest turnover rate. This could be indicative of the aggressive nature of the 
tumour.
6.6 C onclusions
It is important to note, within any clinical study, there will always be 
great variability in the results obtained between patients. Clinical research only 
determines trends in results, and thus a greater understanding of more basic 
science is required to elucidate the underlying problem.
CHAPTER 7
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